THE HEALTH BENEFITS OF RACERUNNING FOR THOSE WITH A MODERATE-TO-SEVERE NEURODEVELOPMENTAL DISABILITY.

E. THACKER

Msc by Research

University of Gloucestershire

THE HEALTH BENEFITS OF RACERUNNING FOR THOSE WITH A MODERATE-TO-SEVERE NEURODEVELOPMENTAL DISABILITY.

ELIZABETH THACKER



A thesis submitted to the University of Gloucestershire in accordance with the requirements for the degree of Masters by Research in the School of Applied Sport and Exercise Science

December 2022

Word Count: 16,991 words

Declaration

I declare that the work in this thesis was carried out in accordance with the regulations of the University of Gloucestershire and is original except where indicated by specific reference in the text. No part of the thesis has been submitted as part of any other academic award. The thesis has not been presented to any other education institution in the United Kingdom or overseas.

Any views expressed in the thesis are those of the author and in no way represent those of the University.

Signed



Date 16.12.2022

Acknowledgements

Firstly, I would like to thank my supervisors Nicola Theis and Dan Cowen for all of their guidance, support and encouragement throughout my dissertation.

Secondly, I would like to thank the RaceRunning clubs in Gloucester, Cardiff and North Devon, for allowing me to conduct my dissertation.

Finally, I would like to thank my friends and family for all of their ongoing encouragement and support throughout my years of study and my dissertation. Without them, I would have not been able to achieve all the things I have done over the last few years.

Abstract

Introduction: Neurodevelopmental disabilities can cause restrictions in mobility, increasing the risk of individuals developing secondary health conditions. For individuals with moderate-to-severe neurodevelopmental disabilities, it can be difficult to find activities which improve physical health and reduce this risk. RaceRunning is a developing disability sport designed specifically for individuals with moderate-to-severe disabilities, enabling them to move independently with the potential to improve physical health outcomes.

Aim: The present study aims to investigate the effect of RaceRunning on physical health in individuals with moderate-to-severe neurodevelopmental disabilities.

Method: Five males and 4 females with neurodevelopmental disabilities (18.1 ± 9.8y) completed a 12-week intervention consisting of a 1-hour RaceRunning session per week. Sessions involved a warm-up section, a skills section and a cool down. At baseline and 12 weeks, resting heart rate, blood pressure and thigh and calf circumference were measured. Isometric strength in both legs were also recorded. Cardiorespiratory response to RaceRunning was assessed via a 6-minute RaceRunning test and kinematics of running technique were recorded and analysed during the test.

Results: Significant decreases in resting heart rate were observed post intervention (p = 0.038) with no changes in blood pressure (systolic = p = 0.242) (diastolic = p=0.846). No significant differences were observed in thigh (left = p=0.922, right = p = 0.404) or calf circumference (left = p = 0.377, right = p = 0.310). Knee flexion isometric strength was significantly higher in both left (p = 0.021) and right (p = 0.006) legs but only significantly higher in the left knee for knee extension (p = 0.018). Plantarflexion saw no significantly different (left = p = 0.139, right = p = 0.075) changes in isometric strength. There was no significant change in the 6-minute RaceRunning test and kinematic changes were only observed in the knee following 12 weeks of RaceRunning.

Conclusion: This preliminary evidence suggests there may be some health benefits of RaceRunning to those with neurodevelopmental disabilities. Recruiting a larger cohort and assessing other measures of health may better reflect these changes.

iv

List of Tables

Table 1.	Demographic Information.	30
Table 2.	Average and SD of ankle kinematic values at baseline and 12-weeks.	34
Table 3.	Average and SD of knee kinematic values at baseline and 12-weeks.	34
Table 4.	Average and SD of hip kinematic values at baseline and 12-weeks.	35

List of Figures

Figure 1.	An example of a RaceRunning frame.	7
Figure 2.	Differences in resting heart rate between baseline and 12-weeks of RaceRunning training.	31
Figure 3.	Differences in knee flexor strength for the left and right legs between baseline and 12-weeks of RaceRunning training.	32
Figure 4.	Differences in knee extensor strength for the left and right legs between baseline and 12-weeks of RaceRunning training.	33

List of Appendices Appendix 1.1	Project Approval Form	78
Appendix 1.2	Participant Information Letter (Adult)	92
Appendix 1.3	Parent/Guardian Information Letter	96
Appendix 1.4	Informed Consent Form	100
Appendix 1.5	Raw Data	101

List of Abbreviations

6MRT	-	6-minute Racerunner Test
ADLs	-	Activities of Daily Living
BP	-	Blood Pressure
CP	-	Cerebral Palsy
CoV	-	Coefficient of Variance
DB	-	Drawback
KE	-	Knee Extension
KF	-	Knee Flexion
GMFCS	-	Gross Motor Function Classification System
HP	-	Heel Plant
HIT	-	High Intensity Training
HR	-	Heart Rate
IC	-	Initial Contact
MST	-	Midstance
MSW	-	Mid-swing
NDD	-	Neurodevelopmental Disabilities
QoL	-	Quality of Life
RHR	-	Resting Heart Rate
TD	-	Typical Developing
ТО	-	Toe-off
WHO	-	The World Health Organisation

Contents

Declarationii
Acknowledgementsiii
Abstractiv
List of Tablesv
List of Figures
List of Appendicesvii
List of Abbreviations
Chapter 1 – Introduction1
1.1 Aims
1.2 Hypothesis
Chapter 2 – Literature Review
2.1 Neurodevelopmental Disabilities8
2.1.1 Muscle Weakness8
2.1.2 Reduced Muscle Size10
2.1.3 Gait/Kinematics11
2.2 Reduced Physical Activity and Secondary Health Problems11
2.2.1 Cardiovascular Responses12
2.2.2 Cardiorespiratory Fitness14
2.2.3 Quality of Life16
2.3 Interventions Available to Improve Physical Activity
2.3.1 Established Interventions17
2.3.2 Interventions for moderate-to-severe conditions
2.4 Summary
Chapter 3 – Methods25
3.1 Participants
3.2 Study Design

3.2.1 Ethical Principles26		
3.2.2 Pilot study		
3.3 Procedures		
3.3.1 Heart rate		
3.3.2 Blood pressure27		
3.3.3 Circumference27		
3.3.4 Strength27		
3.3.5 6-minute run test		
3.3.6 Kinematic analysis28		
3.4 Data Analysis		
Chapter 4 – Results		
4.1 Heart Rate and Blood Pressure		
4.2 Circumference		
4.3 Knee and Ankle Isometric Strength Test		
4.4 6-minute RaceRunning Test		
4.5 Kinematic Values and Speed		
Chapter 5 – Discussion		
5.1 Heart Rate and Blood Pressure		
5.2 Thigh Circumference, Calf Circumference and Isometric Strength 39		
5.3 6-minute RaceRunning Test42		
5.4 Kinematic Analysis45		
5.5 Sample Size		
5.6 Clinical Implications		
5.7 Future Research		
Chapter 6 – Conclusion		
References		
Appendices		

Appendix 1.1 Project Approval Form	78
Appendix 1.2 Participant Information Letter (Adult)	92
Appendix 1.3 Parent/Guardian Information Letter	96
Appendix 1.4 Informed Consent Form	100
Appendix 1.5 Raw Data	101
1.5.1 SPSS Output for Descriptives (Mean and SD)	101
1.5.2 SPSS Output for Normality Test	147
1.5.3 SPSS Output Differences Tests	155

Chapter 1 – Introduction

Approximately 6% of the UK population have some form of neurological motor disorder that affects participation in a range of daily activities (Shafizadeh et al., 2019). Neurodevelopmental disabilities (NDD) encompass a highly heterogenous group of diseases that have a wide range of neurological problems (Shevell, 2010; Moreno-De-Luca et al., 2013). The etiology of NDD that negatively affects neurodevelopment include genetic predispositions, brain lesions and material/environmental exposures which can occur congenitally or be acquired during childhood (Whitney et al., 2020). It can result in neurological functioning and/or processing impairments involving cognition, communication, behaviour and motor functioning (Moreno-De-Luca et al., 2013; Whitney et al., 2020). Typically, NDD is clustered into developmental skill domains: gross and fine motor, speech and language, personal-social cognition, and activities of daily living (ADLs) (Shevell, 2010). Many individuals will possess more than one impaired developmental domain (Miller et al., 2013; Arim et al., 2017). These impairments can manifest into variables such as muscle weakness, reduced muscle size and impaired gait (Van der Linden et al., 2018; Shafizadeh et al., 2019). This in turn can lead to further complications such as restricted mobility, reduced cardiovascular responses and an overall reduction in physical health (Liptak et al., 2001; Jacobson, 2020).

The neurodevelopmental changes that occur in individuals with NDD have been linked to a reduction in physical activity (Jacobson, 2020; Whitney et al., 2020). Children with cerebral palsy (CP) have been reported to have excess body fat, lower levels of physical activity and underdeveloped musculoskeletal systems (Liptak et al., 2001; Stevenson et al., 2006; Whitney et al., 2020). Childhood obesity rates have been shown to be disproportionately higher by at least 38% in individuals with NDD compared to typically developed peers (TD) (Irby et al., 2012). This can link to an increased risk of developing secondary comorbidities in adulthood (Sukal-Moulton et al., 2022). Concerns over health problems across a 10-year period have been shown to increase amongst this population (29 to 54%, p=0.008), with restrictions in ADLs increasing by 26% (p=.002) (Benner et al., 2017). This could be reduced or slowed by participating in physical activity.

Approximately 70-75% of individuals with a disability do not participate in physical activity and have reduced habitual activity levels up to 30% below the recommended guidelines (Carlon et al., 2013; Verschuren et al., 2016; Kwon et al., 2019; Shafizadeh et al., 2019). Across a 7-year period, individuals with CP saw a reduction in walking by up to 20%, with further increases in fatigue and the intensity and frequency of pain (Opheim et al., 2009). Furthermore, individuals with NDD spend 63% more time being sedentary, with less time doing physical activity compared to TD peers (Ryan et al., 2014). This is exhibited in individuals with Spina Bifida, with reports of spending more time being sedentary per hour (49.5 \pm 5.78min/hr) compared to TD peers (41.0 \pm 5.76min/hr, p = 0.001) but also spending less time doing light (p = 0.003) or moderate (p= 0.001) physical activity. Prolonged bouts of sedentary activity increase cardiometabolic risk factors such as increases in abdominal obesity and elevated blood pressure (BP) (Ganz et al., 2021). This can increase the risk of developing secondary health conditions such as cardiovascular disease, ischemic stroke, type II diabetes mellitus, obesity and cancers (Kwon et al., 2019; Whitney et al., 2020). Furthermore the reduced level of physical activity in individuals with NDD can lead to a cycle of deconditioning, impairing multiple bodily systems and causing further subsequent reductions in physical activity (Durstine et al., 2000).

To prevent secondary health conditions and the reduction of quality of life (QoL) in those with NDD, there is a need to develop physical activities that are adapted for individuals with participation limitations and restrictions (Meester-Delver et al., 2007; Dahan-Oliel et al., 2012). Physical activity has been reported to have numerous health benefits in TD children, with improvements in cardiopulmonary health, strength, flexibility and endurance (Van Schie et al., 2022). However, due to problems in mobility, individuals with NDD may struggle to access activities which promote health benefits (Dolk et al., 2010; Rimmer et al., 2017; Van Schie et al., 2022; Sukal-Moulton et al., 2022; WHO, 2022). Interventions that are designed for NDD populations are often focussed on addressing the underlying developmental impairments such as poor muscle tone, decreased attention span, poor dexterity or difficulties with perceptual concepts (Dahan-Oliel et al., 2012). Interventions such as cycling, resistance training and strengthening programmes are available for individuals with NDD with

improvements in aspects such as muscular strength (Park & Kim, 2014). Swimming, walking and functional exercises are also available for individuals with NDD and have been shown to improve cardiorespiratory endurance (Verschuren et al., 2016). However, whilst these activities do provide both physical and psychological benefits, they are not always catered to severe conditions, presenting a big gap in participation (Wright et al., 2019; Van Lindert et al., 2023). In group activities, individuals with moderate-to-severe conditions are more dependent on others to help them to participate compared to more mild and ambulant severities (Wright et al., 2019). This can present a barrier to participation as many individuals wish to be independent in group-specific activities (Jaarsma et al., 2015; Wright et al., 2019). Whilst facilities may offer opportunities for participation in sports, the sports themselves may be deemed too physically challenging for individuals with more severe disabilities (Jaarsma et al., 2015). This presents the ongoing issue amongst NDD populations regarding access and availability of facilities, with the impairments associated with their condition resulting in many individuals being inactive.

One suggested intervention to overcome these barriers could be the sport of RaceRunning. RaceRunning is a sport that provides social and physical benefits to NDD participants (Sukal-Moulton et al., 2022). RaceRunning is a niche, developing disability sport designed specifically for individuals with moderate to severe impairments (gross motor function classification system [GMFCS] IV and V) (Kristjánsson, 2018; Shafizadeh et al., 2019; Kossakowski et al., 2021). Initially developed in Denmark, there are around 2000 bikes used worldwide which consist of a chest plate, handlebars, a saddle with thoracic support and a belt that securely fastens the individual into position as they manoeuvre (Figure 1.) (Kristjánsson, 2018; Shafizadeh et al., 2019). The sport is recognised on an international scale with a proposal of the sport for inclusion in the Paris 2024 Paralympic programme (RaceRunning.org, 2020, May 5). Currently, there are 13 clubs across England, Scotland and Wales (Quest, 2020, June 2). Whilst the sport is predominantly for individuals with CP and is governed by CP Sport, it is not exclusive to this group (CPISRA, 2021). It provides individuals with a variety of disabilities the opportunity to be active, with the frames being suitable from 5 years of age through to adulthood (CPISRA, 2021; Van der Linden et al., 2022). RaceRunning

can enable a population that have limited opportunities to take part in traditional sports (Kristjánsson, 2018; Johnson, 2021).

This links to the 'F words (2001) in childhood disability', a conceptual foundation designed by the International Classification of Functioning, Disability and Health (ICF) (Rosenbaum & Gorter, 2012; Soper et al., 2019). It consists of 6 categories: function, family, fitness, fun, friends and future, which contribute towards participation in physical activity within a broader socio-ecological context (Rosenbaum & Gorter, 2012; Soper et al., 2019). The implications of all ICF 'F' words can play a role in the care and QoL of individuals with disabilities (Rosenbaum & Gorter, 2012; Soper et al., 2019; Kerem-Günel et al., 2023). Function and fitness involve an individual's body and structure in relation to their ability to participate in activities and tasks within a given environment, as often their impairments present challenges (Kerem-Günel et al., 2023). Fun refers to the personal factors of participation, with individuals with disabilities having lower rates of involvement in activities compared to able bodied individuals, due to activities not being as adaptive or as enjoyable (Rosenbaum & Gorter, 2012). Family and friends relate to the basic environment of the individual in terms of social interactions and an overall family-centred service as both often influence the wellbeing of the individual (Kerem-Günel et al., 2023). Future encompasses all aspects of the 'F' words in relation to the impact their condition has on their future development and in turn their overall QoL (Rosenbaum & Gorter, 2012). Overall, it is aimed towards providing a family-centred, strengths-based and holistic approach to child health and development (Cross et al., 2022). Engaging in these areas is important as it believed to provide a greater understanding of childhood disability, placing the emphasis on what an individual can do as opposed to their restrictions (Soper et al., 2019).

RaceRunning is a platform for inclusion amongst individuals with disabilities and could provide the opportunity for them to adopt an entirely different schema (Kossakowski et al., 2021). This can be through creating greater autonomy over their lives, promoting positive behavioural changes (Walkeden & Walker, 2015: Hartley 2019; Kossakowski et al., 2021) and encouraging a greater participation in physical activity for individuals with moderate-to-severe NDD (Bauman et al., 2006; Ryan et al., 2020b). Whilst RaceRunning is predominantly an individual sport, the formation of clubs across the UK

(Quest, 2020, June 2) enables individuals with NDD to form a community, building into the family and friends aspect of the ICF 'F' words. The physicality of RaceRunning itself targets both the function and fitness categories as the sport requires individuals to propel themselves forward and run, which studies have investigated further in relation to fitness outcomes such as cardiovascular fitness (Hjalmarsson et al., 2020). As the sport is specifically for individuals with disabilities, it is gives them the opportunity to enjoy participating in sport and be active (Van der Linden et al., 2022), which encompasses both fun and future aspects of the 'F' words as RaceRunning could lay the foundation to more activity and a better lifestyle.

Physical and psychological wellbeing is an important aspect of QoL, with physical activity being considered the most influential in improvements regarding autonomy and independence (Dahan-Oliel et al., 2012; Zhang & Chen, 2019). Whilst resistance exercises have been shown to produce the greatest physical benefits, teaching movements and sport skills provide both physical and psychosocial health benefits (Kapsal et al., 2019). In a recent survey, 93% of RaceRunning athletes reported improvements in self-confidence as a result of RaceRunning (Van der Linden et al., 2022). This is supported by Johnson (2021), as they investigated the psychological impact of RaceRunning, with athletes reporting the sport has improved their confidence, with a sense of inclusion and belonging being a big part of their social development (Johnson, 2021). Furthermore, they determined that these improvements in psychological wellbeing translated to greater positive QoL and health outcomes. This emphasises the importance of introducing RaceRunning to individuals with NDD.

Available research into RaceRunning have found improvements in QoL and overall wellbeing due to RaceRunning participation have been determined amongst surveys, whilst pilot and full-scale studies have reported improvements in bone health, competency using the racerunner (Johnson, 2021; Sukal-Moulton et al., 2022; Van der Linden et al., 2022; Van Schie et al., 2022), muscular thickness (9%) and cardiovascular and aerobic fitness (34%) (Donnell et al., 2010; Bryant et al., 2015; Phillips et al., 2017; Hjalmarsson et al., 2020). Locomotor adaptations, muscle fatigue and the influence of lower limb impairments on performance such as spasticity, poor voluntary motor control and reduced passive knee extension have also been assessed

within RaceRunning research (Kristjánsson, 2018; Van der Linden et al., 2018; Shafizadeh et al., 2019; Van der Linden et al., 2022). Although these findings are positive, due to NDD being a lifelong condition (Palisano et al., 2017), it is important to consider outcomes over a prolonged period. Overall, the research surrounding RaceRunning is very limited, with only a few studies focussing on the long-term effects of the sport on health.

RaceRunning is a sport that allows individuals with a wide variety of conditions the opportunity to participate in sport however, the high prevalence of individuals with CP that participate in RaceRunning often results in other NDD being excluded from research (Hjalmarsson et al., 2020; Kossakowski et al., 2021). Encouraging RaceRunning research to include a variety of disabilities and disorders would benefit the sport by spreading awareness. Researchers have stated that due to the specificity and technical requirements of RaceRunning, only individuals with CP can access the potential benefits (Kossakowski et al., 2021). The limited research available causes speculation and a need for investigation to determine the extent of potential benefits across multiple NDD conditions. This underlines the importance of investigating the health benefits to RaceRunning on a population of those with NDD that have limited opportunities for physical activity.



Figure 1. RaceRunning frame example taken from the side and rear. Cushioning is added to the chest plate and saddle to provide comfort. The RaceRunning frame is adjusted to a comfortable setting. Helmets are worn throughout training and competition. Permission was granted by the participant and parent to use these images.

1.1 Aims

This study is part of a multicentred feasibility trial in partnership with Queen Margaret University. This feasibility study aims to investigate the effects of RaceRunning on measures of physical health in individuals with moderate-to-severe NDD.

Measures include resting HR and BP, thigh and calf circumference, knee flexor and extensor strength, ankle plantarflexion strength, and the distance travelled during the 6-minute RaceRunning test at baseline and 12 weeks.

Kinematic gait analysis via sagittal joint angles will also be measured at and between the stance and swing phases in the ankle, knee and hip pre and post 12 weeks.

1.2 Hypothesis

The study hypothesis is that there will be a significant difference in measures of physical health between baseline and 12-weeks of RaceRunning training.

The study null hypothesis is that there will be no significant differences in measures of physical health between baseline and 12-weeks of RaceRunning training.

Chapter 2 – Literature Review

2.1 Neurodevelopmental Disabilities

Neurodevelopmental Disabilities (NDD) refers to a diverse group of conditions that can impact affected individuals throughout their whole life (Dahan-Oliel et al., 2012). It affects approximately 2% of the general population, with cognitive, physical and emotional impairments of varying degrees (Angriman et al., (2015). Conditions include cerebral palsy (CP), congenital anomalies, intellectual disabilities, genetic syndromes and neurological disorders etc (Jones et al., 2007; Shevell, 2010; Rosenbaum et al., 2007; Dahan-Oliel et al., 2012; Thapar & Rutter, 2015; Whitney et al., 2020). CP remains the largest single cause of childhood physical disability within the developed world, with a prevalence around 2.0-2.5 per 1000 live births (Surman et al., 2009). Defined as a movement and posture disorder, it is used to describe motor syndromes that are caused by nonprogressive contusions, lesions or malformations during the early stages of the developing brain (Rosenbaum et al., 2007; Kristjánsson, 2018; Noorkoivet al., 2019; Jacobson, 2020). Congenital anomalies or more commonly referred to as birth defects, are structural or functional deviations that develop prenatally and may be identified before, at birth or later in life (WHO, 2022). Neurological disorders are structural, biochemical or electrical anomalies within the brain, spinal cord or other nerves throughout the body that result in a variety of symptoms (Siuly & Zhang, 2016). Research demonstrated that often these clinical manifestations and/or symptoms will change over time (Rosenbaum et al., 2007; Kvarnung & Nordgren, 2017; Gulati & Sondhi, 2018). The severity of the functional impairment can also alter due to a variety of factors (Hjalmarsson et al., 2020). It is therefore important to understand the various limitations associated with the condition severity as whilst some conditions are considered nonprogressive, the nature and severity of their disability may change over time.

2.1.1 Muscle Weakness

Understanding whether muscular strength can be developed or maintained by RaceRunning is of interest due to individuals with moderate-to-severe NDD having a reduced ability to weight bear, limiting their mobility and independence (Van der Linden et al., 2018; Ryan et al., 2020b). In general, individuals with physical disabilities may

present with muscle weakness due to inactivity, which can elevate the prevalence of secondary health conditions and complications such as reduced bone density and further reductions in muscular strength (Okuyama & Oka, 2009; Van der Linden et al., 2018; Shafizadeh et al., 2019; Whitney et al., 2020). In individuals with CP, muscle weakness can occur due to lesions within the brain, impairing cortical innervation of descending pathways, resulting in secondary adaptations such as smaller muscle size and reduced muscle activation (Hussain et al., 2014). Reports show a 30-35% decrease in muscular strength within the dorsiflexors and plantar flexors in individuals with CP, when compared to TD peers (Burdea et al., 2012). Decreased knee extension strength in adolescents is associated with further increases in disability in adulthood (Henriksson et al., 2019; Fraser et al., 2021). This is primarily due to the gradual deterioration of muscular function if left untreated (Boström & Ahlström, 2004). As individuals with severe impairments have a wide variation in motor control capacity and restricted mobility, determining muscle strength could be an important consideration. The combination of muscular weakness and reduced aerobic fitness are important risk factors that can cause subsequent disability (Henriksson et al., 2019). This can lead to a cycle of inactivity, increasing muscular weakness and potentially accelerating the progression of their condition (Durstine et al., 2000; Boström & Ahlström, 2004). This highlights the importance of developing interventions that promote muscular growth and strength, to reduce the overall deterioration of their condition.

Poor selective control of the ankle dorsiflexors and spasticity and muscle weakness of the plantar flexors can cause the foot to drop, increasing the incidence of tripping and falling (Mathewson & Liebar, 2015; Moll et al., 2017). Defined as an abnormal muscle contraction, spasticity is characterised by an increased velocity dependent tonic stretch reflex, in combination with exaggerated tendon jerks resulting from stretch reflex hyperexcitability (Jones et al., 2007; Etoom et al., 2018; Lindén et al., 2019). It can impair the full range of motion of a joint through a shorter muscle-tendon-complex length (Mockford & Caulton, 2010; Mathewson & Liebar, 2015; Jacobson, 2020). Within a normal muscle bundle, the composition of a muscle consists of 95% of muscle fibres (Lieber et al., 2003). Spastic muscles have been found to consist of 40% of muscle fibres with increases in intramuscular fat and connective tissue (Lieber et al., 2003;

Mockford & Caulton, 2010). In cross section, spastic muscle exhibits abnormalities such as fibre size variability, increased rounded and 'moth-eaten' fibres and in some instances, increased extracellular space (Lieber et al., 2003; Foran et al., 2005; Mockford & Caulton, 2010). This contributes towards the abnormal contractions often observed in individuals with spasticity (Jones et al., 2007; Etoom et al., 2018; Verschuren et al., 2018; Lindén et al., 2019). In combination, muscle weakness, spasticity and poor selective motor control can inhibit mobility, which subsequently worsens due to inactivity.

2.1.2 Reduced Muscle Size

Abnormal or reduced muscle tone is an underlying developmental impairment often observed within this population resulting in associated complications (Dahan-Oliel et al., 2012). In individuals with CP, muscle volumes have been found to be reduced up to 50% in the lower limbs compared to TD peers, particularly in the paretic limb (Shortland, 2009; Dahan-Oliel et al., 2012; Hussain et al., 2014). Children with NDD may appear weak due to the alterations within the myosin expression and potential structural abnormalities during the perinatal period (Mockford and Caulton, 2010). These include sarcomere length, fibre size, whole muscle length and cross-sectional area and viscoelastic properties (Theis et al., 2016; Mockford & Caulton, 2010). Gastrointestinal problems, growth, malnutrition and inactivity have also been shown to contribute towards decreased muscle size in individuals with NDD (Liptak et al., 2001; Sullivan, 2008; Opheim et al., 2009; Guleti & Sondhi, 2018; Kristjánsson, 2018; Jacobson, 2020). This can be related to the prevalence of sedentary behaviour, with increases in condition severity being associated with greater healthcare days and missed social activity opportunities (Stevenson et al., 2006). These limitations on opportunities for physical activity may lead to physical deterioration and further health complications.

Small muscle size can be associated with spasticity and limited activity, with a link towards cardiovascular and coronary diseases (Heitmann & Frederiksen, 2009; Chen et al., 2018). In relation to function, a study of 38 children with CP saw those with more severe impairments showed greater indications that decreases in muscle thickness linked to decreased functional capacity (Mockford & Caulton, 2010). This is due to reduced selective motor control in individuals with CP being unable to reflect the forces

produced during physical activity (Noble et al., 2019). It is therefore important to consider both muscle control and muscle size when conducting research on individuals with moderate-to-severe NDD to more accurately explain RaceRunning outcomes.

2.1.3 Gait/Kinematics

Restricted mobility in NDD populations is a key influence on physical health due to the limited opportunities to be active. Difficulties in maintaining an ankle isometric contraction within the fascicles and poor selective control of dorsiflexors can lead the foot to drop (Moll et al., 2017; Noorkoiv et al., 2019). This reduces walking efficiency, resulting in a higher consumption of oxygen, increasing heart rate and greater levels of fatigue (Almuhtaseb et al., 2014). Reduced knee and hip joint extension are also associated with inefficiency of gait in NDD populations, as 50% of the energy expenditure is utilised to lift the centre of mass (Dallmeijer et al., 2017; Noorkoiv et al., 2019; Hjalmarsson et al., 2020). The increased energy expenditure and fatigue can often influence decisions regarding physical activity participation (Mockford & Caulton, 2010; Mathewson & Liebar, 2015; Smith et al., 2019; Johnson, 2021). Furthermore, the inefficiency in walking gait plays a considerable role in the reduction of mobility, adding both physical and psychological factors towards inactivity within the NDD population (Ong et al., 2019). This can be through decreases in confidence when balancing and a greater perceived limitation in walking ability (Nogueira et al., 2013). Individuals reported 'unwanted attention' due to their gait, using walking aids as a result of dysfunctional gait, increased energy demands and overall, a reduced functional capacity (Gjesdal et al., 2020). It is therefore important to investigate the different avenues of potential improvement in walking gait, kinematic values and overall mobility. As RaceRunning enables individuals with moderate-to-severe NDD to be more independent and active (Kristjánsson, 2018; Shafizadeh et al., 2019; Kossakowski et al., 2021) and there being limited research surrounding the topic (Shafizadeh et al., 2019; Maas & Vanwanseele 2022), understanding the kinematics of RaceRunning could help further develop the sport and encourage future research.

2.2 Reduced Physical Activity and Secondary Health Problems

Individuals with NDD have a high prevalence of health disparities with the associated risk often being attributed by condition severity (Jeon et al., 2015; Whitney et al., 2020).

Restricted functional mobility and increased sedentary behaviour have been shown to increase the risk of developing secondary health conditions and/or comorbidities (Carlon et al., 2013; Lauglo et al., 2016; Noorkoiv et al., 2019). Comorbidities refers to a list of relevant diseases, disorders or illnesses that coexist with another condition (Hall, 2006; Sethi, 2010). Physical activity has been shown to alleviate health-related problems, but is often dependent on the individual's ability to be active on a regular basis (Shafizadeh et al., 2019; Jacobson, 2020; Shirazipour et al., 2020; Johnson, 2021). However, approximately 70-75% of individuals with a disability do not participate in any physical activity, with habitual activity levels being 30% below recommended guidelines (Carlon et al., 2013; Shafizadeh et al., 2019). It has also been shown that immobility has been independently predictive of low levels of physical activity (p = 0.007) (Finlayson et al., 2009). Due to many individuals with moderate-to-severe NDD being unable to be active as a result of their condition, it is important to distinguish the consequences of inactivity within this population, with the potential of utilising RaceRunning to reduce these associated risks.

2.2.1 Cardiovascular Responses

Cardiovascular disease are the leading cause of mortality worldwide, with reduction in physical activity contributing towards this associated risk (Mc Namara et al., 2019). This is particularly prevalent amongst NDD populations due to restricted mobility (Whitney et al., 2020). Heart rate (HR) and blood pressure (BP) are widely used to assess health statuses and cardiovascular risk, with a resting heart rate (RHR) between 60-80bpm and a BP of 120/80 mmHg being deemed to be healthy amongst the general population (Cook et al., 2006; Ryan et al., 2015; Guo et al., 2019; Osibogun et al., 2020; Reedman et al., 2022). In conditions such as CP, they have a less efficient autonomic mechanism at rest and are less adaptive to exercise compared to TD peers (Gąsior et al., 2020). This is an important consideration to the study as NDD is a diverse population, adaptations such as reduced RHR may not be apparent across all participants.

When an injury occurs within the cerebral cortex and/or the cerebellum on either side, it can cause a central dysregulation of the sympathetic and parasympathetic outflow to the cardiovascular system, increasing HR (Shanks & Herring, 2013; Shaffer & Ginsberg, 2017; Findling et al., 2020). Individuals with CP have a higher average RHR (104.34 ±

20.30) compared to TD peers (84.17 \pm 13.27) (Ferreira et al., 2011). Due to the nature of NDD conditions, the abnormal RHR places them at a greater risk of a cardiac event (Tadic et al., 2018). Studies have determined that individuals with a RHR of above 80bpm have a 47% increased risk of haemorrhagic stroke, 38% for ischaemic stroke and 65% of an unclassified stroke compared to a RHR of below 65bpm (Tadic et al., 2018; Mills et al., 2020). The prevalence of cardiovascular risk within NDD population emphasises the importance of engaging in physical activity to regulate and improve cardiovascular health.

Measuring RHR through heart rate monitors has proven to be a repeatable and valid method of assessing cardiac health amongst the general population (Engström et al., 2012; Chow & Yang, 2020). Engström et al., (2012) did this through determining a correlation coefficient of 0.97 – 1.0 in relation to an ECG machine for validity. For repeatability, they expressed the coefficient of repeatability variation in percent with the mean ECG measurements being 9% and the polar measurements at 11% and reported no significant differences. This is supported by Waninge et al., (2013), as they stated that the validity of the Polar monitors in recording heart rate had been tested against a variety of electrocardiograms. They also utilised the devices in their study whereby individuals with profound intellectual and multiple disabilities were assessed. Ge et al., (2016) also supports the accuracy of chest strap heart rate monitors as it produces a more accurate reading than other portable heart rate equipment. This endorses the use of the devices within current research and in future studies where individuals with disabilities are involved.

High levels of sympathetic activity are associated with increasing cardiovascular risks such as hypertension (Mancia et al., 2021). This can result from a dysregulation of afferent input and central integration of autonomic balance (Shanks & Herring, 2013). Hypertension is defined as a systolic BP above 140mmHg and/or a diastolic BP above at 90mmHg (Mills et al., 2020). Utilising non-invasive BP monitors is a common clinical practice amongst researchers as it is an easy and repeatable measure of collecting resting BP (Marshall et al., 2002). An investigation into the validation of non-invasive central BP devices was conducted, concluding that following the correct protocol, the BP monitors can be considered a reliable and valid method of assessing BP (Sharman

et al., 2017). These include listing the manufacturer model, defining, and using appropriate cuff sizes, familiarisation of the testing procedure to the participants and performing multiple tests with the removal of outliers if needed. Additional influences should also be considered when collecting BP measurements as whilst familiarisation of testing procedures is key for reducing psychological influences, the "white coat" effect has been reported in previous studies to increase systolic and diastolic BP (Kallioinen et al., 2017; Buljina et al., 2022). Research has shown that significant increases in systolic and diastolic pressure during the first 10 seconds of cuff inflation (p<0.05) (Gazzola et al., 2018). These findings outline the psychological influences associated with increased BP and should be made aware when utilising this method. In a study conducted by Jung et al., (2015), they evaluated the accuracy and validity of home blood pressure monitors, concluding that validated machines were 85.4% accurate. There were also reports of significant differences in accuracy in validated versus non-validated devices (p = 0.017). This highlights the importance of utilising validated BP monitors in addition to following correct procedures to increase the likelihood of valid and reliable data collection.

Restricted functional mobility and sedentary behaviours have been shown to cause vascular remodelling as blood vessels narrow, increasing the risk of hypertension (Carlon et al., 2013; Lauglo et al., 2016; Caruso et al., 2017; Noorkoiv et al., 2019; Song et al., 2020). Physical activity at a high intensity has been shown to be a key influence on the improvement of cardiovascular health (Lauglo et al., 2016; Van Biljon et al., 2018), however, in individuals with mobility or cognitive impairments, this may not be possible (Johnson, 2021). This is particularly apparent amongst more severe conditions, due to the added mobility restrictions associated with their condition (Liptak et al., 2001; Jacobson, 2020). As RaceRunning is often implemented at a high intensity (Donnell et al., 2010; Hjalmarsson et al., 2020), it is possible for cardiovascular changes to occur. However, this possibility has yet to be investigated, highlighting the importance of determining the potential for RaceRunning to improve cardiovascular health.

2.2.2 Cardiorespiratory Fitness

Cardiorespiratory fitness is reflective of cardiovascular, metabolic and functional health (Butler et al., 2010; Billinger et al., 2012). Individuals with NDD have been shown to

have poor cardiorespiratory fitness compared to TD individuals due to higher oxygen uptakes and lower physical work capacities (Butler et al., 2010; Ryan et al., 2015; Bricout et al., 2018; Hjalmarsson et al., 2020). In addition, it is important to consider the type of condition an individual has as well as the level of severity when assessing cardiorespiratory fitness. For instance, individuals with Morquio syndrome have been shown to have deformed thoracic cages, which in combination with paralysis of the respiratory muscles and the deposition of mucopolysaccharides in the soft tissues, can result in respiratory issues (Savci et al., 2006). In CP, differences in respiratory function can be related to condition severity, with reports that individuals with GMFCS level III having worse pulmonary capacity and weaker respiratory muscles compared to lower GMFCS classifications (Kwon & Lee, 2014). This can be attributed to reductions in walking efficiency, resulting in higher oxygen consumption, increasing fatigue and cause a cessation in physical activity (Almuhtaseb et al., 2014). Overall, this can hinder their ability to perform activities of daily living (ADLs), reducing independence and impairing multiple systems (Durstine et al., 2000). This can lead to a cycle of deterioration, deterring the individual from participating in ADLs (Ryan et al., 2015; Johnson, 2021).

Improvements in cardiorespiratory fitness can produce physiological adaptations that can improve the efficiency of the circulatory and respiratory transport system, providing numerous health benefits (Cairney et al., 2017). Furthermore, high habitual physical activity levels have also been shown to reduce arterial stiffness, lower aortic media thickness and improve endothelial function (Haapala et al., 2017). However, the combination of mobility restrictions and decreased cardiorespiratory fitness in individuals with NDD, makes it challenging for them to meet the recommended exercise guidelines (Carlon et al., 2013; Shafizadeh et al., 2019). Research has determined that the sedentary times amongst young people with CP was twice the maximum amount recommended (Carlon et al., 2013). This places them at greater risk of developing further health complications (Liptak et al., 2001; Carlon et al., 2013; Shafizadeh et al., 2019; Jacobson et al., 2020; Johnson, 2021). This stresses the importance of engaging in physical activities that have a cardiorespiratory element that is suitable for participation in NDD populations. As RaceRunning can be associated with cardiorespiratory fitness (Hjalmarsson et al., 2020), it could provide individuals with

moderate-to-severe conditions the opportunity to reduce secondary health risks, improve their ability to perform ADLs and reduce the deterioration of their condition. The limited research available that investigates this potential improvement from RaceRunning it highlights the need to explore cardiorespiratory fitness further within the present study.

2.2.3 Quality of Life

Individuals with NDD present an important public health issue due to the impact of their condition on the QoL of the affected individual and their family (Dolk et al., 2010). Individuals with mobility difficulties report lower health related QoL scores compared to TD peers as a result of reduced mobility, as it can restrict their accessibility to physical and social environments (Block et al., 2005; Liang et al., 2011; Lampousi et al., 2020). Links between loneliness and mental health problems in children with NDD have been established which may impact and extend into adulthood (Kwan et al., 2020). This can lead to social isolation, which is an objective lack of interactions or withdrawal from friends, relatives or the wider community (Freeman et al., 2020). Social isolation occurs more frequently in individuals with disabilities due to their special needs, demands and restricted ability to socialise (Block et al., 2005; Freeman et al., 2020). Low habitual activity can have a detrimental effect on physical, psychological, behavioural and emotional health (Ryan et al., 2015). Researchers often strive to improve QoL within NDD populations, with some research determining some of the psychological benefits of RaceRunning (Johnson, 2021; Van Schie et al., 2022). Sport can provide a variety of psychosocial benefits such as increased self-esteem, wellbeing, QoL and reduced anxiety (Barak et al., 2016). This was demonstrated by Kapsal et al., (2019), determining the largest effect sizes were associated with psychological outcomes (g =0.754), behavioural outcomes (g = 0.986) and social outcomes (g = 0.723), with a 5.7% between-study variance. Developing and delivering effective intervention can provide physical and psychological benefits that can enable a better QoL for individuals with NDD.

Parents of children with NDD often experience a considerable burden from the need to attend specialty medical and allied health services such as neurology paediatrics and physiotherapy (Shevell, 2010; Novak-Pavlic et al., 2022). This can lead to greater

feelings of life dissatisfaction, with worse self-reported health statuses and health behaviours (Froehlich-Grobe et al., 2016). This can increase with condition severity due to having multiple health-related problems resulting in more days of social participation days missed (Boyle & Cordero, 2005; Froehlich-Grobe et al., 2016; WHO, 2022). The considerable burden placed on the individual and their support network demonstrates the need for effective and efficient long-term interventions (Carroll, 2019; Mitrushina & Tomaszewski, 2019) to improve overall wellbeing and health.

2.3 Interventions Available to Improve Physical Activity

Encouraging individuals with NDD towards physical activity can present a multitude of barriers (Shirazipour et al., 2020). Factors such as lack of facilities, transport limitations and a lack of inclusivity have been shown to be some of the main issues regarding physical activity participation (Rimmer, 2005; Jaarsma et al., 2015; Rimmer et al., 2017; Gagnon, 2020). This was demonstrated by Rimmer (2005) who determined that within indoor facilities, accessibility was restricted due to difficulties opening doors, smaller facilities and equipment such as cardiovascular machines being on different floors with no access apart from stairs. The outdoor environment can also be restricted due to the streets not having curbs, poorly lit facilities and the terrain being too difficult for individuals with disabilities to manoeuvre (Rimmer 2005; Rimmer et al., 2017). Similarly, whilst in the UK the curriculum contents are intended to provide students with disabilities the opportunity to participate in physical activity, it is often not applied, excluding them from such activities (Tant & Watelain, 2016). Healthcare practitioners and researchers are continuing to implement interventions to maintain physical activity and mobility (Park & Kim 2014; Kalkman et al., 2019), with an emphasis on the importance of designing interventions for their specific needs.

2.3.1 Established Interventions

There are a variety of interventions that promote the integration and participation in physical activity in individuals with NDD despite limitations due to impairments (Shevell, 2010). Functional electrical stimulation is used to stimulate impaired motor control muscles, causing the muscle to contract (Moll et al., 2017; Armstrong et al., 2020). After 8 weeks of functional electrical stimulation, cycling combined with goal-directed training and adapted cycling training, gross motor function (GMFM-88) significantly improved

from 52.8 to 62.6 in individuals with CP (GMFCS levels II – IV) (Armstrong et al., 2020). These interventions can result in specific muscular strength changes being observed, through improvements in active dorsiflexion angle, strength and overall selective motor control, balance and gait kinematics following a systematic review on functional electrical stimulation (Moll et al., 2017). Through a meta-analysis of cycling, resistance training, functional electrical stimulation and strengthening programmes, it was established that 40–50-minute sessions three times per week was the most optimal for muscular strength improvements (Park & Kim, 2014). This demonstrates that regardless of intervention type, improvements in muscular strength can be improved if conducted for a set time over a prolonged period.

Endurance training interventions have been shown to reduce RHR (Van Biljon et al., 2018), with positive correlations between RHR-decreasing effect and initial RHR (Reimers et al., 2018). Van Biljon et al., (2018) demonstrated that across 5-weeks, improvements in RHR were observed through high intensity interval training (92.0 ± 14.1 bpm to 79.2 ± 10.2 bpm), moderate-intensity continuous training (87.2 ± 10.6 bpm to 82.6 ± 12.8 bpm) and/or a combination of both (92.7 ± 13.3 bpm to 80.3 ± 10.3 bpm). High intensity interval training is often utilised in conjunction with endurance training to improve cardiorespiratory responses. Studies have determined that short-term cardiorespiratory training (approximately 2-4 months), increased aerobic fitness by 18-22% whereas long-term training (approximately 8-9 months) improved by 26-41% (Butler et al., 2010). Similar results were presented by Lauglo et al., (2016), as across 24 high intensity interval training sessions (2 - 4 sessions per week), there was a significant increase in VO2max of 10% and a decline in percent utilisation of VO2max (48.8 vs 39.4). High intensity interval training has been shown to reduce C-reactive protein (CRP) (p=0.016) an indicator for arterial inflammation, reducing the risk of developing coronary heart disease (Casas et al., 2008; Van Biljon et al., 2018). These physiological alterations could aid an individual in the improvement of cardiovascular and cardiorespiratory health, reducing the overall risk of the development of secondary health conditions. This emphasises the importance of long-term interventions to improve cardiovascular and cardiorespiratory health.

2.3.2 Interventions for moderate-to-severe conditions

Whilst many interventions promote an increase in physical activity, some inclusive programmes available may not be appropriate for everyone with a disability (Shields & Synnot, 2016). This is applicable in individuals with moderate-to-severe NDD (GMFCS III – V) as they have difficulties weight bearing and are more reliant on mobility aids than those with milder severities (GMFCS I – II) (Van der Linden et al., 2018; Shafizadeh et al., 2019). Limited access to adapted physical activities for moderate-to-severe conditions can prevent them from being active, making them more susceptible to additional health consequences (Surman et al., 2009; Ryan et al., 2020b). This is important to establish, as whilst interventions may be available, due to the severity of their condition they may not be physically able to participate, further restricting their opportunities to be active.

2.3.2.1 Boccia

Boccia is one of the most popular adapted sports for individuals with severe musculoskeletal disorders (Faria et al., 2014). A minimum of two players will compete, with the aim of throwing their ball closest to the target ball, 'the Jack' (Barack et al., 2016). It provides an opportunity for individuals with disabilities to integrate with a variety of people, reducing the feelings of social isolation and improving QoL (Łosień et al., 2018). In a longitudinal Boccia study across a 4-month period, psychological QoL saw improvements up to 29% (Barack et al., 2016). However, whilst it does provide many psychological benefits, there is little physiological benefit from participation that could reduce the risk of secondary health conditions due to the low cardiorespiratory demand (Carlon et al., 2013; Faria et al., 2014; Łosień et al., 2018; Hjalmarsson et al., 2020). The demand for sports and interventions to be developed that provide physiological and psychological benefits is prevalent amongst individuals with moderate-to-severe NDD.

2.3.2.2 Adapted Football

It has been established that in many instances, opportunities to participate in sport is often not applicable for individuals with more severe disabilities due to it being too physically challenging for them to engage (Jaarsma et al., 2015). Adapted sports such as powerchair football is a sanctioned sport available to individuals with severe mobility impairments (Barfield, Newsome & Malone, 2016). It is one of the fastest growing UK disability team sports, involving adapted electric wheelchairs for mobility and an enlarged football from which they play with (Muscular Dystrophy UK, 2015; Barfield et al., 2016). However similar to Boccia, whilst it the sport provides many psychological benefits including improved QoL (Jeffress & Brown, 2017), reports of physical benefits are limited. This still places them at risk of developing secondary health conditions.

2.3.2.3 RaceRunning

RaceRunning is a sport discipline based on strength and stamina that can enable those with moderate-to-severe NDD to be active (Kossakowski et al., 2021). Training sessions are designed towards developing the basic skills in using the RaceRunning frame, to progress onto a moderate-to-vigorous exercise intensity (Reedman et al., 2022). Many research articles have focussed on the psychological aspects of RaceRunning, with improvements exhibited in QoL, psychosocial aspects of life and overall health and wellbeing (Bryant et al., 2015; Johnson, 2021; Van der Linden et al., 2022). Physical benefits have also been investigated however available research is very limited.

Through ongoing research within RaceRunning, the 6-minute RaceRunning test (6MRT) was developed to enable researchers assess the physical capabilities of RaceRunning (Bolster et al., 2017; Hjalmarsson et al., 2020). Some researchers have stated that the 6MRT appears to be not exhausting enough, with some implications regarding cardiorespiratory fitness and experienced fatigue (Kristjánsson, 2018). The reliability and construct validity of the 6MRT was assessed by Bolster et al., (2017), via calculating the intraclass correlation coefficient (ICC), standard error of measurement (SEM) and the smallest detectable differences (SDD) of the test. They determined that the ICC of the test was 0.89 amongst GMCS level III and 0.91 for GMFCS level IV, supporting the use of the 6MRT as a reliable and repeatable method. Furthermore, they validated the test by comparing the two groups, finding that lower GMFCS levels translated to better 6MRT performances on two separate occasions, with a mean distance covered was 413 metres in GMFCS III and 239 metres in GMFCS IV after the second set of testing. This is important as the 6MRT could be used to track initial progress when first using the racerunner, which can be applicable to the present study (Johnson, 2021). Studies have utilised the 6MRT as a means of investigating the long-

term effects utilising 6MRT over a prolonged period (Sperl, 2018; Hjalmarsson et al., 2020; Sukal-Moulton, 2022) achieving mixed results, emphasising the demand for more research to be conducted utilising the test as a means of cardiorespiratory assessment.

Limited research has been conducted on the potential muscular adaptations from a prolonged RaceRunning intervention. In a 12-week RaceRunning study, medial gastrocnemius thickness increased by 9% proposing that the combination of low daily exercise and a low starting point, stimulated the hypertrophic response (Hjalmarsson et al., 2020). Measuring muscle thickness though anthropometric measurements such as muscle circumference has been utilised to estimate appendicular muscle mass, particularly calf circumference (Santos et al., 2019). This is beneficial as the NDD population reportedly have smaller muscles and increased muscular atrophy compared to TD populations (Verschuren et al., 2018). Thigh circumference is also used as a determinant of health, due to a low thigh circumference being associated with increased risk of cardiovascular mortality (Chen et al., 2020). In combination with restricted mobility, this could increase the risk of further health complications.

Utilising a tape measure has been a reliable method of recording muscle circumference, with minimal modifications (Kennedy et al., 2022). An investigation into the reliability of tape measurement assessments was conducted, determining the reliability coefficient of measures being 0.996 (Labs et al., 2000). Previous studies have utilised the anthropometric measurements as a basis for assessing the validity and reliability of other new established methods, with supportive findings in terms of reliability but varying degrees of validity depending on the participants recruited (Xia et al., 2019; Kennedy et al., 2022). In a validity study by Layec et al., (2014), they determined that whilst anthropometric measurements often overestimated muscle volume, it was proportional to the volume determined by MRI with close correlation scores between the two ($r^2 = 0.89$ in the thigh and 0.98 in the lower limb). They also stated that these results confirmed anthropometric measurements provide a valid index for muscle volume and with appropriate corrections, could be applicable for individuals with severe muscle atrophy. Following the guidelines (Labs et al., 2000), anthropometric measurements provide repeatable and cost-effective methods that although time-consuming, can be produced on a large scale. It is important to understand the various reliability, validity

and repeatability of selected methods in order to gage the potential limitations associated within the intended study.

As muscle weakness is one of the main symptoms associated with individuals with NDD (Lindén et al., 2019; Ryan et al., 2020b), studies have been conducted using isometric strength tests to determine RaceRunning classifications (Van der Linden et al., 2021). Isometric strength has not been conducted in relation to health and the potential longterm effects of RaceRunning. Furthermore, whilst these interventions are beneficial, they utilise individuals with experience within the sport. It is important to understand the extent of RaceRunning on inexperienced individuals, as it gives researchers a greater overview of the sport as a potential therapeutic treatment intervention. Considerations for hand-held dynamometry such as accounting for reported measurement error, separating muscle groups into impaired and less impaired, and reporting strength in relation to body weight or as a torque measurement were reported when assessing individuals with CP (Crompton et al., 2007). When muscle groups are stabilised, the hand-held dynamometer is a valid source as compared to an isokinetic dynamometer, with strong positive correlations between the two for both flexor (r = 0.72) and extensor isometric strength (r=0.82) (Muff et al., 2016). Furthermore, reproducibility saw a coefficient of variation to be 3.2 - 4.2%. An investigation into the reliability of the handheld dynamometer in individuals with CP was conducted determining that correlation coefficient values of single use being between 0.7 and 0.9 across all lower limb muscle groups (Willemse et al., 2013). Furthermore, additional testing reduced the smallest detectable change from 9% to 14%. Overall, utilising hand-held dynamometers has been determined to be a valid and reproduceable method of assessing isometric strength in individuals with NDD (Crompton et al., 2007; Willemse et al., 2013; Muff et al., 2016).

Due to the limited research available on RaceRunning, it is important to explore other avenues that can be developed and contribute towards future research. Physical activity interventions such as RaceRunning are being designed with the aim to improve mobility and functionality (Ryan et al., 2020b; Johnson, 2021). Researchers have established five different RaceRunning styles that were dependent on disability type (Mac Cann, 2018). Shock absorption patterns have also been established in RaceRunning, with

resemblances to forefront runners without disabilities as characterised by an active peak during the initial stance phase (Shafizadeh et al., 2019). This emphasises the importance of identifying kinematic values on a variety of individuals and the potential of determining gait kinematic values in motion across a prolonged period.

When collecting kinematic values, research has been conducted in a variety of ways. In a 12-week of RaceRunning training intervention it was established that in the lessaffected side, passive hip flexion significantly increased (p= 0.015) whilst on the moreaffected side, passive ankle dorsiflexion significantly decreased (p = 0.026) (Hjalmarsson et al., 2020). Although these measures were collected through a physical examination at rest, the findings provide useful information in terms of the potential use of kinematic values in a RaceRunning intervention. An investigation of 2-dimensional video analysis determined it to be an accurate measurement tool when recorded within the camera's measurement plane with less than a 2° of measurement error when held in a fixed position error (Peebles et al., 2021). Furthermore, researchers found no clear trend on optimal kinematic parameters determining a better validity and reliability when categorising movement patterns rather than quantifying specific angles (Hensley et al., 2022). This is important as it ensures an appropriate selection of methods, with considerations to measurement parameters and categorising movements.

2.4 Summary

In conclusion, NDD populations are at risk of developing secondary health conditions and further health complications due to restricted mobility. This increases with severity as individuals classified as moderate-to-severe are unable to participate in physical activity on a regular basis. This is due to a multitude of barriers, of which one is the limited adaptability of sport. This creates a cycle of deterioration, with the subsequent cessation of physical activity. Whilst there are some sports available such as Boccia and Powerchair Football that provide individuals with moderate-to-severe disabilities the opportunity to participate and provide psychological benefits, there is little to no cardiorespiratory demand. It is therefore important to establish sports and interventions that can provide physiological benefits in addition to psychological. RaceRunning is a new and developing sport with reports of physiological improvements over a short and prolonged period. However, the research available is very limited, highlighting the need

for additional studies to focus on reproducible practices but also introduce aspects of RaceRunning that have not previously been considered.

Chapter 3 – Methods

3.1 Participants

Based on previous research (Hjalmarsson et al., 2020), an observed power of 0.8 and an effect size of 0.426, sample size calculations revealed an initial recruitment aim of 10 participants. 20 individuals with NDD who had been taking part in RaceRunning for <1 month were approached for the study. Participant recruitment was staggered across the year due to the timings of training sessions and the locations of the RaceRunning clubs. 15 individuals gave consent, 6 withdrew after baseline testing as they were not regularly attending RaceRunning sessions. The remaining 5 males and 4 females (18.1 ± 9.8y) completed the 12-week study. Participants were recruited across three RaceRunning clubs based in Cardiff (n = 3), North Devon (n = 3) and Gloucester (n = 3). Exclusion criteria consisted of no lower limb surgery within 12 months and no musculoskeletal injury within the last 6 months. Ethical approval was obtained from the University of Gloucestershire Research Ethics Committee. Information sheets and written and verbal informed consent was gained from participants (Appendix 1.2 and 1.4) and parents/guardians (if under the age of 18 y) (Appendix 1.3 and 1.4) prior to the commencement of the study.

3.2 Study Design

Participants were assessed at baseline (0 weeks) and 12 weeks. At each point, participants completed a series of tests measuring resting HR and BP, isometric strength of the knee and ankle, cardiorespiratory fitness, muscle circumference and running technique. Each week throughout the study period, participants took part in a 1hour RaceRunning session led by an experienced coach who had attended a RaceRunning coaching course. Training generally consisted of a warm-up, skills that were dependent on the aims of the session and a cool down (Johnson, 2021). Coaching style of each location slightly differed, with the location in Gloucester focussing on competitive elements, Cardiff was recreationally based, and North Devon was a combination of both. All participants adhered to between 75-90% of all sessions and the results were collected at baseline and at 12-weeks. Due to the limited research available in RaceRunning and the study being a feasibility study, there was no control group.

3.2.1 Ethical Principles

As the study recruited individuals that are within the vulnerable population category, ethical principles are especially important when conducting this intervention. To ensure non-maleficence and beneficence, participants always had a parent, carer or coach with them throughout testing procedures. To ensure autonomy, participants and parents were reminded that up to the point of submission, the individual was allowed to withdraw at any time. The principle of justice was upheld by treating the participants equally and fairly, ensuring that they understood the given tasks. Consent was given by the individual and from the parent/guardian if they were under the age of 18 either in writing or verbally. Confidentiality and anonymity were ensured by anonymising all data collected, removing any key identifiable features. All data collected will be held in a secure location for up to 5 years after the intervention from which it will be disposed of. A pilot study was also conducted to ensure the tests ran smoothly but also to reduce the risk of harm to the participants.

3.2.2 Pilot study

A pilot study was conducted prior to the main intervention. One participant separate from the main intervention group, completed the initial testing for all measures within the study. This ensured that the measures were suitable for the population and that the tests were conducted correctly. Any issues with tests were amended prior to the main intervention. This enabled the tests to be run smoothly and ensure the safety of the participants.

3.3 Procedures

Demographic information (Table 1.) was gathered prior to the commencement of this study. At each visit, measures of HR, BP, muscle circumference, isometric strength, cardiorespiratory fitness and running technique were taken.

3.3.1 Heart rate

HR monitors and ultrasound gel were applied and attached to the chest. Participants were asked to sit for five minutes prior to recording. Heart rate readings were then

recorded for a minute using the Polar H7[™] HR monitors (Models Fs3c, FT1, 610i, 810i, RS800CX, RCX5, FT7, Polar, Electro Oy, Kempele, Finland).

3.3.2 Blood pressure

A BP cuff was placed on the middle upper left arm (Omron M3 Intellisense device, Omron Healthcare, Kyoto, Japan) however if readings could not be obtained then BP was measured at the wrist (Omron RX-M, HEM-628-E, Omron Corporation, Kyoto, 600-8530, Japan). In total three participants did not record BP readings due to equipment failure or not giving consent for this section of the study.

3.3.3 Circumference

Thigh circumference was measured using an anthropometric tape measure (Silverline Tools Ltd, Yeovil, UK) at 50% of the line from the anterior superior iliac spine to the superior part of the patella whilst calf circumference was measured at the most prominent part of the muscle belly (Ryan et al., 2020b) to represent muscle size. As some conditions do not have an affected side, measurements were labelled as 'left' and 'right' for later analysis. Due to all tests being conducted outdoors, participants wore clothing appropriate for the weather conditions but wore the same for both baseline and 12-week testing periods. This ensured that the thickness of the material did not interfere during the anthropometric measurements. Three measures at each landmark were taken and averaged.

3.3.4 Strength

For the isometric strength tests, a handheld dynamometer pad (Lafayette Manual Muscle Test System, Model 01163, Lafayette Instrument Company, Lafayette, IN, USA) was placed on a circumferential line of the lateral malleolus (ankle) for knee flexion and extension (Fosang & Baker, 2006). Whilst sitting down, the leg remained in a neutral position (with the knee flexed at approximately 90 degrees) whilst the handheld dynamometer was placed on the anterior (front) surface of the leg for extension (left coefficient of variation [CoV] = 16.74%, right CoV = 17.39%) and posterior (back) surface for flexion (left CoV = 12.38%, right CoV = 13.94%). For plantarflexion strength, the knee remained in full extension, with the handheld dynamometer positioned on the metatarsal head (left CoV = 9.88%, right CoV = 12.61%). The researcher assisted in

moving the foot into the initial position (approximately 90 degrees or 'neutral') before the handheld dynamometer was placed, followed by stabilising the leg throughout the movement. Both left and right legs were assessed. For all strength assessments, the movement was demonstrated. Participants were instructed to perform three maximal trials for each movement which was recorded and averaged. Each trial consisted of a maximal isometric contraction for five seconds, with a 30 second rest in between to minimise variability due to fatigue. Verbal encouragement was given throughout.

3.3.5 6-minute run test

The 6-minute RaceRunning Running test (6MRT) is a reliable method of assessing cardiorespiratory fitness in this population (Bolster et al., 2017; Hjalmarsson et al., 2020). Participants began with a warm-up. Participants were asked to run for 6 minutes around a track and to cover as much distance as possible in that time. The distance covered was recorded as well as average speed over the 6 minutes. Verbal encouragement was provided throughout. Due to the intensity of 6MRT and the gradual increase in fatigue, this test was conducted on a separate occasion to all other tests. This ensured that participants could perform to the best of their ability.

3.3.6 Kinematic analysis

Reflective tape was placed on the participant's greater trochanter, lateral femoral epicondyle, lateral malleolus and fifth metatarsal on the right side of the body. To record the kinematic changes during running, a 2D Camera (Canon Inc., Tokyo, Japan) on a tripod was placed 5 metres back, perpendicular to the running track and triangulated to two cones 5 metres apart. This ensured the optical axis of the camera was aligned with the centre of the capture area on the track. Pan, roll and tilt were also adjusted. Height and zoom of the camera were also adjusted in accordance with the hip, knee and ankle.

Video recordings of the participant's gait were taken during the first initial stages of the 6MRT. It was then uploaded and analysed using Quintic Biomechanics version 26 (Quintec, Sutton Coldfield, UK). Speed across the 5-metres was also calculated. Analysis of hip knee and ankle were conducted in the sagittal plane, focussing on flexion-extension of the hip and knee. In the ankle, angles are in the sagittal plane and focus on dorsiflexion-plantar flexion. Reference points in the ankle throughout gait

include initial contact, mid-stance and toe-off during the stance phases and drawback, mid-swing and heel plant (Klaewkasikum et al., 2022). Four participants did not consent to be filmed and therefore were not included.

3.4 Data Analysis

Descriptive statistics (mean and standard deviation) were calculated for all tests using Excel (Version Excel 365). IBM SPSS (Version 28) was used for data analysis. The data collected was tested for normal distribution and differences between 0 and 12 weeks were assessed using a series of paired samples t-tests or Wilcoxon tests in the case of non-parametric data. An alpha level of $p \le 0.05$ was set for all statistical tests. The effect size calculated was referenced to Cohen's D, which sees small effect sizes around 0.2, medium effects around 0.5 and larger effect sizes around 0.8 (Goulet-Pelletier & Cousineau, 2018). Due to performing multiple t-tests, it does increase the possibility of a type 1 error whereby the null hypothesis is rejected (Banerjee et al., 2009) and so it should be considered when reviewing the results of the intervention.

Chapter 4 – Results

The study investigated a variety of areas through a series of t-tests and Wilcoxon tests to determine whether RaceRunning would improve initial scores, with mixed results. Table 1 illustrates the demographics of the recruited participants. Specific results have been discussed below, with interests in RHR, isometric strength and kinematic values.

	Description of
	participants (n=9)
Age (y)	18 ± 10
Sex	
Male	5
Female	4
Primary Diagnosis	
Ataxic CP	2
Diplegia CP	1
Dyskinetic (Dystonic) CP	1
Spastic Diplegia	1
Progressive Ataxia	1
Spina Bifida + CP	1
Morquio Syndrome	1
Undiagnosed	1

Table 1. Demographic information within this study.

4.1 Heart Rate and Blood Pressure

There was a significant reduction in RHR (0 weeks: 84 ± 22 bpm, 12 weeks: 74 ± 15 bpm) (z = -2.079, p = 0.038) (Figure 2) with an observed power of 0.541 and a medium effect size of 0.53. However, there was no significant change in resting systolic BP (0 weeks: 137 ± 18 mmHg, 12 weeks: 144 ± 19 mmHg) and diastolic BP (Figure 4) (0 weeks: 93 ± 10 mmHg, 12 weeks: 95 ± 28 mmHg) (systolic: t = -1.32, p = 0.242; diastolic: t = -0.846, p = 0.846). Within systolic BP, the observed power was 0.278 and effect size was 0.38 whilst diastolic BP resulted in an observed power of 0.70 and effect size of 0.10.




Figure 2. Differences in resting Heart Rate between baseline and 12-weeks of RaceRunning training, p = 0.038 (*).

4.2 Circumference

There was no significant change in thigh circumference in the left (0 weeks: 43.4 ± 10.6 cm, 12 weeks: 43.5 ± 11.2 cm) (t = -0.101, p = 0.922) or right legs (0 weeks: 44.1 ± 11.2 cm, 12 weeks: 43.1 ± 10.9 cm) (t = 0.882, p = 0.404) after 12 weeks of RaceRunning. For thigh circumference, the left observed power was 0.51 compared to the right which was 0.122. A small effect size of 0.01 in the left and 0.09 in the right was reported.

6.38 cm, 12 weeks: 31.7 ± 6 cm) (t = 1.094, p = 0.310). For calf circumference, the left observed power was 0.130, whilst the right was 0.158. A small effect size of 0.17 in the left and 0.14 in the right was reported.

4.3 Knee and Ankle Isometric Strength Test

There was a significant increase in knee flexion (KF) strength in both the left (45.2 ± 44 Nm to 64.5 ± 48.8 Nm) (z = -2.310, p=0.021) and right legs (41 ± 29.8 Nm to 71.1 ± 51.1 Nm) (z = -3.743, p = 0.006) following 12 weeks of RaceRunning (Figure 8.). Observed power was 0.679 in the left and 0.904 in the right. A medium effect size of 0.42 on the left side was calculated, whilst on the right there was a large effect of 0.61.

Significant improvements were also demonstrated in knee extension (KE) strength in the left leg (87.8 ± 53.7 Nm to 110.8 ± 63.7 Nm) (t = -2.967, p = 0.018) with an observed power of 0.739 and a medium effect size of 0.39. In the right leg non-significant results were reported (90.6 ± 53.1 Nm to 106.1 ± 52.8 Nm) (t = -2.079, p = 0.071) (Figure 9) with an observed power of 0.448 and a small effect size of 0.29.

No significant changes were found in plantarflexion strength observed after 12 weeks of RaceRunning in the left (56.3 ± 42.3 Nm to 74.2 ± 39.9 Nm) (t = -1.518, p=0.167) and right legs (44.7 ± 32.5 Nm to 62.1 ± 33 Nm) (z = 1.779, p=0.075). Observed power was 0.268 in the left and 0.508 in the right. Medium effect sizes of for both left (0.43) and right (0.53) was reported.




Figure 3. Differences in knee flexor strength for the left and right legs between baseline and 12-weeks of RaceRunning training, p<0.05(*).




Figure 4. Differences in knee extension strength for the left and right legs between baseline and 12-weeks of RaceRunning training, left - p < 0.05(*), right - p > 0.05.

4.4 6-minute RaceRunning Test

There was no significant change in distance covered over the 6-minute test between baseline ($802 \pm 412 \text{ m}$) compared to 12 weeks ($722 \pm 392 \text{ m}$) (t=1.672, p=0.155). Observed power was 0.275 with a small effect size of 0.20.

There was also no significant change in average speed over the 6 minutes at baseline $(2.2 \pm 1.2 \text{ m/s})$ and 12 weeks $(2.0 \pm 1.1 \text{ m/s})$ (t = 1.671, p = 0.156), with an observed power of 0.253 and a small effect size of 0.20.

4.5 Kinematic Values and Speed

There was no significant change in 5m running speed after 12 weeks of RaceRunning (0 weeks: 3.2 ± 2.1 m/s, 12-weeks: 2.3 ± 1.3 m/s) (t = 1.711, p = 0.148), with an observed power of 0.275 and medium effect size of 0.55.

No significant changes in ankle angle (Table 2) or hip angle (Table 4) throughout the gait cycle were observed after 12 weeks of RaceRunning. At the knee, there was a significant decrease in the amount of knee flexion from toe-off to drawback phase (t = - 2.966, p=0.041), drawback phase (z = -2.023, p = 0.043) and drawback to mid-swing phase (t = -7.598, p = 0.002), after 12 weeks of RaceRunning (Table 3).

Table 2. Average and SD of ankle kinematic values at baseline and 12-weeks					
	Baseline (°)	12-Weeks (°)	Significance (p value)	Observed Power	Effect size
Ankle					
Initial Contact	-2.5 ± 15.47	-0.16 ±10.82	0.829	0.054	0.18
IC -> MST	1.26 ± 14.98	0.13 ± 9.78	0.874	0.052	0.09
Midstance	7.36 ± 14.11	6.6 ± 12.25	0.893	0.053	0.06
MST ->TO	3.4 ± 12.14	1.55 ± 7.22	0.500	0.085	0.19
Toe-off	-9.77 ± 12.19	-15.62 ± 9.68	0.463	0.097	0.53
TO -> DB	-28.06 ± 13.80	-22.52 ± 10.21	0.391	0.117	0.46
Drawback	-21.32 ± 8.99	-18.46 ± 14.60	0.768	0.057	0.24
DB -> MSW	-6.28 ± 8.89	-7.56 ± 7.01	0.571	0.077	0.16
Mid-swing	12.82 ± 15.40	17.3 ± 3.82	0.674	0.072	0.40
MSW -> HP	5.64 ± 15.11	6.63 ± 8.12	0.871	0.052	0.08
Heel plant	-1.53 ± 9.38	3.62 ± 12.17	0.193	0.228	0.47
HP ->	-7.49 ± 9.93	1.01 ± 13.24	0.167	0.255	0.73

Negative values represent dorsi flexion. Positive values represent plantarflexion

Table 3. Average and SD of knee kinematic values at baseline and 12-weeks.					
	Baseline (°)	12-Weeks (°)	Significance	Observed	Effect
			(p value)	Power	Size
Knee					
Initial Contact	-5.94 ± 8.19	0.26 ±10.49	0.363	0.126	0.60
IC -> MST	-5.64 ± 11.14	0.5 ± 11.52	0.124	0.321	0.54
Midstance	-0.78 ± 17.26	0.1 ± 22.09	0.782	0.56	0.04
MST ->TO	0.71 ± 14.10	3.25 ± 18.61	0.520	0.086	0.002
Toe-off	17.69 ± 5.18	14.66 ± 16.83	0.686	0.065	0.24
TO -> DB	24.55 ± 8.17	15.57 ± 10.06	0.041*	0.610	0.98
Drawback	45.52 ± 21.58	26.96 ± 11.34	0.043*	0.765	1.07
DB -> MSW	53.52 ± 17.87	27.27 ± 11.06	0.002*	1.000	1.77
Mid-swing	49.65 ± 24.99	33.08 ± 6.93	0.287	0.159	0.70
MSW -> HP	33.82 ± 23.64	18.28 ± 12.82	0.296	1.000	0.82
Heel plant	11.49 ± 19.70	-0.08 ± 11.99	0.349	0.131	0.70
HP ->	3.89 ± 12.00	-1.23 ± 12.52	0.686	0.077	0.42

*p<0.05. Negative values represent extension. Positive values represent flexion

	Table 4. Average and SD of hip kinematic values at baseline and 12-weeks					
	Baseline (°)	12-Weeks (°)	Significance (p value)	Observed Power	Effect size	
Hip						
Initial Contact	9.18 ± 14.38	6.1 ± 14.42	0.489	0.092	0.21	
IC -> MST	3.31 ± 16.65	7.89 ± 14.04	0.393	0.116	0.30	
Midstance	-5.2 ± 19.83	1.76 ± 24.52	0.261	0.174	0.31	
MST ->TO	-14.28 ± 19.08	-6.28 ± 21.06	0.250	0.181	0.40	
Toe-off	-18.62 ± 16.05	-12.12 ± 19.37	0.247	0.183	0.37	
TO -> DB	-17.49 ± 9.83	-8.95 ± 20.76	0.062	0.187	0.53	
Drawback	-3.64 ± 14.54	-11.18 ± 13.59	0.241	0.187	0.54	
DB -> MSW	8.0 ± 7.96	-3.35 ± 16.37	0.80	0.495	0.88	
Mid-swing	28.54 ± 18.50	18.12 ± 18.37	0.148	0.281	0.57	
MSW -> HP	28.97 ± 15.51	19.49 ± 24.40	0.144	0.287	0.46	
Heel plant	28.5 ± 17.41	15.74 ± 13.78	0.076	0.443	0.81	
HP ->	25.44 ± 14.17	15.3 ± 13.54	0.065	0.485	0.73	

Negative values represent extension. Positive values represent flexion.

Chapter 5 – Discussion

Individuals with moderate-to-severe NDD have reduced levels of physical activity, increasing the risk of secondary health-related problems (Van Biljon et al., 2018; Jacobson, 2020; Whitney et al., 2020). Finding ways in which these individuals can access physical activity capable of improving physical health outcomes is a priority amongst researchers (Carlon et al., 2013; Kristjánsson, 2018; Sukal et al., 2022). The purpose of this study was to investigate the effect of 12-weeks of RaceRunning training on physical health amongst individuals with moderate-to-severe NDD. Overall, there were no significant changes in resting BP (systolic 137 ± 18 mmHg versus 144 ± 19 mmHg and diastolic 93 \pm 10 mmHg versus 95 \pm 28 mmHg, p > 0.05), thigh (left 43.4 \pm 10.6 cm versus 43.5 ± 11.2 cm, p = 0.992, right 44.1 ± 11.2 cm versus 43.1 ± 10.9 cm, p = 0.404) and calf circumference (left 32.9 ± 8.1 cm versus 31.6 ± 6.1 cm, p = 0.377, right 30.9 ± 6.38 cm versus 31.7 ± 6 cm, p = 0.310), 6MRT (802 ± 412 m versus 722 ± 392 m, p = 0.155), plantarflexion strength (56.3 \pm 42.3 Nm versus 74.2 \pm 39.9 Nm, p = 0.167) and the majority of kinematic values (p>0.05) over 12 weeks. Only RHR (84 ± 22) bpm versus 74 \pm 15 bpm, p = 0.038), knee flexion strength (left 45.2 \pm 44 Nm versus 64.5 ± 48.8 Nm, p = 0.021, right 41 ± 29.8 Nm versus 71.1 ± 51.1 Nm, p = 0.006) knee extension strength on the left leg $(87.8 \pm 53.7 \text{ Nm versus } 110.8 \pm 63.7 \text{ Nm}, p = 0.018)$ and knee kinematic values during toe-off, toe-off to drawback and drawback to midswing phases (p<0.05) demonstrated significant changes following 12-weeks of RaceRunning. Overall, the findings of the study demonstrated the overall acceptance of the null hypothesis.

One consideration that should be acknowledged is the statistical analysis used in the present study. When conducting analysis on data, it is important to identify whether the variable being compared between data collection groups is normally distributed (Sedgwick, 2015). This is due to there being differences in the specific hypotheses being tested. The null hypothesis of a two-sample t-test (parametric) is that the mean of the two groups is equal; whereas the null hypothesis of the Wilcoxon test (non-parametric), is that the probability distributions of the two groups are equal (Goldstein-Greenwood, 2022). Whilst it is accepted amongst researchers to utilise both methods of

analysis (Sedgwick, 2015; Goldstein-Greenwood, 2022), it is important to recognise these dissimilarities when determining the outcome of the present study.

5.1 Heart Rate and Blood Pressure

One important finding was the significant reduction in resting heart rate (RHR) of participants from 84 ± 22bpm to 74 ± 15bpm (p=0.038) over the 12 weeks. RHR is a significant determinant of cardiovascular health (Cook et al., 2006; Ryan et al., 2015; Guo et al., 2019; Jensen, 2019; Reedman et al., 2022), with research showing that individuals with a RHR between 70-79bpm have a greater cardiovascular health outlook than those with RHR above 80bpm (Osibogun et al., (2020). It has been widely reported that training at a heart rate close to 70-80% of the maximum heart rate can bring about positive changes in RHR (Sylta et al., 2014; Lauglo et al., 2016; Van Biljon et al., 2018), however it is not clear if these thresholds also apply to those with NDD. Children with CP have been shown to have an average RHR of 104 ± 20 bpm compared to the average in TD peers of 84 ± 13 bpm (Ferreira et al., 2011). In individuals with Morquio syndrome, their lower left ventricular dimensions, lower stroke volumes and smaller left ventricular mass in addition to higher wall thickness and higher work index, makes it difficult for them to maintain cardiac output (Hendriksz et al., 2015; Kampmann et al., 2016). This results in increases in RHR of up to 21% (94.5 ± 2.7 bpm) compared to TD peers (Kampmann et al., 2016). This associated risk increases the likelihood of developing a cardiometabolic morbidity, with research determining that individuals with CP or spina bifida, have a significantly higher (41.5%) risk compared to those without either condition (30.6%) (Peterson et al., 2020). It is therefore important to find activities capable of inducing a cardiovascular response to lower RHR (Piepoli et al., 2014). Hjalmarsson et al., (2020) determined the average heart rate throughout RaceRunning training sessions was 136bpm or 69% of estimated heart rate max. Despite heart rate not being measured during training in the present study, the previous research coupled with reductions in RHR found in this study, demonstrates that RaceRunning could induce a positive cardiovascular response.

Despite the positive change in RHR, there was no significant change in resting blood pressure (BP). Moderate-to-vigorous physical activity has been associated with reductions in cardiometabolic diseases risk factors such as elevated BP (Theis et al.,

2021). Sustained changes in resting BP have been shown to be affected by duration, intensity and frequency of training sessions (Lee et al., 2010). Previous physical activity trials that have shown improvements in resting BP, have tended to include longer intervention periods and higher intensities (Johnson et al., 2007; He et al., 2018; Van Biljon et al., 2018). An investigation into the effects of 8 weeks of high intensity interval training, twice weekly on health and fitness on individuals with disabilities was conducted (Zwinkels et al., 2019), determining a significant reduction in systolic (pre = 123 ± 14.0 bpm, post 20 ± 12.8 bpm, p = 0.008) and diastolic (pre = 7.8 ± 10.3 bpm, post = 65.4 \pm 8.5bpm, p = 0.022) BP. This supports and challenges the present study, due to the timeframe of their investigation (Zwinkels et al., 2019) being shorter but had an increase in frequency of sessions. In a RaceRunning specific intervention, Hjalmarsson et al., (2020) monitored the intensity of training sessions and stated participants were encouraged to have a high work rate. This bears similarities to the present study, as due to the nature of the data collection being from 3 different RaceRunning clubs and each offering varying levels of training, the intensity of sessions was not controlled. This can make it difficult to determine whether the present intervention needed to have a higher frequency of training sessions and an extended period of monitoring, or whether the RaceRunning training itself does not elicit positive changes in BP. Establishing the timeframe threshold and dosage could be useful in future RaceRunning research.

The methods of collecting BP in those with NDD can also introduce error within the measurement. For example, incorrect BP cuff size has been reported to influence systolic and diastolic BP, with discrepancies as large as 30 mmHg (Palatini & Asmar, 2018). Cuff sizes deemed too large saw a 10-30 mmHg decreases in BP whilst cuff sizes deemed too small resulted in increases in BP levels by 2-8 mmHg in obese people and around 30 mmHg in individuals of a healthy weight (Tolonen et al., 2015). In individuals with a shorter arm length relative to circumference such as those with NDD, proper cuff fit can be problematic (Palatini et al., 2020) leading to inaccurate results. One further variable with the potential to influence results was the environmental impact of weather and temperature on BP readings. Testing sessions were staggered over June-December and were often taken outside at the track where participants trained. Exposure to cold temperatures has been shown to increase systolic BP (5-32 mmHg)

and diastolic BP (4-23 mmHg) (Kallioinen et al., 2017) through activation of the sympathetic nervous system. This elevates angiotensin II levels (protein hormone that causes blood vessel narrowing) and stimulates the release of the neurotransmitter norepinephrine, activating the renin-angiotensin system and increasing BP (Zhang et al., 2014). Thus, it is possible that methodological factors influenced the change in BP recorded from baseline to post intervention.

Whilst reductions in BP were not demonstrated in the present study with RaceRunning, the selection of participants could have played a role in this outcome. A significant correlation was found between disability type and severity with the occurrences of hypertension (p < 0.001) (Lin et al., 2012). In addition, when adjusting for demographic variables, there were higher instances of hypertension in physical disabilities compared to other disabilities (Wu et al., 2021). Researchers have stated that most studies often focus on hypertension in the general population rather than the subpopulation that experience disabilities (Nam & Yoon, 2022). This can be related to previous RaceRunning studies as although RaceRunning is open to anyone with a disability (Lebau, 2020), RaceRunning specific interventions predominantly focus on the effects on CP, due to majority of participants having this condition (Kristjánsson, 2018; Hjalmarsson et al., 2020). There is however a shift towards inclusivity of participants as more recent studies (Sukal-Moulton et al., 2022; Van Schie et al., 2022) have branched out to other conditions such as arthrogryposis, Dandy-Walker malformation transverse myelitis and other neurological disorders with promising results in similar or contrasting measurement outcomes. As no previous RaceRunning studies were found investigating resting BP, it is important to consider whether the outcomes of the present study were due to the severity of conditions, the types of disabilities participating, or if the methods of collecting BP contributed towards the non-significant outcome. More research into this area should be considered to get a better understanding of the impact RaceRunning has on cardiovascular outcomes.

5.2 Thigh Circumference, Calf Circumference and Isometric Strength

Within the general population, low thigh and calf circumference is associated with higher risks of all-cause and cardiovascular mortality (Abreo et al., 2021). As individuals with moderate-to-severe disabilities have restricted mobility (Jacobson, 2020), this can

increase their associated risk. Researchers confirmed this with reductions in lower limb muscle volume of up to 50% in individuals with CP compared to TD peers being determined (Shortland, 2009; Dahan-Oliel et al., 2012; Hussain et al., 2014), highlighting the importance of this outcome measure within the present study. Thigh and calf circumference showed no significant changes following 12 weeks of RaceRunning training. In a group of individuals with CP, research has found that on the least affected side, there was no change in muscle thickness after 12-weeks of RaceRunning training (Hjalmarsson et al., 2020) which supports our findings. However, they did find improvements in the medial gastrocnemius muscle thickness in the most affected limb but not in the vastus lateralis. The separation of affected and unaffected limb contrasts the present study, with both muscle thickness and strength being separated into right and left limbs. This is due to the present study focussing on the NDD population and not specific conditions (Moreno-De-Luca et al., 2013). Although some conditions such as CP have commodities such as spasticity which have been shown to effect muscle size and muscle weakness (Chen et al., 2018; Lindén et al., 2019), this is not applicable to all NDD populations. Therefore, the study focussed on the overall picture, separating the data into left and right to make the results more readable. Often studies will randomise which leg will be tested, but due to the small participant size, it was deemed that both should be assessed.

Age is a contributing factor to muscle hypertrophy, with suggestions that younger participants may achieve greater improvements in muscle mass during resistance exercise (Peterson et al., 2011). Furthermore, adaptations such as muscle hypertrophy could occur at a much slower rate despite improvements in muscular strength (Wang et al., 2021). It is also possible that RaceRunning was able to offset the deterioration in muscle size, rather than increasing it. Individuals with a calf circumference of less than 31cm have a significantly higher risk of mortality compared to those with greater calf sizes (Abreo et al., 2021). Participants in the present study recorded a calf circumference of 31cm on average on both legs, with limited improvements post 12-week intervention. This highlights that RaceRunning can demonstrate some positive effects even if the results were deemed non-significant.

Strengthening weak muscles has been highlighted by researchers as an important factor in improving activity capacity (Dallmeijer et al., 2017). As individuals with CP tend to present with a reduction in walking ability as they age (Opheim et al., 2009), maintaining their function or even improving it is vital. Knee flexion isometric strength was found to be significantly greater in both the left leg from 45.2 ± 44 Nm to $64.5 \pm$ 48.8 Nm and in the right leg from 41 ± 29.8 Nm to 71.1 ± 51.1 Nm following 12 weeks of RaceRunning. Knee extension isometric strength saw significant improvements in the left leg from 87.8 ± 53.7 Nm to 110.8 ± 63.7 Nm but no significant differences within the right leg. This is supported by previous research, stating that RaceRunning has been shown to stimulate skeletal muscle hypertrophy (Hjalmarsson et al., 2020). A metaanalysis of exercise-based therapy intensity on gross motor function in individuals with CP concluded that gross motor function score was greatly associated with the number of daily training hours and the programme duration (Hsu et al., 2019). Whilst the extent of training may have not been sufficient for some measured outcomes in the present study, it could have been enough for other outcomes such as strength. Neural adaptations to training have been reported within the motor cortex, spinal cord and/or neuromuscular junction (Hedayatpour & Falla, 2015). For example, following resistance training, increases in force production were suggested to be due to the changes in excitation and inhibition from the motor cortex to the spinal cord, increasing motor neurone output (Siddique et al., 2020). The increased maximal motor unit discharge rates, increased incidence of brief interspike intervals and decreased internal interspike variability, subsequently increase force production (Hedayatpour & Falla, 2015; Siddique et al., 2020). In those with CP, peak muscle activity was a stronger predictor of change in muscle strength after 10 weeks of resistance training compared to 22 weeks (Theis et al., 2021). Some TD adults respond to exercise with an increase in strength only but not in muscle size or vice versa (Ahtiainen et al., 2016). Whilst traditional training can improve strength, muscle mass does not increase the potential for strength gain (Buckner et al., 2021). These adaptations could explain the disproportionate increase in isometric strength tests compared to muscle size following the 12-week RaceRunning intervention.

Improvements in isometric strength however did not translate to all areas of assessment. No significant results were found in both the left and right during plantarflexion. Research has shown during plantarflexion, individuals with CP will have coactivity near to 35% compared to 22 and 24% in those without CP (Tedroff et al., 2008). This can cause incomplete muscle activation and an inability to select the correct muscle for a given action. Indeed, individuals who had low muscle activation in the gastrocnemius had a more limited response to resistance training compared with those who had higher voluntary activation (Theis et al., 2021). Furthermore, researchers have determined that using a dynamometer for measuring ankle plantarflexion can be difficult in the NDD population due to some individuals being unable to maintain the plantargrade position (Crompton et al., 2007). This could explain the improvements within knee flexion and extension strength, but no significant improvements observed within ankle plantarflexion strength. It may also be argued that RaceRunning does not offer enough specificity of training for muscular strength adaptations to be observed. A study investigating the effects of an adapted physical education programme in adolescents with intellectual disabilities across a 3-year period, found that there were improvements in muscular endurance but not in BMI or flexibility (Pan et al., 2022). This supports the idea that even after an extensive intervention period not all fitness components can be resolved in a single intervention and require extensive work to achieve specific. Kossakowski et al., (2021) supports and challenges this by stating that due to the specificity and technical requirements of RaceRunning, benefits can only be achieved by individuals with a particular disability type. Whilst the present study did not determine significant differences in muscle thickness, the overall improvements in isometric strength within the knee demonstrates that RaceRunning can be an effective training method for the NDD population in improving muscular adaptations in the longterm.

5.3 6-minute RaceRunning Test

Individuals with chronic diseases or physical disabilities have been reported to have lower cardiorespiratory fitness, highlighting the importance of interventions to help increase their aerobic capacity (Haapala et al., 2017). There was no significant change in the speed and distance covered during the 6-minute RaceRunning Test (6MRT) from

baseline to 12-weeks after the RaceRunning intervention. This is supported by Sperl (2018) but contrasts Hjalmarsson et al., (2020), who showed significant improvements in 6MRT distance after their 12-week intervention. Gillett et al., (2018), showed that maximum isometric plantarflexion strength explained 61% of variance in 6-minute walking test, with Dallmeijer et al., (2017) supporting this by showing hip adductors and knee flexors also contributed towards mobility. Since no change in 6MRT distance was also coupled with no changes in plantarflexion strength in the present study, these findings from previous research indicate that plantarflexion strength may contribute to the non-significant changes in 6MRT.

For cardiorespiratory training, researchers have conducted interventions with reported improved cardiorespiratory outcomes from exercising for around 20 minutes at least two to four times a week at a moderate intensity (around 60-70% of maximum heart rate) (Verschuren et al., 2016). Previous RaceRunning studies have conducted in a similar manner by having sessions twice per week and saw 6MRT performance improvements but monitored intensity of sessions through perceived exertion (Hjalmarsson et al., 2020). This is an important consideration as the present study only conducted sessions once per week, indicating that this may not have been enough for cardiorespiratory adaptations. Similarly, Sperl (2018) conducted their intervention with RaceRunning sessions being held once per week for 8 weeks and determined similar results to the present study regarding 6MRT performance. They also concluded that RaceRunning could provide an opportunity to improve cardiorespiratory endurance through increases in heart rate as a result. As the present study saw decreases in RHR, it indicates that whilst the intensity of training sessions could have contributed towards improvements in 6MRT performance, the reduced frequency of sessions per week could have resulted in the nonsignificant findings. Furthermore, due to the limited experience prior to the commencement of the study, it is possible that these adaptations could have occurred at a later stage. This highlights that the intensity and frequency of RaceRunning sessions as well as the length of the intervention is important to potentially help the NDD population to improve their cardiorespiratory endurance.

Performance in 6MRT will also largely be determined by volitional effort (the use of one's will). Schlichta et al., (2022) found a significant reduction in time to exhaustion

with both mental fatique (29%) and emotional suppression (20.7%) within physically active males during high intensity endurance exercise. Mental fatigue can be defined as a psychobiological state which is caused by prolonged periods of demanding cognitive activity (Van Cutsem et al., 2017; Schlichta et al., 2022). Studies have shown that mental fatigue and emotion suppression can increase the perception of effort, resulting in a detrimental effect on endurance performance (McCormick et al., 2019). Due to resource constraints, both tests were conducted through field testing, limiting the ability to control variables such as the environment. In marathon runners, a reported head or side wind showed significant decreases in running performance (p<0.001) (Knechtle et al., 2019). This is important to consider as whilst wind speed and direction were not recorded, due to the study being conducted outside, it could have played a role in the decreased performances observed in the present study. Those that are new to RaceRunning may not be used to performing at high intensities and may struggle to provide the volitional effort necessary to perform the 6MRT accurately. Kossakowski et al., (2021) and Van der Linden et al., (2022) support this as they reported 4% of participants felt extreme fatigue and sore muscles after training. In a systematic review on the effect of mental fatigue on performance, they concluded that the decline in endurance performance was due to mental fatigue and was associated with increased perceived exertion (Van Cutsem et al., 2017). They also determined that maximal strength, power, anaerobic work and physiological variables that are associated with endurance (e.g heart rate, blood lactate, oxygen uptake, cardiac output, VO2) were not affected by mental fatigue. Mentally fatigued individuals have been shown to have a substantial depletion of cognitive resources, which could negatively impact situational motivation and subjective fatigue (Schlichta et al., 2022). It is possible that whilst physiologically participants saw improvements, psychologically they were not as motivated to perform at a high intensity. This is seen within the present study as whilst 6MRT decreased, isometric strength tests and resting heart rate improved post intervention. This highlights that mental fatigue could have played a role in decreasing 6MRT performance and should be investigated further.

5.4 Kinematic Analysis

Kinematic changes during RaceRunning were recorded at baseline and 12 weeks to identify any changes in running technique. The limited equipment available could have been a contributing factor to the findings of the present study. Most angles measured at the ankle, knee and hip during stance and swing phases did not show any significant changes. However, knee angle was significantly lower at the toe-off to drawback, drawback and drawback to mid-swing phases. Often when analysing movements, multiple cameras are placed across the playing area and are calibrated to the dimensions of the area, which enables a greater calculation of speeds (Shih, 2017). However due to equipment availability, only one camera was used. As there is a such a wide range of disabilities and disorders amongst this population and therefore a variety of impairments, collection of video recordings should have been collected on both sides. This is important to note as whilst majority of kinematic values were deemed nonsignificant, the researcher is unsure as to whether this is a reliable assumption due to only one side being recorded and analysed.

Plantarflexion was recorded during the initial contact phase at both baseline (-2.5 \pm 15.47) and 12-weeks (-0.16 \pm 10.82) which supports the findings by Shafizadeh et al., (2019) who noted the similarity in technique to forefoot runners. A 12-week longitudinal intervention using minimalistic shoes determined significant changes in plantarflexion from 0.61 (\pm 3.76) to -1.89 (\pm 5.27) during stance phases but no significant changes in hip kinematics (Yang et al., 2020). As they utilised individuals that do not have a disability, they would be considered to have an efficient gait, enabling far greater improvements to be observed compared to individuals with NDD as demonstrated in the present study. This is supported by Ryan et al., (2020a) as they determined that isometric plantar flexor strength explained at least 50% of walking capacity measure variance in adults with CP during progressive resistance training. In an ankle specific intervention focussing on improving muscular strength, they determined substantial improvements in gait function in ankle kinematics, speed and endurance (Burdea et al., 2012). Therefore, it is possible that the lack of improvement in plantarflexion strength in the present study contributed to no significant results within ankle kinematics.

Reduced knee angle during swing phases is associated with lower locomotory energy costs, producing a better running economy (Folland et al., 2017). As kinematic values were taken during the 6MRT, the significant reductions in knee flexion during toe-off to drawback (24.55 ± 8.17 to 15.57 ± 10.06), drawback (45.52 ± 21.58 to 26.96 ± 11.34) and drawback to mid-swing (53.52 ± 17.87 to 27.27 ± 11.06) phases could be due to participants running more economically by maintaining a more consistent speed. After a 12-week running programme for beginners, researchers found no significant differences observations that could indicate a more progressive and less injury prone running style (Maas & Vanwanseele 2022). However, as this article utilised ambulant individuals with no reported disabilities, they may not have an inefficient running gait as observed amongst individuals with NDD (Noorkoiv et al., 2019). As the design of the RaceRunning frame helps supports their bodies, it enables them to propel forward and compensate for an impaired limb or joint (Van der Linden et al., 2021). This could allow participants to focus more on running technique, improving knee kinematic values during initial swing phases.

Running-induced fatigue amongst novice runners has reportedly resulted in no significant differences in kinematics within the knee and hip during flexion and extension (Koblbauer et al., 2014). In conjunction with Van der Linden et al., (2022) reporting increases in muscle tightness, this is important as it demonstrates that even in TD individuals, some running aspects are more difficult to change over a prolonged period when interventions solely focus on increasing endurance (Maas & Vanwanseele, 2022). Research has shown that interventions that report fatigue-induced kinematic value changes in running are not always generalisable to outdoor running as they often utilise treadmills (Strohrmann et al., 2012). This could explain the differences in results amongst the knee and hip within the present study compared to previous research with the few significant changes in knee kinematics but no reported significance within the hip. This highlights the need for further investigations on a larger and longer intervention scale, to fully assess kinematic changes within RaceRunning.

5.5 Sample Size

On a more quantitative level, the observed power and effect size gives some insight into the sample size recruited, in addition to the p (alpha) value. Whilst the overall aim for

recruitment was to get as many people involved in the study, only 9 participants were able to complete the 12-week study. A type I error occurs when the hypothesis is falsely accepted and is calculated through the alpha or p-value (Yuan & Maxwell, 2005). In measurements such as RHR, KF, KE and some kinematic values, significant results (p<0.05) were recorded. If a non-significant result is produced (p>0.05), utilising power and effect size helped determine whether the study was underpowered (Yuan & Maxwell, 2005; Serdar et al., 2021). A power calculation which is usually set at 0.8, is used to assess the probability of accepting a false null hypothesis, known as a type II error (Serdar et al., 2021). As RHR, KF and KE produced significant results with a medium to high effect size, it demonstrates that for these areas, the sample size was deemed appropriate. However, other aspects of testing produced non-significant results, which when delving into the observed power and effect sizes, raises concerns of an underpowered study.

Observed power varied amongst BP, with systolic results being 0.278 and diastolic being 0.70 however both effect sizes were low. Previous studies that have investigated BP have recruited large participant sizes to produce significant results (Zhang et al., 2021), which could explain the non-significant results in the present study. Similarly, thigh and calf circumference studies utilised large participants sample sizes of over 100 participants and saw significant results (Mienche et al., 2019). While this may not be the case for all studies investigating thigh and calf circumference, the low observed power and effect size determined in the present study supports the proposal that of a larger participant sample pool is required in future research. Despite the right leg KE showing non-significant results and an observed power of 0.448, the significant results on the left size (p = 0.018), in addition to significant results in KF, reduces the likelihood of a type II error. Plantarflexion saw medium effect sizes (0.43 and 0.53) but non-significant results, which in combination with the observed power of 0.268 in the left an 0.508 in the right, suggests that with a larger participant sample, significant results may have been observed.

The 6MRT also saw non-significant results which showed similarities to Sperl (2018). However, in comparison to Hjalmarsson et al., (2020) they determined significant results but recruited 15 participants compared to six participants in Sperl (2018) and nine in the

present study. This is important as both average speed and overall performance had an observed power of around 20% which could explain the non-significant findings, increasing the likelihood of a type II error. While kinematic analysis did show some significant values it is likely that both a type I and type II error occurred as only five participants took part in this study. In the instances that significant results were reported, the observed power and effect size showed the test was overpowered. This seems unlikely due to the other kinematic values determined the sample size recruited to be underpowered. This means that a type I error likely occurred within the present study. A greater participant size would be useful for future research as exhibited by Straudi et al., (2009) whereby they recruited 34 participants and clustered them into walking performance groups for later analysis. As the present study had limited participants, grouping participants into subgroups was not possible, which could be a contributing factor to nonsignificant results for majority of results. Overall, the present study may not have enough participants for some areas of interest. Future research should strive towards recruiting more participants to help improve the observed power and to reduce the likelihood of type I and type II errors.

5.6 Clinical Implications

Whilst the majority of measures included in the study were found not to change significantly following 12 weeks of RaceRunning, the present study does suggest that RaceRunning can provide some benefits in terms of muscle strength, muscle size and resting heart rate. In combination with previous findings which demonstrate some positive changes as a result of RaceRunning, this highlights the importance of recommending the sport to a population that has restricted opportunities to be physically active. The lack of facilities (Rimmer 2005; Rimmer et al., 2017) and a lack of inclusivity (Tant & Watelain, 2016) are often the main contributors to reduced physical activity which RaceRunning can help alleviate due the nature and accessibility of the sport. This was demonstrated by Sukal-Moulton et al., (2022) as they determined amongst individuals with movement challenges, those that liked to exercise found RaceRunning to be a good outlet to participate in with improvements physically and socially. As the sport is catered towards individuals with disabilities, it reduces the need for adaptation and could be integrated into either a school curriculum or community service which has

been highlighted in previous studies (Rimmer, 2005; Tant & Watelain, 2016; Rimmer et al., 2017).

There is also evidence that RaceRunning can provide an activity which increases heart rate and induces a cardiovascular response that may be able to reduce the risk of developing secondary health conditions if used in the long term. This research highlights that those new to RaceRunning may not initially be familiar or comfortable with exercising at a moderate-to-high intensities and this may have impacted some of the potential results found in this study. Indeed, there were a wide range of responses to some tests, with some individuals showing improvements in thigh circumference of up to 17.1% whilst others showing only minimal or no improvement. Many previous studies have only recruited participants with CP (Bryant & Pickering, 2015; Kristjánsson, 2018; Hjalmarsson et al., 2020; Reedman et al., 2022). This one of the few studies that aimed to recruit individuals of other NDD types. Ataxic CP for example accounts for 5% of CP cases and is often associated with spastic diplegic CP (Jones et al., 2007). Dyskinetic CP accounts for 7% of all CP cases (Krägeloh-Mann, 2007). These subtypes were included in the present study, which can provide useful data on a rare condition, often overlooked in NDD research. Due to the heterogenous nature of NDD and the wide range of disability symptoms present, a large sample size would be needed in order to detect some changes in variables (Reedman et al., 2022). The number of participants within the present study is significantly smaller than the average study for this area. This was a limitation of the present study. Nevertheless, the current study provides some important preliminary data and supports the limited number of studies to date looking at the effects of RaceRunning.

5.7 Future Research

Future research should investigate these physiological measures on a larger scale, with a greater sample size and involve a wide variety of disabilities and disorders. Recruiting a wider variety of disability types would ensure that findings are not influenced by a particular condition. This would make it more applicable to a wider population of NDD individuals. A longer intervention could see further developments in cardiorespiratory fitness but would have to be in a controlled environment to reduce the limiting factors found within the present study. Conducting more studies that were open to the diverse

disability types other than CP would be beneficial for researchers and to demonstrate that the sport is inclusive. It could even extend towards studies investigating RaceRunning within the elderly, with similarities being observed amongst previous studies between this group and disability types such as CP (Shortland, 2009). In addition, assessing the extent of improvements within disability types including the various CP subtypes would enable a better overview of the effects of the intervention. Similarly, performing a large-scale study on demographics within RaceRunning would be beneficial as it can establish the variety of conditions within the sport. It would also provide researchers with an idea of how to best represent the population in terms of recruitment within future studies. It would also highlight to practitioners that RaceRunning is open to a much wider population of individuals who may currently be unaware of the sport. Raising awareness would encourage more RaceRunning groups within the community.

Researchers could focus on investigating the various types of running style further, with an emphasis on those susceptible to contractures. By categorising the running techniques, it would enable healthcare practitioners and coaches to better understand the mechanics behind individuals running styles. This would enable them to focus on improving specific aspects that may not be apparent in other running techniques. Determining the extent of improvements within gait at similar speeds across a long-term intervention would be beneficial to fully understand whether kinematic values change over time. In addition, taking these recordings on both sides to ensure there are no generalisations due to lack of data. Performing gait analysis on a large scale at grass root through to elite, could provide coaches with the information to understand the differences in performance. This could be utilised to develop future training programmes to increase overall performance for athletes at lower levels. In addition, with the findings from previous research in relation to running speed such as spasticity, it would be beneficial to conduct a study in which the varying levels of impairments are analysed to understand the specific mechanisms for this reduction in speed. Measuring both active and passive kinematic values would be useful in terms of assessing the extent of angular differences for both a health and performance perspective. An investigation using a mixed method approach on the effects of RaceRunning on wellbeing and QoL

would provide useful information on both physiological and psychological effects. By incorporating both, it would enable a greater insight on the overall impact RaceRunning has on the NDD population particularly when testing on the same group of individuals. It can also help better understand how each aspect effects and interchanges with one another.

Chapter 6 – Conclusion

Individuals with NDD are more at risk of developing a secondary health problems, particularly in severe cases. Researchers have highlighted that RaceRunning may be able to provide this population with physical benefits to reduce these risks. This study aimed to investigate the effects over a 12-week period. In summary, whilst there were significant improvements within resting heart rate and isometric strength and trends towards other measures due to the observed power and the small sample size, it is difficult to fully understand the extent of improvements. Further analysis of the observed power and effect size revealed the present study to be underpowered. Kinematic values also found significant differences within the knee kinematics during the initial swing phases as a result of RaceRunning training but through further analysis, a type I error may have occurred. In conclusion, RaceRunning does provide some benefits towards improvements in physical health and recommends that healthcare practitioners promote the sport to individuals with moderate-to-severe NDD. The full extent of the physical benefits should be investigated further on a larger scale.

References

Abreo, A. P., Bailey, S. R., & Abreo, K. (2021). Associations between calf, thigh, and arm circumference and cardiovascular and all-cause mortality in NHANES 1999–2004. *Nutrition, Metabolism and Cardiovascular Diseases*, *31*(5), 1410-1415.

Ahtiainen, J. P., Walker, S., Peltonen, H., Holviala, J., Sillanpää, E., Karavirta, L., Sallinen, J., Mikkola, J., Valekeinen, H., Mero, A., Hulmi, J. J., & Häkkinen, K. (2016). Heterogeneity in resistance training-induced muscle strength and mass responses in men and women of different ages. *Age*, *38*(1), 1-13.

Almuhtaseb, S., Oppewal, A., & Hilgenkamp, T. I. (2014). Gait characteristics in individuals with intellectual disabilities: A literature review. *Research in developmental disabilities*, *35*(11), 2858-2883.

Angriman, M., Caravale, B., Novelli, L., Ferri, R., & Bruni, O. (2015). Sleep in children with neurodevelopmental disabilities. *Neuropediatrics*, *46*(03), 199-210.

Arim, R. G., Miller, A. R., Guèvremont, A., Lach, L. M., Brehaut, J. C., & Kohen, D. E. (2017). Children with neurodevelopmental disorders and disabilities: a population-based study of healthcare service utilization using administrative data. *Developmental Medicine & Child Neurology*, *59*(12), 1284-1290.

Armstrong, E. L., Boyd, R. N., Horan, S. A., Kentish, M. J., Ware, R. S., & Carty, C. P. (2020). Functional electrical stimulation cycling, goal-directed training, and adapted cycling for children with cerebral palsy: a randomized controlled trial. *Developmental Medicine & Child Neurology*, *62*(12), 1406-1413.

Banerjee, A., Chitnis, U. B., Jadhav, S. L., Bhawalkar, J. S., & Chaudhury, S. (2009). Hypothesis testing, type I and type II errors. *Industrial psychiatry journal*, *18*(2), 127.

Barak, S., Mendoza-Laiz, N., Gutiérrez Fuentes, M. T., Rubiera, M., & Hutzler, Y. (2016). Psychosocial effects of competitive Boccia program in persons with severe chronic disability. *Journal of Rehabilitation Research & Development*, *53*(6).

Barfield, J. P., Newsome, L., & Malone, L. A. (2016). Exercise intensity during power wheelchair soccer. *Archives of physical medicine and rehabilitation*, *97*(11), 1938-1944.

Bauman, A., Phongsavan, P., Schoeppe, S., & Owen, N. (2006). Physical activity measurement-a primer for health promotion. *Promotion & education*, *13*(2), 92-103.

Benner, J. L., Hilberink, S. R., Veenis, T., Stam, H. J., van der Slot, W. M., & Roebroeck, M. E. (2017). Long-term deterioration of perceived health and functioning in adults with cerebral palsy. *Archives of physical medicine and rehabilitation*, *98*(11), 2196-2205.

Billinger, S. A., Coughenour, E., MacKay-Lyons, M. J., & Ivey, F. M. (2012). Reduced cardiorespiratory fitness after stroke: biological consequences and exercise-induced adaptations. *Stroke research and treatment*, 2012.

Block, P., Skeels, S. E., Keys, C. B., & Rimmer, J. H. (2005). Shake-It-Up: health promotion and capacity building for people with spinal cord injuries and related neurological disabilities. *Disability and rehabilitation*, *27*(4), 185-190.

Boström, K., & Ahlström, G. (2004). Living with a chronic deteriorating disease: the trajectory with muscular dystrophy over ten years. *Disability and Rehabilitation*, *26*(23), 1388-1398.

Bolster, E. A., Dallmeijer, A. J., de Wolf, G. S., Versteegt, M., & Schie, P. E. V. (2017). Reliability and construct validity of the 6-minute Racerunner test in children and youth with cerebral palsy, GMFCS levels III and IV. *Physical & Occupational Therapy in Pediatrics*, *37*(2), 210-221.

Boyle, C. A., & Cordero, J. F. (2005). Birth defects and disabilities: a public health issue for the 21st century. *American Journal of Public Health*, *95*(11), 1884-1886.

Bricout, V. A., Pace, M., Dumortier, L., Baillieul, F., Favre-Juvin, A., & Guinot, M. (2018). Reduced cardiorespiratory capacity in children with autism spectrum disorders. *Journal of clinical medicine*, *7*(10), 1-10.

Bryant, E., Pickering, D., Henshaw, R. (2015, December 8). *RaceRunning: improving health and wellbeing in people with cerebral palsy* [Conference presentation] Disability Sports Development Conference, Nottingham, UK.

Bryant, E., Cowan, D., & Walker-Bone, K. (2015). The introduction of Petra running bikes to non-ambulant children with cerebral palsy. Abstract from 27th Annual Meeting of the European Academy of Childhood Disability (EACD), Copenhagen, Denmark, 34-35.

Buckner, S. L., Yitzchaki, N., Kataoka, R., Vasenina, E., Zhu, W. G., Kuehne, T. E., & Loenneke, J. P. (2021). Do exercise-induced increases in muscle size contribute to strength in resistance-trained individuals?. *Clinical Physiology and Functional Imaging*, *41*(4), 326-333.

Buljina, A., Herić, A., & Pamukcu, S. A. (2022). Blood Pressure Measurement and Signal Analysis: Impact on Measurement Error. In *2022 11th Mediterranean Conference on Embedded Computing (MECO)* (pp. 1-5). IEEE.

Burdea, G. C., Cioi, D., Kale, A., Janes, W. E., Ross, S. A., & Engsberg, J. R. (2012). Robotics and gaming to improve ankle strength, motor control, and function in children with cerebral palsy—a case study series. *IEEE Transactions on Neural Systems and Rehabilitation Engineering*, *21*(2), 165-173.

Butler, J. M., Scianni, A., & Ada, L. (2010). Effect of cardiorespiratory training on aerobic fitness and carryover to activity in children with cerebral palsy: a systematic review. *International Journal of Rehabilitation Research*, *33*(2), 97-103.

Cairney, J., Veldhuizen, S., King-Dowling, S., Faught, B. E., & Hay, J. (2017). Tracking cardiorespiratory fitness and physical activity in children with and without motor coordination problems. *Journal of science and medicine in sport*, *20*(4), 380-385.

Carlon, S. L., Taylor, N. F., Dodd, K. J., & Shields, N. (2013). Differences in habitual physical activity levels of young people with cerebral palsy and their typically developing peers: a systematic review. *Disability and rehabilitation, 35*(8), 647-655.

Carroll, W. M. (2019). The global burden of neurological disorders. *The Lancet Neurology*, *18*(5), 418-419.

Caruso, M. V., Serra, R., Perri, P., Buffone, G., Caliò, F. G., Franciscis, S., & Fragomeni, G. (2017). A computational evaluation of sedentary lifestyle effects on

carotid hemodynamics and atherosclerotic events incidence. *Acta of bioengineering and biomechanics*, *19*(3), 43-52.

Casas, J. P., Shah, T., Hingorani, A. D., Danesh, J., & Pepys, M. B. (2008). C-reactive protein and coronary heart disease: a critical review. *Journal of internal medicine*, *264*(4), 295-314.

Chen, C. L., Liu, L., Huang, J. Y., Yu, Y. L., Shen, G., Lo, K., ... & Feng, Y. Q. (2020). Thigh circumference and risk of all-cause, cardiovascular and cerebrovascular mortality: a cohort study. *Risk Management and Healthcare Policy*, 1977-1987.

Chen, Y., He, L., Xu, K., Li, J., Guan, B., & Tang, H. (2018). Comparison of calf muscle architecture between Asian children with spastic cerebral palsy and typically developing peers. *Plos one*, *13*(1), 1-14.

Chow, H. W., & Yang, C. C. (2020). Accuracy of optical heart rate sensing technology in wearable fitness trackers for young and older adults: Validation and comparison study. *JMIR mHealth and uHealth*, *8*(4), e14707.

Cook, S., Togni, M., Schaub, M. C., Wenaweser, P., & Hess, O. M. (2006). High heart rate: a cardiovascular risk factor?. *European heart journal*, *27*(20), 2387-2393.

CPISRA (2021) *RaceRunning*.CPISRA.org. Accessed from <u>https://cpisra.org/racerunning/</u>.

Crompton, J., Galea, M. P., & Phillips, B. (2007). Hand-held dynamometry for muscle strength measurement in children with cerebral palsy. *Developmental Medicine & Child Neurology*, *49*(2), 106-111.

Cross, A., Soper, A. K., Tomas, V., Grahovac, D., Brocklehurst, J., Kay, D., ... & Rosenbaum, P. (2022). Exploring 10 years of dissemination of the F-words for Child Development: A multifaceted case study. *Child: Care, Health and Development, 48*(5), 751-762.

Dahan-Oliel, N., Shikako-Thomas, K., & Majnemer, A. (2012). Quality of life and leisure participation in children with neurodevelopmental disabilities: a thematic analysis of the literature. *Quality of Life Research*, *21*(3), 427-439.

Dallmeijer, A. J., Rameckers, E. A., Houdijk, H., de Groot, S., Scholtes, V. A., & Becher, J. G. (2017). Isometric muscle strength and mobility capacity in children with cerebral palsy. *Disability and rehabilitation*, *39*(2), 135-142.

Di Stefano, V., Battaglia, G., Giustino, V., Gagliardo, A., D'Aleo, M., Giannini, O., Palma, A., & Brighina, F. (2021). Significant reduction of physical activity in patients with neuromuscular disease during COVID-19 pandemic: the long-term consequences of quarantine. Journal of Neurology, 268(1), 20-26.

Dolk, H., Loane, M., & Garne, E. (2010). The prevalence of congenital anomalies in Europe. *Rare diseases epidemiology*, 349-364.

Donnell, R. O., Verellen, J., Van de Vliet, P., & Vanlandewijck, Y. (2010). Kinesiologic and metabolic responses of persons with cerebral palsy to sustained exercise on a petra race runner. *European Journal of Adapted Physical Activity*, *3*(1), 7-17.

Durstine, J. L., Painter, P., Franklin, B. A., Morgan, D., Pitetti, K. H., & Roberts, S. O. (2000). Physical activity for the chronically ill and disabled. *Sports Medicine*, *30*(3), 207-219.

Engström, E., Ottosson, E., Wohlfart, B., Grundström, N., & Wisén, A. (2012). Comparison of heart rate measured by Polar RS400 and ECG, validity and repeatability. *Advances in Physiotherapy*, *14*(3), 115-122.

Etoom, M., Khraiwesh, Y., Lena, F., Hawamdeh, M., Hawamdeh, Z., Centonze, D., & Foti, C. (2018). Effectiveness of physiotherapy interventions on spasticity in people with multiple sclerosis: a systematic review and meta-analysis. *American journal of physical medicine & rehabilitation*, *97*(11), 793-807.

Faria, B. M., Silva, A., Faias, J., Reis, L. P., & Lau, N. (2014). Intelligent wheelchair driving: a comparative study of cerebral palsy adults with distinct boccia experience. In *New Perspectives in Information Systems and Technologies,* Volume 2, 329-340, Springer, Cham.

Ferreira, M. C., Pastore, C., Imada, R., Guare, R., Leite, M., Poyares, D., & Santos, M. T. (2011). Autonomic nervous system in individuals with cerebral palsy: a controlled study. *Journal of oral pathology & medicine*, *40*(7), 576-581.

Finlayson, J., Jackson, A., Cooper, S. A., Morrison, J., Melville, C., Smiley, E., ... & Mantry, D. (2009). Understanding predictors of low physical activity in adults with intellectual disabilities. *Journal of Applied Research in Intellectual Disabilities*, *22*(3), 236-247.

Findling, O., Hauer, L., Pezawas, T., Rommer, P. S., Struhal, W., & Sellner, J. (2020). Cardiac autonomic dysfunction in multiple sclerosis: a systematic review of current knowledge and impact of immunotherapies. *Journal of clinical medicine*, *9*(2), 335-360.

Folland, J. P., Allen, S. J., Black, M. I., Handsaker, J. C., & Forrester, S. E. (2017). Running technique is an important component of running economy and performance. *Medicine and science in sports and exercise*, *49*(7), 1412.

Foran, J. R., Steinman, S., Barash, I., Chambers, H. G., & Lieber, R. L. (2005). Structural and mechanical alterations in spastic skeletal muscle. *Developmental medicine & Child neurology*, *47*(10), 713-717.

Fosang, A., & Baker, R. (2006). A method for comparing manual muscle strength measurements with joint moments during walking. *Gait & Posture*, *24*(4), 406-411.

Fraser, B. J., Blizzard, L., Buscot, M. J., Schmidt, M. D., Dwyer, T., Venn, A. J., & Magnussen, C. G. (2021). Muscular strength across the life course: The tracking and trajectory patterns of muscular strength between childhood and mid-adulthood in an Australian cohort. *Journal of Science and Medicine in Sport*, *24*(7), 696-701.

Freeman, J., Gorst, T., Gunn, H., & Robens, S. (2020). "A non-person to the rest of the world": Experiences of social isolation amongst severely impaired people with multiple sclerosis. *Disability and rehabilitation*, *4*2(16), 2295-2303.

Froehlich-Grobe, K., Jones, D., Businelle, M. S., Kendzor, D. E., & Balasubramanian, B. A. (2016). Impact of disability and chronic conditions on health. *Disability and health journal*, *9*(4), 600-608.

Gagnon, M. (2020). Assessments and interventions for youths with arthrogryposis multiplex congenita. McGill University, Canada.

Gąsior, J. S., Zamunér, A. R., Silva, L. E. V., Williams, C. A., Baranowski, R., Sacha, J., ... & Werner, B. (2020). Heart rate variability in children and adolescents with cerebral palsy—a systematic literature review. *Journal of Clinical Medicine*, *9*(4), 1141.

Ganz, F., Hammam, N., & Pritchard, L. (2021). Sedentary behavior and children with physical disabilities: a scoping review. *Disability and Rehabilitation*, *43*(20), 2963-2975.

Gazzola, K., Honingh, M., Truijen, J., Zuliani, G., & Van Den Born, B. J. H. (2018). Effect of anticipation and cuff inflation on blood pressure during selfmeasurement. *Journal of Hypertension*, *36*(9), 1798-1802.

Ge, Z., Prasad, P. W. C., Costadopoulos, N., Alsadoon, A., Singh, A. K., & Elchouemi, A. (2016, September). Evaluating the accuracy of wearable heart rate monitors. In *2016 2nd International Conference on Advances in Computing, Communication,* & *Automation (ICACCA)(Fall)* (pp. 1-6). IEEE.

Gillett, J. G., Lichtwark, G. A., Boyd, R. N., & Barber, L. A. (2018). Functional capacity in adults with cerebral palsy: lower limb muscle strength matters. *Archives of Physical medicine and Rehabilitation*, *99*(5), 900-906.

Gjesdal, B. E., Jahnsen, R., Morgan, P., Opheim, A., & Mæland, S. (2020). Walking through life with cerebral palsy: reflections on daily walking by adults with cerebral palsy. *International journal of qualitative studies on health and well-being*, *15*(1), 1746577.

Goulet-Pelletier, J. C., & Cousineau, D. (2018). A review of effect sizes and their confidence intervals, Part I: The Cohen'sd family. *The Quantitative Methods for Psychology*, *14*(4), 242-265.

Goldstein-Greenwood, J. (2022). Nonparametric and Parametric Power: Comparing the Wilcoxon Test and the t-test. *University of Virginia Library.*

Gulati, S., & Sondhi, V. (2018). Cerebral palsy: an overview. *The Indian Journal of Pediatrics*, *85*(11), 1006-1016.

Guo, J., Brooks, M. M., Muldoon, M. F., Naimi, A. I., Orchard, T. J., & Costacou, T. (2019). Optimal blood pressure thresholds for minimal coronary artery disease risk in type 1 diabetes. *Diabetes care*, *4*2(9), 1692-1699.

Haapala, E. A., Lankhorst, K., de Groot, J., Zwinkels, M., Verschuren, O., Wittink, H., ... & Takken, T. (2017). The associations of cardiorespiratory fitness, adiposity and sports participation with arterial stiffness in youth with chronic diseases or physical disabilities. *European journal of preventive cardiology*, *24*(10), 1102-1111.

Hall, S. F. (2006). A user's guide to selecting a comorbidity index for clinical research. *Journal of clinical epidemiology*, *59*(8), 849-855.

Hartley, S. E. (2019). Re-imagining the role of the physiotherapist when managing people with long-term conditions. *Physiotherapy Theory and Practice*, *35*(11), 1005-1014.

He, L. I., Wei, W. R., & Can, Z. (2018). Effects of 12-week brisk walking training on exercise blood pressure in elderly patients with essential hypertension: a pilot study. *Clinical and Experimental Hypertension*, *40*(7), 673-679.

Hedayatpour, N., & Falla, D. (2015). Physiological and neural adaptations to eccentric exercise: mechanisms and considerations for training. *BioMed research international*, 2015.

Heitmann, B. L., & Frederiksen, P. (2009). Thigh circumference and risk of heart disease and premature death: prospective cohort study. *Bmj*, *339*, 1-8.

Hendriksz, C. J., Berger, K. I., Giugliani, R., Harmatz, P., Kampmann, C., Mackenzie, W. G., ... & Savarirayan, R. (2015). International guidelines for the management and treatment of Morquio A syndrome. *American Journal of Medical Genetics Part A*, *167*(1), 11-25.

Henriksson, H., Henriksson, P., Tynelius, P., & Ortega, F. B. (2019). Muscular weakness in adolescence is associated with disability 30 years later: a population-based cohort study of 1.2 million men. *British Journal of Sports Medicine*, *53*(19), 1221-1230.

Hensley, C. P., Kontos, D., Feldman, C., Wafford, Q. E., Wright, A., & Chang, A. H. (2022). Reliability and validity of 2-dimensional video analysis for a running task: A systematic review. *Physical Therapy in Sport*.

Hjalmarsson, E., Fernandez-Gonzalo, R., Lidbeck, C., Palmcrantz, A., Jia, A., Kvist, O., Pontén, E., & von Walden, F. (2020). RaceRunning training improves stamina and promotes skeletal muscle hypertrophy in young individuals with cerebral palsy. *BMC musculoskeletal disorders*, *21*, 1-9.

Hsu, C. W., Kang, Y. N., & Tseng, S. H. (2019). Effects of therapeutic exercise intensity on cerebral palsy outcomes: A systematic review with meta-regression of randomized clinical trials. *Frontiers in Neurology*, *10*, 657.

Hussain, A. W., Onambele, G. L., Williams, A. G., & Morse, C. I. (2014). Muscle size, activation, and coactivation in adults with cerebral palsy. *Muscle & nerve*, *49*(1), 76-83.

Irby, M. B., Kolbash, S., Garner-Edwards, D., & Skelton, J. A. (2012). Pediatric obesity treatment in children with neurodevelopmental disabilities: a case series and review of the literature. *ICAN: Infant, Child, & Adolescent Nutrition, 4*(4), 215-221.

Jaarsma, E. A., Dijkstra, P. U., de Blécourt, A. C., Geertzen, J. H., & Dekker, R. (2015). Barriers and facilitators of sports in children with physical disabilities: a mixed-method study. *Disability and rehabilitation*, *37*(18), 1617-1625.

Jacobson, D. (2020). Cerebral palsy: studies on health and social outcomes in young adulthood, and on treatments for spasticity and pain. [Doctoral Thesis] Karolinska Instituet.

Jeffress, M. S., & Brown, W. J. (2017). Opportunities and benefits for powerchair users through power soccer. *Adapted Physical Activity Quarterly*, *34*(3), 235-255.

Jensen, M. T. (2019). Resting heart rate and relation to disease and longevity: past, present and future. *Scandinavian journal of clinical and laboratory investigation*, *79*(1-2), 108-116.

61

Jeon, B., Kwon, S., & Kim, H. (2015). Health care utilization by people with disabilities: a longitudinal analysis of the Korea Welfare Panel Study (KoWePS). *Disability and health journal*, *8*(3), 353-362.

Johnson, H. (2021). *Running free: the impact of RaceRunningon the psychosocial wellbeing and quality of life of novice and experienced athletes with cerebral palsy.* [Doctoral Dissertation]. University of Edinburgh.

Johnson, J. L., Slentz, C. A., Houmard, J. A., Samsa, G. P., Duscha, B. D., Aiken, L. B., McCartney, J. S., Tanner, C. J., & Kraus, W. E. (2007). Exercise training amount and intensity effects on metabolic syndrome (from Studies of a Targeted Risk Reduction Intervention through Defined Exercise). *The American journal of cardiology*, *100*(12), 1759-1766.

Jones, M. W., Morgan, E., Shelton, J. E., & Thorogood, C. (2007). Cerebral palsy: introduction and diagnosis (part I). *Journal of Pediatric Health Care*, *21*(3), 146-152.

Jung, M. H., Kim, G. H., Kim, J. H., Moon, K. W., Yoo, K. D., Rho, T. H., & Kim, C. M. (2015). Reliability of home blood pressure monitoring: in the context of validation and accuracy. *Blood Pressure Monitoring*, *20*(4), 215-220.

Kallioinen, N., Hill, A., Horswill, M. S., Ward, H. E., & Watson, M. O. (2017). Sources of inaccuracy in the measurement of adult patients' resting blood pressure in clinical settings: a systematic review. *Journal of hypertension*, *35*(3), 421-441.

Kalkman, B. M., Holmes, G., Bar-On, L., Barton, G. J., Maganaris, C. N., Bass, A., ... & O'Brien, T. D. (2019). Resistance training combined with stretching increases tendon stiffness and is more effective than stretching alone in children with cerebral palsy: A randomised controlled trial. *Frontiers in Pediatrics*, *7*, 333.

Kampmann, C., Abu-Tair, T., Gökce, S., Lampe, C., Reinke, J., Mengel, E., ... & Wiethoff, C. M. (2016). Heart and cardiovascular involvement in patients with Mucopolysaccharidosis type IVA (Morquio-a syndrome). *PLoS One*, *11*(9), e0162612.

Kapsal, N. J., Dicke, T., Morin, A. J., Vasconcellos, D., Maïano, C., Lee, J., & Lonsdale, C. (2019). Effects of physical activity on the physical and psychosocial health of youth

with intellectual disabilities: A systematic review and meta-analysis. *Journal of Physical Activity and Health*, *16*(12), 1187-1195.

Kennedy, S., Smith, B., Sobhiyeh, S., Dechenaud, M. E., Wong, M., Kelly, N., ... & Heymsfield, S. B. (2022). Digital anthropometric evaluation of young children: comparison to results acquired with conventional anthropometry. *European journal of clinical nutrition*, *76*(2), 251-260.

Kerem-Günel, M., Arslan, U. E., Seyhan-Bıyık, K., Özal, C., Numanoğlu-Akbaş, A., Üneş, S., ... & Green, D. (2023). Evaluation of daily and social participation of children with Cerebral Palsy across different age groups with a focus on the 'F'-words: Function, family, fitness, fun, friends and future. *Research in Developmental Disabilities*, *140*, 104588.

Klaewkasikum, K., Patathong, T., Angsanuntsukh, C., Woratanarat, T., Sanguantrakul, J., & Woratanarat, P. (2022). The ankle kinematic reference of normal gait pattern in Thai adults. *Frontiers in Surgery*, *9*.

Knechtle, B., Di Gangi, S., Rüst, C. A., Villiger, E., Rosemann, T., & Nikolaidis, P. T. (2019). The role of weather conditions on running performance in the Boston Marathon from 1972 to 2018. *PloS one*, *14*(3), e0212797.

Koblbauer, I. F., van Schooten, K. S., Verhagen, E. A., & van Dieën, J. H. (2014). Kinematic changes during running-induced fatigue and relations with core endurance in novice runners. *Journal of science and medicine in sport*, *17*(4), 419-424.

Kossakowski, R., Witecka-Wiese, M., & Mańkowski, D. (2021). Identity reconstruction among people with physical disabilities practising Race Running. *Physical Culture and Sport*, *93*(1), 49-61.

Krägeloh-Mann, I. (2007). Dyskinetic cerebral palsy: prevalence and neuroimaging. *Developmental medicine and child neurology*, *49*(4), 244.

Kristjánsson, L. M. (2018). Lower Limb Muscle Fatigue Analysis of RaceRunning Athletes with Cerebral Palsy. [Masters Dissertation] KTH Royal Institute of Technology. Kvarnung, M., & Nordgren, A. (2017). Intellectual disability & rare disorders: a diagnostic challenge. *Rare Diseases Epidemiology: Update and Overview*, 39-54.

Kwan, C., Gitimoghaddam, M., & Collet, J. P. (2020). Effects of social isolation and loneliness in children with neurodevelopmental disabilities: a scoping review. *Brain Sciences*, *10*(11), 786.

Kwon, S. J., Choi, E. K., Lee, K. H., & Im, Y. M. (2019). Factors influencing physical activity in adolescents with complex congenital heart disease. *Child Health Nursing Research*, *25*(3), 262.

Kwon, Y. H., & Lee, H. Y. (2014). Differences of respiratory function according to level of the gross motor function classification system in children with cerebral palsy. *Journal of physical therapy science*, *26*(3), 389-391.

Labs, K. H., Tschoepl, M., Gamba, G., Aschwanden, M., & Jaeger, K. A. (2000). The reliability of leg circumference assessment: a comparison of spring tape measurements and optoelectronic volumetry. *Vascular Medicine*, *5*(2), 69-74.

Lampousi, A. M., Berglind, D., & Forsell, Y. (2020). Association of changes in cardiorespiratory fitness with health-related quality of life in young adults with mobility disability: secondary analysis of a randomized controlled trial of mobile app versus supervised training. *BMC public health*, *20*(1), 1-12.

Lauglo, R., Vik, T., Lamvik, T., Stensvold, D., Finbråten, A. K., & Moholdt, T. (2016). High-intensity interval training to improve fitness in children with cerebral palsy. *BMJ Open Sport & Exercise Medicine*, *2*(1), 1-6.

Lebau, G. (2020) RaceRunning Pathways. RaceRunning Australia.

Lee, L. L., Watson, M. C., Mulvaney, C. A., Tsai, C. C., & Lo, S. F. (2010). The effect of walking intervention on blood pressure control: a systematic review. *International journal of nursing studies*, *47*(12), 1545-1561.

Liang, H., Xue, Y., & Chase, S. K. (2011). Online health information seeking by people with physical disabilities due to neurological conditions. International Journal of Medical Informatics, 80(11), 745-753.

Lieber, R. L., Runesson, E., Einarsson, F., & Fridén, J. (2003). Inferior mechanical properties of spastic muscle bundles due to hypertrophic but compromised extracellular matrix material. *Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine*, *28*(4), 464-471.

Lin, L. P., Liu, C. T., Liou, S. W., Hsu, S. W., & Lin, J. D. (2012). High blood pressure in adults with disabilities: influence of gender, body weight and health behaviors. *Research in Developmental Disabilities*, *33*(5), 1508-1515.

Lindén, O., Hägglund, G., Rodby-Bousquet, E., & Wagner, P. (2019). The development of spasticity with age in 4,162 children with cerebral palsy: a register-based prospective cohort study. *Acta orthopaedica*, *90*(3), 286-291.

Liptak, G. S., O'Donnell, M., Conaway, M., Chumlea, W. C., Worley, G., Henderson, R. C., Fung, E., Stallings, V. A., Samson-Fang, L., Calvert, R., Rosenbaum, P., & Stevenson, R. (2001). Health status of children with moderate to severe cerebral palsy. *Developmental Medicine & Child Neurology, 43*(6), 364-370.

Łosień, T., Mędrak, A., Plaskacz, P., Bajerska, I., Reut, M., Dragon, E., Polko, M., & Cebula, A. (2018). The influence of boccia on self-esteem and increasing the functional capabilities of disabled people. *Journal of Education, Health and Sport, 8*(8), 1099-1105.

Maas, E., & Vanwanseele, B. (2022). Changes in running kinematics and kinetics after a 12-week running program for beginners. *Sports Biomechanics*, *21*(2), 201-211.

Mac Cann, R. (2018). An exploration of the relationship between newly identified patterns of propulsion technique, measures of lower limb impairment and performance in RaceRunning athletes (Doctoral dissertation).

Mancia, G., Masi, S., Palatini, P., Tsioufis, C., & Grassi, G. (2021). Elevated heart rate and cardiovascular risk in hypertension. *Journal of Hypertension*, *39*(6), 1060-1069.

Mathewson, M. A., & Lieber, R. L. (2015). Pathophysiology of muscle contractures in cerebral palsy. *Physical Medicine and Rehabilitation Clinics*, *26*(1), 57-67.

65

Marshall, T., Anantharachagan, A., Choudhary, K., Chue, C., & Kaur, I. (2002). A randomised controlled trial of the effect of anticipation of a blood test on blood pressure. *Journal of Human Hypertension*, *16*(9), 621-625.

McCormick, A., Meijen, C., Anstiss, P. A., & Jones, H. S. (2019). Self-regulation in endurance sports: theory, research, and practice. *International Review of Sport and Exercise Psychology*, *12*(1), 235-264.

Mc Namara, K., Alzubaidi, H., & Jackson, J. K. (2019). Cardiovascular disease as a leading cause of death: how are pharmacists getting involved?. *Integrated pharmacy research & practice*, *8*, 1.

Meester-Delver, A., Beelen, A., Hennekam, R., Nollet, F., & Hadders-Algra, M. (2007). The Capacity Profile: a method to classify additional care needs in children with neurodevelopmental disabilities. *Developmental Medicine & Child Neurology*, *49*(5), 355-360.

Mienche, M., Setiati, S., Setyohadi, B., Kurniawan, J., Laksmi, P. W., Ariane, A., & Tirtarahardja, G. (2019). Diagnostic performance of calf circumference, thigh circumference, and SARC-F questionnaire to identify sarcopenia in elderly compared to asian working group for sarcopenia's diagnostic standard. *Acta Med Indones*, *51*(2), 117-127.

Miller, A. R., Mâsse, L. C., Shen, J., Schiariti, V., & Roxborough, L. (2013). Diagnostic status, functional status and complexity among Canadian children with neurodevelopmental disorders and disabilities: a population-based study. *Disability and Rehabilitation*, *35*(6), 468-478.

Mills, K. T., Stefanescu, A., & He, J. (2020). The global epidemiology of hypertension. *Nature Reviews Nephrology*, *16*(4), 223-237.

Mitrushina, M., & Tomaszewski, R. (2019). Factors associated with return to work in patients with long-term disabilities due to neurological and neuropsychiatric disorders. *Neuropsychological rehabilitation*, *29*(9), 1313-1331.

Mockford, M., & Caulton, J. M. (2010). The pathophysiological basis of weakness in children with cerebral palsy. *Pediatric Physical Therapy*, *22*(2), 222-233.

Moll, I., Vles, J. S., Soudant, D. L., Witlox, A. M., Staal, H. M., Speth, L. A., Janssen-Potten, Y. J. M., Coenen, M., Koudijs, S. M., & Vermeulen, R. J. (2017). Functional electrical stimulation of the ankle dorsiflexors during walking in spastic cerebral palsy: a systematic review. *Developmental Medicine & Child Neurology*, *59*(12), 1230-1236.

Moreno-De-Luca, A., Myers, S. M., Challman, T. D., Moreno-De-Luca, D., Evans, D. W., & Ledbetter, D. H. (2013). Developmental brain dysfunction: revival and expansion of old concepts based on new genetic evidence. *The Lancet Neurology*, *12*(4), 406-414.

Muff, G., Dufour, S., Meyer, A., Severac, F., Favret, F., Geny, B., ... & Isner-Horobeti, M. E. (2016). Comparative assessment of knee extensor and flexor muscle strength measured using a hand-held vs. isokinetic dynamometer. *Journal of physical therapy science*, *28*(9), 2445-2451.

Muscular Dystrophy UK (2015). Powerchair football. *Muscular Dystrophy UK*. Retrieved from <u>https://www.musculardystrophyuk.org/get-involved/your-money/powerchair-</u>football/

Nam, H. J., & Yoon, J. Y. (2022). Factors and at-risk group associated with hypertension self-management patterns among people with physical disabilities: a latent class analysis. *BMC Public Health*, 22(1), 1-12.

Noble, J. J., Gough, M., & Shortland, A. P. (2019). Selective motor control and gross motor function in bilateral spastic cerebral palsy. *Developmental Medicine & Child Neurology*, *61*(1), 57-61.

Nogueira, L. A. C., Teixeira, L., Sabino, P., Filho, H. A., Alvarenga, R. M. P., & Thuler, L. C. (2013). Gait characteristics of multiple sclerosis patients in the absence of clinical disability. *Disability and rehabilitation*, *35*(17), 1472-1478.

Noorkoiv, M., Lavelle, G., Theis, N., Korff, T., Kilbride, C., Baltzopoulos, V., Shortland, A., & Ryan, J. M. (2019). Predictors of walking efficiency in children with cerebral palsy: lower-body joint angles, moments, and power. *Physical therapy, 99*(6), 711-720.

Novak-Pavlic, M., Rosenbaum, P., Macedo, L. G., Di Rezze, B., Yong, J., Noori, A., & Hughes, D. (2022). Effectiveness of Interventions to Promote Physical, Psychological, and Socioeconomic Well-being Outcomes of Parents of Children With Neurodevelopmental Disabilities: Protocol for a Systematic Review. *JMIR Research Protocols*, *11*(7), 1-8.

Okuyama, F., & Oka, K. (2009). Correlates of physical inactivity among individuals with physical disabilities. *International Journal of Sport and Health Science*, *7*, 69-78.

Ong, C. F., Geijtenbeek, T., Hicks, J. L., & Delp, S. L. (2019). Predicting gait adaptations due to ankle plantarflexor muscle weakness and contracture using physicsbased musculoskeletal simulations. *PLoS computational biology*, *15*(10), e1006993.

Opheim, A., Jahnsen, R., Olsson, E., & Stanghelle, J. K. (2009). Walking function, pain, and fatigue in adults with cerebral palsy: a 7-year follow-up study. *Developmental Medicine & Child Neurology*, *51*(5), 381-388.

Osibogun, O., Ogunmoroti, O., Spatz, E. S., Fashanu, O. E., & Michos, E. D. (2020). Ideal cardiovascular health and resting heart rate in the Multi-Ethnic Study of Atherosclerosis. *Preventive medicine*, *130*, 1-8.

Palatini, P., & Asmar, R. (2018). Cuff challenges in blood pressure measurement. *The Journal of Clinical Hypertension*, *20*(7), 1100-1103.

Palatini, P., Asmar, R., O'Brien, E., Padwal, R., Parati, G., Sarkis, J., Stergiou, G., & European Society of Hypertension Working Group on Blood Pressure Monitoring.
(2020). Recommendations for blood pressure measurement in large arms in research and clinical practice: position paper of the European society of hypertension working group on blood pressure monitoring and cardiovascular variability. *Journal of Hypertension*, *38*(7), 1244-1250.

Palisano, R. J., Di Rezze, B., Stewart, D., Rosenbaum, P. L., Hlyva, O., Freeman, M., ...
& Gorter, J. W. (2017). Life course health development of individuals with
neurodevelopmental conditions. *Developmental Medicine & Child Neurology*, *59*(5),
470-476.

68

Park, E. Y., & Kim, W. H. (2014). Meta-analysis of the effect of strengthening interventions in individuals with cerebral palsy. *Research in developmental disabilities*, *35*(2), 239-249.

Peebles, A. T., Carroll, M. M., Socha, J. J., Schmitt, D., & Queen, R. M. (2021). Validity of using automated two-dimensional video analysis to measure continuous sagittal plane running kinematics. *Annals of biomedical engineering*, *49*, 455-468.

Peterson, M. D., Lin, P., Kamdar, N., Mahmoudi, E., Schmidt, M. M., Haapala, H. J., & Hurvitz, E. A. (2020). Cardiometabolic morbidity in adults with cerebral palsy and spina bifida. *The American journal of medicine*, *133*(12), e695-e705.

Peterson, M. D., Pistilli, E., Haff, G. G., Hoffman, E. P., & Gordon, P. M. (2011). Progression of volume load and muscular adaptation during resistance exercise. *European journal of applied physiology*, *111*(6), 1063-1071.

Phillips, S., Turner, A., & Lousada, H. (2017). *Physiological responses of individuals with Cerebral Palsy to Racerunning training*. Poster session presented at UK Paralympic Performance Conference, Burton upon Trent, United Kingdom.

Piepoli, M. F., Corrà, U., Adamopoulos, S., Benzer, W., Bjarnason-Wehrens, B., Cupples, M., ... & Giannuzzi, P. (2014). Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery: a policy statement from the cardiac rehabilitation section of the European Association for Cardiovascular Prevention & Rehabilitation. Endorsed by the Committee for Practice Guidelines of the European Society of Cardiology. *European journal of preventive cardiology*, *21*(6), 664-681.

Quest (2020, June 2) *Introducing Running frames and frame running*. Quest88. https://quest88.com/blogs/knowledge-centre/get-involved-with-racerunning.

RaceRunning.org. (2020, May 5). WPA are proposing to the IPC to include RaceRunning in Paris 2024. <u>https://racerunning.org/news/wpa-are-proposing-to-the-ipc-to-include-frame-running-in-paris-2024/</u>. Reedman, S. E., Sakzewski, L., McNamara, L., Sherrington, C., Beckman, E., West, K., Trost, S. G., Thomas, R., Chatfield, M. D., Dutia, I., Gennen, A., Dodds, B., Cotton, Z., & Boyd, R. N. (2022). Study protocol for Running for health (Run4Health CP): a multicentre, assessor-blinded randomised controlled trial of 12 weeks of two times weekly RaceRunningtraining versus usual care to improve cardiovascular health risk factors in children and youth with cerebral palsy. *BMJ open*, *12*(4), 1-12.

Reimers, A. K., Knapp, G., & Reimers, C. D. (2018). Effects of exercise on the resting heart rate: a systematic review and meta-analysis of interventional studies. *Journal of clinical medicine*, *7*(12), 503.

Rimmer, J. H. (2005). The conspicuous absence of people with disabilities in public fitness and recreation facilities: lack of interest or lack of access?. *American Journal of Health Promotion*, *19*(5), 327-329.

Rimmer, J. H., Padalabalanarayanan, S., Malone, L. A., & Mehta, T. (2017). Fitness facilities still lack accessibility for people with disabilities. *Disability and health journal*, *10*(2), 214-221.

Rosenbaum, P., Paneth, N., Leviton, A., Goldstein, M., Bax, M., Damiano, D., ... & Jacobsson, B. (2007). A report: the definition and classification of cerebral palsy April 2006. *Dev Med Child Neurol Suppl, 109*, 8-14.

Rosenbaum, P., & Gorter, J. W. (2012). The 'F-words' in childhood disability: I swear this is how we should think!. *Child: care, health and development*, *38*(4), 457-463.

Ryan, J. M., Crowley, V. E., Hensey, O., Broderick, J. M., McGahey, A., & Gormley, J. (2014). Habitual physical activity and cardiometabolic risk factors in adults with cerebral palsy. *Research in developmental disabilities*, *35*(9), 1995-2002.

Ryan, J. M., Hensey, O., McLoughlin, B., Lyons, A., & Gormley, J. (2015). Associations of sedentary behaviour, physical activity, blood pressure and anthropometric measures with cardiorespiratory fitness in children with cerebral palsy. *PloS one*, *10*(4), 1-13.

Ryan, J. M., Lavelle, G., Theis, N., Noorkoiv, M., Kilbride, C., Korff, T., Baltzopoulos, V., Shortland, A., Levin, W., & Star Trial Team. (2020a). Progressive resistance training for

adolescents with cerebral palsy: the STAR randomized controlled trial. *Developmental Medicine & Child Neurology*, 62(11), 1283-1293.

Ryan, J., Theis, N., Koufaki, P., Phillips, S., Anokye, N., Andreopoulou, G., Kennedy, F., Jagadamma, K. C., van Schie, P., Dines, H & van der Linden, M. L. (2020b). Effect of RaceRunning on cardiometabolic disease risk factors and functional mobility in young people with moderate-to-severe cerebral palsy: protocol for a feasibility study. *BMJ open*, *10*(7), e036469.

Santos, L. P., Gonzalez, M. C., Orlandi, S. P., Bielemann, R. M., Barbosa-Silva, T. G., Heymsfield, S. B., & Coconut Study Group. (2019). New prediction equations to estimate appendicular skeletal muscle mass using calf circumference: results from NHANES 1999–2006. *Journal of Parenteral and Enteral Nutrition*, *43*(8), 998-1007.

Savci, S., Ozturk, M., Inal-Ince, D., Gultekin, Z., Arikan, H., & Sivri, H. S. K. (2006). Inspiratory muscle training in Morquio's syndrome: a case study. *Pediatric pulmonology*, *41*(12), 1250-1253.

Schlichta, C., Cabral, L. L., da Silva, C. K., Bigliassi, M., & Pereira, G. (2022). Exploring the Impact of Mental Fatigue and Emotional Suppression on the Performance of High-Intensity Endurance Exercise. *Perceptual and Motor Skills*, *129*(4) 1053–1073.

Sedgwick, P. (2015). A comparison of parametric and non-parametric statistical tests. *BMJ*, *350*.

Serdar, C. C., Cihan, M., Yücel, D., & Serdar, M. A. (2021). Sample size, power and effect size revisited: simplified and practical approaches in pre-clinical, clinical and laboratory studies. *Biochemia medica*, *31*(1), 27-53.

Sethi, S. (2010). Infection as a comorbidity of COPD. *European Respiratory Journal*, *35*(6), 1209-1215.

Shaffer, F., & Ginsberg, J. P. (2017). An overview of heart rate variability metrics and norms. *Frontiers in public health*, *5*, 258-275.

Shafizadeh, M., Theis, N., & Davids, K. (2019). Locomotor adaptations during RaceRunning in people with neurological motor disorders. *Adapted physical activity quarterly*, *36*(3), 325-338.

Shanks, J., & Herring, N. (2013). Peripheral cardiac sympathetic hyperactivity in cardiovascular disease: role of neuropeptides. *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology*, 305(12), R1411-R1420.

Sharman, J. E., Avolio, A. P., Baulmann, J., Benetos, A., Blacher, J., Blizzard, C. L., ... & Vlachopoulos, C. (2017). Validation of non-invasive central blood pressure devices: ARTERY Society task force consensus statement on protocol standardization. *European heart journal*, *38*(37), 2805-2812.

Shevell, M. I. (2010). Present conceptualization of early childhood neurodevelopmental disabilities. *Journal of Child Neurology*, *25*(1), 120-126.

Shields, N., & Synnot, A. (2016). Perceived barriers and facilitators to participation in physical activity for children with disability: a qualitative study. *BMC pediatrics*, *16*(1), 1-10.

Shih, H. C. (2017). A survey of content-aware video analysis for sports. IEEE Transactions on Circuits and Systems for Video Technology, 28(5), 1212-1231.

Shirazipour, C. H., Evans, M. B., Leo, J., Lithopoulos, A., Martin Ginis, K. A., & Latimer-Cheung, A. E. (2020). Program conditions that foster quality physical activity participation experiences for people with a physical disability: a systematic review. *Disability and rehabilitation*, *42*(2), 147-155.

Shortland, A. (2009). Muscle deficits in cerebral palsy and early loss of mobility: can we learn something from our elders?. *Developmental Medicine & Child Neurology*, *51*, 59-63.

Siddique, U., Rahman, S., Frazer, A. K., Pearce, A. J., Howatson, G., & Kidgell, D. J. (2020). Determining the sites of neural adaptations to resistance training: a systematic review and meta-analysis. *Sports Medicine*, *50*(6), 1107-1128.

Siuly, S., & Zhang, Y. (2016). Medical big data: neurological diseases diagnosis through medical data analysis. *Data Science and Engineering*, *1*(2), 54-64.

Smith, M., Neibling, B., Williams, G., Birks, M., & Barker, R. (2019). A qualitative study of active participation in sport and exercise for individuals with multiple sclerosis. *Physiotherapy Research International*, *24*(3), e1776.

Song, P., Fang, Z., Wang, H., Cai, Y., Rahimi, K., Zhu, Y., Fowkes, F. G. R., Fowkes, F. J. I., & Rudan, I. (2020). Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study. *The Lancet Global Health*, *8*(5), e721-e729.

Soper, A. K., Cross, A., Rosenbaum, P., & Gorter, J. W. (2019). Exploring the international uptake of the "F-words in childhood disability": A citation analysis. *Child: Care, Health and Development, 45*(4), 473-490.

Sperl, C. (2018) Race Running-ein Sport mit noch unentdecktem Potential: Verbesserung der Leistungsfähigkeit und der Lebensqualität von Menschen mit Zerebralparese/vorgelegt von Christina Sperl, Bakk. phil., BSc [Doctoral dissertation] Karl-Franzens-Universität Graz.

Stevenson, R. D., Conaway, M., Chumlea, W. C., Rosenbaum, P., Fung, E. B.,
Henderson, R. C., Worley, G., Liptak, G., O'Donnell, M., Samson-Fang, L., & Stallings,
V. A. (2006). Growth and health in children with moderate-to-severe cerebral palsy. *Pediatrics, 118*(3), 1010-1018.

Straudi, S., Manca, M., Aiello, E., Ferraresi, G., Cavazza, S., & Basaglia, N. (2009). Sagittal plane kinematic analysis of the six-minute walk test: a classification of hemiplegic gait. *Eur J Phys Rehabil Med*, *45*(3), 341-347.

Strohrmann, C., Harms, H., Kappeler-Setz, C., & Troster, G. (2012). Monitoring kinematic changes with fatigue in running using body-worn sensors. *IEEE transactions on information technology in biomedicine*, *16*(5), 983-990.

Sukal-Moulton, T., Egan, T., Johnson, L., Lein, C., & Gaebler-Spira, D. (2022). Use of RaceRunningfor adolescent athletes with movement challenges to support health and participation. *Frontiers in Sports and Active Living*, 45.

Sullivan, P. B. (2008). Gastrointestinal disorders in children with neurodevelopmental disabilities. *Developmental disabilities research reviews*, *14*(2), 128-136.

Surman, G., Hemming, K., Platt, M. J., Parkes, J., Green, A., Hutton, J., & Kurinczuk, J. J. (2009). Children with cerebral palsy: severity and trends over time. *Paediatric and perinatal epidemiology*, *23*(6), 513-521.

Sylta, Ø., Tønnessen, E., & Seiler, S. (2014). From heart-rate data to training quantification: a comparison of 3 methods of training-intensity analysis. *International journal of sports physiology and performance*, *9*(1), 100-107.

Tadic, M., Cuspidi, C., & Grassi, G. (2018). Heart rate as a predictor of cardiovascular risk. *European journal of clinical investigation*, *48*(3), 1-11.

Tant, M., & Watelain, E. (2016). Forty years later, a systematic literature review on inclusion in physical education (1975–2015): A teacher perspective. *Educational research review*, *19*, 1-17.

Tedroff, K., Knutson, L. M., & Soderberg, G. L. (2008). Co-activity during maximum voluntary contraction: a study of four lower-extremity muscles in children with and without cerebral palsy. *Developmental Medicine & Child Neurology*, *50*(5), 377-381.

Thapar, A., & Rutter, M. (2015). Neurodevelopmental disorders. *Rutter's child and adolescent psychiatry*, 31-40.

Theis, N., Mohagheghi, A. A., & Korff, T. (2016). Mechanical and material properties of the plantarflexor muscles and Achilles tendon in children with spastic cerebral palsy and typically developing children. *Journal of biomechanics*, *49*(13), 3004-3008.

Theis, N., Noorkoiv, M., Lavelle, G., & Ryan, J. (2021). Predictors of treatment response to progressive resistance training for adolescents with cerebral palsy. *Physical Therapy*, *101*(12), pzab202.

Tolonen, H., Koponen, P., Naska, A., Männistö, S., Broda, G., Palosaari, T., & Kuulasmaa, K. (2015). Challenges in standardization of blood pressure measurement at the population level. *BMC medical research methodology*, *15*(1), 1-11.

Van Biljon, A., McKune, A. J., DuBose, K. D., Kolanisi, U., & Semple, S. J. (2018). Do short-term exercise interventions improve Cardiometabolic risk factors in children?. *The Journal of pediatrics*, *203*, 325-329.

Van Cutsem, J., Marcora, S., De Pauw, K., Bailey, S., Meeusen, R., & Roelands, B. (2017). The effects of mental fatigue on physical performance: a systematic review. *Sports medicine*, *47*(8), 1569-1588.

Van der Linden, M. L., Jahed, S., Tennant, N., & Verheul, M. H. (2018). The influence of lower limb impairments on RaceRunning performance in athletes with hypertonia, ataxia or athetosis. *Gait & posture*, *61*, 362-367.

Van der Linden, M. L., Corrigan, O., Tennant, N., & Verheul, M. H. (2021). Cluster analysis of impairment measures to inform an evidence-based classification structure in RaceRunning, a new World Para Athletics event for athletes with hypertonia, ataxia or athetosis. *Journal of Sports Sciences*, *39* (1), 159-166.

Van der Linden, M. L., Van Schie, P. E., Hjalmarsson, E., Andreopoulou, G., Verheul, M. H., & Von Walden, F. (2022). Athlete-perceived impact of RaceRunningon physical fitness, functional mobility and psychosocial outcomes. *Journal of rehabilitation medicine*, *54*, 1-8.

Van Lindert, C., Scheerder, J., & Brittain, I. (2023). The Landscape of Sport for Persons with a Disability: A System Within a System. In *The Palgrave Handbook of Disability Sport in Europe: Policies, Structures and Participation* (pp. 561-598). Cham: Springer International Publishing.

Van Schie, P. E., van Eck, M., Bonouvrié, L. A., Bos, A. M. E., & Buizer, A. I. (2022). The Impact of RaceRunningon Quality of Life in Young Athletes With Mobility Limitations. *Frontiers in sports and active living*, *4*, 1-8. Verschuren, O., Peterson, M. D., Balemans, A. C., & Hurvitz, E. A. (2016). Exercise and physical activity recommendations for people with cerebral palsy. *Developmental Medicine & Child Neurology*, *58*(8), 798-808.

Verschuren, O., Smorenburg, A. R., Luiking, Y., Bell, K., Barber, L., & Peterson, M. D. (2018). Determinants of muscle preservation in individuals with cerebral palsy across the lifespan: a narrative review of the literature. *Journal of cachexia, sarcopenia and muscle*, *9*(3), 453-464.

Waninge, A., Van der Putten, A. A., Stewart, R. E., Steenbergen, B., Van Wijck, R., & Van der Schans, C. P. (2013). Heart rate and physical activity patterns in persons with profound intellectual and multiple disabilities. *The Journal of Strength & Conditioning Research*, *27*(11), 3150-3158.

Walkeden, S., & Walker, K. M. (2015). Perceptions of physiotherapists about their role in health promotion at an acute hospital: a qualitative study. *Physiotherapy*, *101*(2), 226-231.

Wang, L., Yin, L., Zhao, Y., Su, Y., Sun, W., Chen, S., ... & Engelke, K. (2021). Muscle density, but not size, correlates well with muscle strength and physical performance. *Journal of the American Medical Directors Association*, 22(4), 751-759.

Whitney, D. G., Caird, M. S., Jepsen, K. J., Kamdar, N. S., Marsack-Topolewski, C. N., Hurvitz, E. A., & Peterson, M. D. (2020). Elevated fracture risk for adults with neurodevelopmental disabilities. *Bone*, *130*, 115080.

WHO. (2022). *Birth defects*. World Health Organization <u>https://www.who.int/news-</u> room/fact-sheets/detail/birth-defects

Willemse, L., Brehm, M. A., Scholtes, V. A., Jansen, L., Woudenberg-Vos, H., & Dallmeijer, A. J. (2013). Reliability of isometric lower-extremity muscle strength measurements in children with cerebral palsy: implications for measurement design. *Physical therapy*, *93*(7), 935-941.

Wright, A., Roberts, R., Bowman, G., & Crettenden, A. (2019). Barriers and facilitators to physical activity participation for children with physical disability: comparing and

contrasting the views of children, young people, and their clinicians. *Disability and rehabilitation*, *41*(13), 1499-1507.

Wu, H., Wu, J., Zhang, Z., Zheng, Y., Niu, W., Zheng, L., & Li, J. (2021). Prevalence and associated risk factors of hypertension in adults with disabilities: a cross-sectional study in Shanghai, China. *Clinical Epidemiology*, 769-777.

Xia, S., Guo, S., Li, J., & Istook, C. (2019). Comparison of different body measurement techniques: 3D stationary scanner, 3D handheld scanner, and tape measurement. *The Journal of the Textile Institute*, *110*(8), 1103-1113.

Yang, Y., Zhang, X., Luo, Z., Wang, X., Ye, D., & Fu, W. (2020). Alterations in running biomechanics after 12 week gait retraining with minimalist shoes. *International Journal of Environmental Research and Public Health*, *17*(3), 818.

Yuan, K. H., & Maxwell, S. (2005). On the post hoc power in testing mean differences. *Journal of educational and behavioral statistics*, *30*(2), 141-167.

Zhang, Z., & Chen, W. (2019). A systematic review of measures for psychological wellbeing in physical activity studies and identification of critical issues. *Journal of affective disorders*, *256*, 473-485.

Zhang, W., Zhang, S., Deng, Y., Wu, S., Ren, J., Sun, G., ... & Cai, J. (2021). Trial of intensive blood-pressure control in older patients with hypertension. *New England Journal of Medicine*, *385*(14), 1268-1279.

Zhang, X., Zhang, S., Wang, C., Wang, B., & Guo, P. (2014). Effects of moderate strength cold air exposure on blood pressure and biochemical indicators among cardiovascular and cerebrovascular patients. *International journal of environmental research and public health*, *11*(3), 2472-2487.

Zwinkels, M., Verschuren, O., de Groot, J. F., Backx, F. J., Wittink, H., Visser-Meily, A., & Takken, T. (2019). Effects of high-intensity interval training on fitness and health in youth with physical disabilities. *Pediatric Physical Therapy*, *31*(1), 84-93.

Appendices

Appendix 1.1 Project Approval Form





PROJECT APPROVAL

This form should be completed by every candidate and submitted for approval to the School PGR Lead. Please refer to the Research Student Handbook and the Academic Regulations for Research Degrees Provision for further detailed information.

SECTION 1: STU	DENT TO COMPLETE								
Family Name	Thacker	First Name	Elizabeth						
Student number		Mode of Study	Full time						
RESEARCH DEGREE PROJECT: Master of Science by Research COLLABORATING ESTABLISHMENT (A collaborating establishment is an organisation that enters into a formal written agreement with the University to provide facilities and other resources, e.g. access to a database, library, archive etc. A letter of support from the collaborating establishment confirming any agreed arrangements must accompany this application). N/A									
TITLE OF YOUR RESEARCH PROJECT - The effect of RaceRunning on physical health in individuals with moderate-to-severe neurodevelopmental disabilities.									
PROPOSED PLAN OF WORK The total word count for this section, a) to d), is a maximum of 1,500 words, excluding bibliography. All plans should address the required headings set out below a) AIM OF THE RESEARCH									
· ·		the research and	d comment on its wider						

The aim of the research is to determine the effect of 12 weeks RaceRunning on physical health in individuals with moderate-to-severe neurodevelopmental disabilities.

b) RESEARCH OBJECTIVES

(These must be highly focused and feasible)

- 1. To examine the effect of 12 weeks of RaceRunning on, thigh and calf circumference, muscular strength, cardiorespiratory fitness and resting heart rate and blood pressure, in individuals with moderate-to-severe neurodevelopmental disabilities.
- 2. To examine the effect of 12 weeks of RaceRunning on running gait in individuals with moderate-to-severe neurodevelopmental disabilities.

c) IMPORTANCE AND ORIGINALITY OF THE RESEARCH

(This should be related to a brief literature review of the field of study).

Neurodevelopmental disabilities (NDD) is a group of disabilities caused by disruption to the developing brain, such as rare genetic syndromes, cerebral palsy (CP), congenital neural anomalies and neurological motor disorders (Thapar & Rutter, 2015). In the UK approximately 6% of the population have some form of neurological motor disorder that affects participation in everyday activities (Nouraei et al., 2017; Gagnon, 2020; Jacobson, 2020) and makes it challenging for these individuals to access provisions which promote health and wellbeing (Shafizadeh et al., 2019). As a result, those with moderate-to-severe NDD are often at an increased risk of developing cardiorespiratory disorders (Ravesloot et al., 2007; Wu et al., 2010).

Whilst it is well established that exercise provides a wide variety of benefits and can reduce the risk of cardiovascular disease, individuals with disabilities are often presented with several challenges that prevent them from participating in sport or activities that may reduce the risk (Butler et al., 2010; Jaarsma et al., 2015). Around 70-75% of people with disabilities do not participate in any sport or physical activity (Shafizadeh et al., 2019). Of the sports which are specifically designed for moderate-to-severely disabled individuals (e.g Boccia), they lack the intensity which are associated with a greater reduction in cardiovascular disease prevalence (Carlon et al., 2013; Faria et al., 2014; Łosień et al., 2018; Hjalmarsson et al., 2020).

RaceRunning is a growing disability sport specifically for individuals with moderate-to severe-neurological motor disorders. Whilst research around the effects of RaceRunning for those with CP has begun to emerge, there still remains limited findings particularly in other NDD (Ryan et al., 2020). In the few studies that have investigated the effects of RaceRunning, improved aerobic fitness, stamina and overall wellbeing was noted (Bryant, & Pickering., 2015; Phillips et al., 2017; Hjalmarsson et al., 2020). Pilot studies suggest that individuals with severe cases of CP can achieve moderate-to vigorous-physical activity levels through RaceRunning, with positive effects such as improved aerobic capacity, bone health and muscle thickness, cardiorespiratory endurance and passive range of motion, following 12 weeks of RaceRunning training (Bryant et al., 2015; Hjalmarsson et al., 2020). CP is considered the most prevalent physical disability in childhood, with around 2-2.5 per 1000s births (Hjalmarsson et al., 2020; Ostojic et al., 2020). However, whilst these articles highlight the benefits for RaceRunning for individuals with CP, they are not inclusive of other

disabilities. The proposed study will add to the growing body of research, to investigate the effect of 12 weeks RaceRunning on physical health and quality of life for those with NDD.

d) PROPOSED RESEARCH METHODS

(This should state your methods and your rationale for their use. This section should also discuss the ethical dimensions of the chosen research methods and steps taken to address any issues that arise from them)

Based on current research by Hjalmarsson et al., (2020), as a result of similar testing parameters, 10 participants will be recruited as determined via a sample size calculation based on an effect size of 0.426. This will consist of young people and adults with moderate-to-severe NDD. Recruitment will take place through local RaceRunning clubs in Gloucester, Bath and Cardiff. When designing this study, acknowledgements of resource constraints (Lakens, 2021) were made due to there being only 8 clubs that provide RaceRunning opportunities in England and Wales (Quest, 2020, June 2). Participants will be aged 6-35 years to capture the diversity of those involved in RaceRunning and similar reports were shown by Hjalmarsson et al., (2020) as they utilised an age range of 9-29 years old. Written consent will be gained from all participants over the age of 16 years. For those under 16 years, written assent will be gained from the parent/carer and verbal consent will be gained by the participant themselves. Ethical approval for this study has already been granted. To be eligible to take part, participants will be taking part in one hourly RaceRunning session per week for 12 weeks. Sessions at the clubs used for recruitment are led by an experienced coach who has attended the RaceRunning coaching course. These sessions will generally consist of a warm up, followed by a series drills depending on what the aims of the session are and then a cool down to end the session. The nature of delivery will be challenging to control in terms of available facilities as they can contribute to multiple confounding variables such as weather conditions. This could affect the findings of the study. Furthermore, coaching style at each location may differ as a result of different participant aims (recreational versus competitive) and resource constraints resulting in recruitment from multiple locations. Utilising this group regardless of whether they participate in RaceRunning recreationally or competitively is beneficial for the study however will have to be taken into consideration when analysing the findings. As a result of the COVID-19 pandemic, individuals with disabilities have significantly reduced levels of physical activity due to the long-term consequence of quarantine (Di Stefano et al., 2021). This will enable more individuals to be recruited as they have not been participating in the sport for a significant amount of time.

Assessments will be conducted at baseline and 12 weeks. The study will collect demographic information including age, sex, the nature of the disability. Physical health will involve measuring resting heart rate and blood pressure using a heart rate monitor (Heart Rate Monitors: Models Fs3c, FT1, 610i, 810i, RS800CX, RCX5, FT7, Polar, Electro Oy, Kempele, Finland) and blood pressure cuff and machine (Blood pressure machines: Omron RX-M, HEM-628-E, Omron Corporation, Kyoto, 600-8530, Japan). Thigh and calf circumference will be measured using an anthropometric tape measure

at the most prominent point of the muscle belly. Due to the available facilities, all tests will be conducted outdoors which will pose a challenge to control external variables and will be taken into consideration when discussing the findings of the study. The same clothing will be worn to ensure that the thickness of the material does not change and affect the findings. Whilst this method is beneficial in terms of being non-invasive and practical, there is more potential for human error therefore measurements will be taken multiple times to ensure more reliable results. Knee flexor and extensor strength as well as ankle plantarflexion strength will be recorded using a handheld dynamometer.

Participants will also be asked to perform a 6-minute RaceRunning test (6MRT) proposed by Bolster et al., (2017) as a reliable method of assessing cardiorespiratory fitness. It consists of participants propelling themselves continuously for 6 minutes, at a pace that they are able to maintain for the full duration and will be encouraged throughout. As the test progresses, participants will gradually feel fatigued and intensity will generally increase due to the extent they are continually moving for. Participants will do the test on a running track and therefore their pace can be monitored based on the number of laps they are able to complete throughout. Any additional distance will be measured using a measuring wheel (Screwfix, United Kingdom). Finally, video footage of RaceRunning technique will be collected to determine whether there are changes in gait over the 12 weeks. This will be conducted via triangulating a Canon XM2 Digital Video Camera (Canon Inc., Tokyo, Japan) across a 5-metre distance. The video footage will be recorded during the 6MRT and analysed using Quintics Biomechanics Software v.26 (Quintic, Sutton Coldfield, UK). Analysis will consist of collecting all sagittal plane kinematic values for the hip, knee and ankle at initial contact, midstance, toe-off and swing phases. Kinematic curves will help to determine the values of each location. Understanding the gait whilst participating in RaceRunning will be beneficial as there are no reported articles on this specific area. By analysing their gait, the aim is to determine whether there is a difference over the 12-week period, with the findings potentially being used by coaches for performance and/or healthcare professionals in terms of overall health.

Data for all tests will be analysed using a series of t-tests on SPSS to assess differences in each variable at baseline and at 12 weeks.

BIBLIOGRAPHY (20 references should suffice and the bibliography should be presented in the style approved within your discipline. You may wish to refer to your supervisor if unsure).

Bloemen, M., Van Wely, L., Mollema, J., Dallmeijer, A., & de Groot, J. (2017). Evidence for increasing physical activity in children with physical disabilities: a systematic review. Developmental Medicine & Child Neurology, 59(10), 1004-1010.

Bolster, E. A., Dallmeijer, A. J., de Wolf, G. S., Versteegt, M., & Schie, P. E. V. (2017). Reliability and construct validity of the 6-minute Racerunner test in children and youth with cerebral palsy, GMFCS levels III and IV. Physical & Occupational Therapy in Pediatrics, 37(2), 210-221.

Bryant, E., & Pickering, D. (2015, December 8). *RaceRunning: improving health and wellbeing in people with cerebral palsy* [Conference presentation] Disability Sports Development Conference, Nottingham, UK.

Bryant, E., Cowan, D., & Walker-Bone, K. (2015). The introduction of Petra running bikes to non-ambulant children with cerebral palsy. Abstract from 27th Annual Meeting of the European Academy of Childhood Disability (EACD), Copenhagen, Denmark, 34-35.

Butler, J. M., Scianni, A., & Ada, L. (2010). Effect of cardiorespiratory training on aerobic fitness and carryover to activity in children with cerebral palsy: a systematic review. International Journal of Rehabilitation Research, 33(2), 97-103.

Bolster, E. A., Dallmeijer, A. J., de Wolf, G. S., Versteegt, M., & Schie, P. E. V. (2017). Reliability and construct validity of the 6-minute racerunner test in children and youth with cerebral palsy, GMFCS levels III and IV. Physical & occupational therapy in pediatrics, 37(2), 210-221.

Carlon, S. L., Taylor, N. F., Dodd, K. J., & Shields, N. (2013). Differences in habitual physical activity levels of young people with cerebral palsy and their typically developing peers: a systematic review. Disability and rehabilitation, 35(8), 647-655.

Donnell, R. O., Verellen, J., Van de Vliet, P., & Vanlandewijck, Y. (2010). Kinesiologic and metabolic responses of persons with cerebral palsy to sustained exercise on a petra race runner. European Journal of Adapted Physical Activity, 3(1).

Gagnon, M. (2020). Assessments and interventions for youths with arthrogryposis multiplex congenita. McGill University (Canada).

Gitimoghaddam, M., Vanderloo, L. M., Hung, R., Ryce, A., McKellin, W., Miller, A., & Collet, J. P. (2021). Impacts of Participation in Community-Based Physical Activity Programs on Cognitive Functions of Children and Youth with Neurodevelopmental Disabilities: A Scoping Review. Brain Sciences, 11(2), 195.

Hjalmarsson, E., Fernandez-Gonzalo, R., Lidbeck, C., Palmcrantz, A., Jia, A., Kvist, O., ... & von Walden, F. (2020). RaceRunning training improves stamina and promotes skeletal muscle hypertrophy in young individuals with cerebral palsy. BMC musculoskeletal disorders, 21, 1-9.

Johnston, T. E., Moore, S. E., Quinn, L. T., & Smith, B. T. (2004). Energy cost of walking in children with cerebral palsy: relation to the Gross Motor Function Classification System. Developmental Medicine & Child Neurology, 46(1), 34-38.

Jaarsma, E. A., Dijkstra, P. U., de Blécourt, A. C., Geertzen, J. H., & Dekker, R. (2015). Barriers and facilitators of sports in children with physical disabilities: a mixed-method study. Disability and rehabilitation, 37(18), 1617-1625.

Jacobson, D. (2020). Cerebral palsy: studies on health and social outcomes in young adulthood, and on treatments for spasticity and pain. [Doctoral Thesis] Karolinska Instituet.

Kristjánsson, L. M. (2018). Lower Limb Muscle Fatigue Analysis of RaceRunning Athletes with Cerebral Palsy. KTH Royal Institute of Technology. 1-51.

Lakens, D. (2021). Sample size justification. Eindhoven University of Technology, 1-31.

Nouraei, H., Sawatzky, B., MacGillivray, M., & Hall, J. (2017). Long-term functional and mobility outcomes for individuals with arthrogryposis multiplex congenita. American Journal of Medical Genetics Part A, 173(5), 1270-1278.

Opheim, A., Jahnsen, R., Olsson, E., & Stanghelle, J. K. (2009). Walking function, pain, and fatigue in adults with cerebral palsy: a 7 - year follow - up study. Developmental Medicine & Child Neurology, 51(5), 381-388.

Ostojic, K., Paget, S., Kyriagis, M., & Morrow, A. (2020). Acute and chronic pain in children and adolescents with cerebral palsy: prevalence, interference, and management. Archives of physical medicine and rehabilitation, 101(2), 213-219.

Phillips, S., Turner, T., & Louseda, H. (2017). the acute physiological and metabolic response of individuals with CP to RaceRunning Training. Human Performance Science Research, VISTA conference 2017, Toronto, Canada.

Quest (2020, June 2) *Introducing Running frames and frame running*. Quest88. <u>https://quest88.com/blogs/knowledge-centre/get-involved-with-racerunning</u>

Ravesloot, C. H., Seekins, T., Cahill, T., Lindgren, S., Nary, D. E., & White, G. (2007). Health promotion for people with disabilities: development and evaluation of the Living Well with a Disability program. Health education research, 22(4), 522-531.

Rosenbaum, P., Paneth, N., Leviton, A., Goldstein, M., Bax, M., Damiano, D., ... & Jacobsson, B. (2007). A report: the definition and classification of cerebral palsy April 2006. Development Medicine Child Neurology. 109, 8-14.

Ryan, J. M., Cassidy, E. E., Noorduyn, S. G., & O'Connell, N. E. (2017). Exercise interventions for cerebral palsy. Cochrane Database of Systematic Reviews, (6).

Ryan, J., Theis, N., Koufaki, P., Phillips, S., Anokye, N., Andreopoulou, G., ... & van der Linden, M. (2020). The effect of RaceRunning on cardiometabolic disease risk factors and functional

mobility in young people with moderate-to-severe cerebral palsy: protocol for a feasibility study. Developmental Medicine & Child Neurology 2016, 58, 798–808.

Shafizadeh, M., Theis, N., & Davids, K. (2019). Locomotor adaptations during RaceRunning in people with neurological motor disorders. Adapted physical activity quarterly, 36(3), 325-338.

Slocum, C., Blauwet, C. A., & Allen, J. B. A. (2015). Sports medicine considerations for the paralympic athlete. Current Physical Medicine and Rehabilitation Reports, 3(1), 25-35.

Di Stefano, V., Battaglia, G., Giustino, V., Gagliardo, A., D'Aleo, M., Giannini, O., Palma, A., & Brighina, F. (2021). Significant reduction of physical activity in patients with neuromuscular disease during COVID-19 pandemic: the long-term consequences of quarantine. Journal of Neurology, 268(1), 20-26.

Thapar, A., & Rutter, M. (2015). Neurodevelopmental disorders. Rutter's child and adolescent psychiatry, 31-40.

van der Linden, M. L., Jahed, S., Tennant, N., & Verheul, M. H. (2018). The influence of lower limb impairments on RaceRunning performance in athletes with hypertonia, ataxia or athetosis. Gait & posture, 61, 362-367.

Verschuren, O., Peterson, M. D., Balemans, A. C., & Hurvitz, E. A. (2016). Exercise and physical activity recommendations for people with cerebral palsy. Developmental Medicine & Child Neurology, 58(8), 798-808.

Wu, S. K., Lin, H. H., Li, Y. C., Tsai, C. L., & Cairney, J. (2010). Cardiopulmonary fitness and endurance in children with developmental coordination disorder. Research in developmental disabilities, 31(2), 345-349.

TEMPORAL PLAN (Outline the time frame envisaged for your research tasks). Guidance notes: please use Gantt template provided or suitable alternative. This should include work undertaken to date (e.g. pilot study; literature review, etc.). Please refer to the Academic Regulations for Research Degree Provision for the maximum period of registration permitted for your programme of study. *SEE FINAL PAGE for CONTINUATION SHEET*

		Date										
Activities	Ju I	Au g	Sep t	Oc t	No v	De c	Jan	Fe b	Ma r	Ap r	Ma y	Jun e
Background Reading												

Literature							
Review							
Deuticinent							
Participant							
Paperwork							
(Par-Q,							
Health							
Questionnaire							
S,							
Informed							
Consent							
Forms)							
Ethical							
Approval							
Data							
Collection							
Conection							
Data							
Analysis							
, and you							
	$\left \right $						
Project							
Write-up							
Draft Hand In							
Improvement							
S							
Project							
Submission							
Submission							
L							

RESEARCH ETHICS

(The research must be ethically sound, and must be conducted in accordance with
the University's Research Ethics: A Handbook of Principles and Procedures, and with
be within the code of conduct for the specific discipline. Specific ethical issues,
including confidentiality, must be addressed within the proposed plan of work above):

1. My research will be conducted under the guidelines of (please tick):

ig The L	Jniversity of	Gloucestershire's	Handbook	of Research	Ethics
-----------	----------------------	-------------------	----------	-------------	--------

□ The University of Gloucestershire's standa	ard protocols in the exercise
--	-------------------------------

physiology laboratory

□ The NHS Research Governance Framework

 $\hfill\square$ The British Sociological Association

□ The British Psychological Society Code of Conduct

 $\hfill\square$ The British Educational Research Association

 $\hfill\square$ The Market Research Society

□ The Oral History Association

 \Box Other (please state and attach copy) _ _ _ _ _ _ _ _ _ _ _ _

2. Does this proposal contain elements that make reference to the University

Research Ethics Committee mandatory?

🛛 Yes 🗆 No

(Please see *Research Ethics: A Handbook of Principles and Procedures* Part A, section 6, and Guidelines for Working with Children and Young People)

2.3 - Informed Consent, 2.3.8, 2.3.10, 2.5, 2.6.1.6, 2.6.1.7

3. Any specific issues concerning the ethics of this research that require particular comment are detailed in section d) Proposed Research Methods on page _ _ [please enter page number].

STUDENT CHECKLIST

Before submitting your Project Approval Form to your Supervisor, please confirm that you have:

 \boxtimes Completed the form in full.

Checked the ethical implications of your project with your supervisor. Students requiring clearance from the University's Research Ethics Committee (UREC) need to take responsibility for submitting the appropriate paperwork to UREC and gaining the Committee's approval before commencing any data collection.

Signed and dated this page (by hand or electronically, but not a typed signature).

STATEMENT BY THE APPLICANT

I wish to apply for approval to undertake the above mentioned degree on the basis of the proposals given in this application. I confirm that the particulars given are correct and I understand that, except with specific permission, I must prepare and defend my thesis in English. I have read and understood the University of Gloucestershire's *Research Ethics: A Handbook of Principles and Procedures.* I agree to abide by the regulations, and the *Research Ethics Principles and Procedures* of the University.

Signature:

Date: 02/02/2022

NOW SEND THE COMPLETED AND SIGNED FORM TO YOUR SUPERVISOR(S)

RECOMMENDATION BY THE SUPERVISORY TEAM

I/We support this application and believe that the candidate has the potential to complete successfully the programme of work proposed. I/We recommend that the applicant's *Project* for the above research degree be submitted for review. I/We also confirm that the student has been advised of the review process and the possible outcomes.

Attach the **Project Approval - Supervisor Pre-submission checklist** to this document before submitting to the PGR Lead for review.

Are there any budget implications beyond those discussed at candidate's interview stage?

🛛 No

□ Yes. Please contact budget holder (usually the Head of School) and notify School PGR Lead

Name (including title): Dr Kiara Lewis

SIGNATURE:	Date: 26/11/2021
SECOND SUPERVISOR 2 (if applicable) Name (including title) Daniel Cowen	
SIGNATURE:	Date: 26/11/2021

NOW EMAIL THE COMPLETED FORM TO YOUR SCHOOL PGR LEAD OR NOMINATED LOCATION HIGHLIGHTED ON THE PROJECT APPROVAL PRE-SUBMISSION CHECKLIST FOR YOUR SCHOOL

SECTION 3: SCHOOL TO COMPLETE – PGR Lead or nominated member of School staff

I The student checklist has been completed

□ The student indicates the project should be referred to UREC in the 'Research Ethics' section. A copy of the Project Approval form has been passed to the Officer of UREC. [*Note: Approval for the project at REC should normally be confirmed before the PGR Lead passes the Project Approval form on for review.*]

Student and Supervisor(s) signatures have been added to the form

The Project Approval - Supervisor Pre-submission checklist has been received

☑ The supervisory team is appropriate and legal in relation to the Academic Regulations for Research Degree Provision.

If no, outline action to be taken below (e.g. appointment of second supervisor with specific skill range etc.)

If any of the boxes are not checked, please return the Project Approval form to the student for completion/correction.

I confirm that this form has passed an administrative check.

The following have been nominated as reviewer(s) for this proposal.

Reviewer 1: Dr Colin Baker

Reviewer 2: Prof Mark De Ste Croix

PGR LEAD NAME: Dr Colin Baker	Date: 26/11/2021

NOW EMAIL THE FORM TO THE REVIEWER(S)

SECTION 4: PGR LEAD TO COMPLETE						
FINAL RECOMMENDATION OF THE REVIEWERS						
I confirm the final recommendation of the reviewer(s) as						
REJECT (where a different award pathway can be offered, p	please note below)					
OFFER ALTERNATIVE AWARD PATHWAY						
Signature:	Date: 28/04/2022					

NOW EMAIL THE COMPLETED FORM TO THE STUDENT, SUPERVISOR(S) AND RESEARCH ADMINISTRATION OFFICE

CONTINUATION	CONTINUATION OF TEMPORAL PLAN										
	Date										
Activities		ΥΥΥΥ			YY	YY			YY	YY	

Appendix 1.2 Participant Information Letter (Adult)







The effect of RaceRunning on fitness and mobility in young people with cerebral palsy

'RaceRunning' is a sport that allows people who usually have problems walking or propelling a wheelchair, to move on their own using a 'running bike' or RaceRunner. We are trying to find out how RaceRunning affects your child's fitness and your everyday movement.

Before you decide whether you would like to join the study, it is important you know why this research is being done and what your role would be in it. So please read this leaflet carefully. Talk about it with your family, friends, physiotherapist if you want to. You can contact one of us on the email given at the end of this leaflet and ask any questions or concerns you may have.

Why are we doing this research?

People who take part in RaceRunning have told us that RaceRunning makes them feel better and fitter but there is no proper scientific evidence (proof) of this. With this study we want to find out if RaceRunning can improve fitness and mobility (e.g. walking, propelling a wheelchair or transferring in and out of a wheelchair).

Why have I been asked to take part?

You have been asked to take part, because you take part in RaceRunning.

What does the study involve?

If you agree to take part we will ask you to continue taking part in RaceRunning. We will measure a number of things at the start and 6 and 12 weeks later.

What will happen if I take part?

1. Before any assessments take place

We will start by making sure you are still happy to take part and we will ask you to sign a consent form.

We will ask you some questions about your use of a walking aid or wheelchair, if you take any medication, and if you have had surgery for your legs. We will also ask about your everyday mobility.

2. Assessment sessions (at your RaceRunning session) (0, 6 and 12 weeks)

We will ask you to complete some questionnaires, with questions such as how much physical activity you do, how many times you have visited a doctor or a therapist in the past 3 months and quality of life. You can complete these at home.

At each of the three testing sessions, we will start by measuring resting heart rate and blood pressure, which will take around 10 minutes. We will also measure muscle strength of the muscles in your legs, using a special machine called a hand-held dynamometer.

After this, we will ask you to do a RaceRunning specific fitness test on the track. We will ask you to run around the track for 6 minutes and cover as much distance as possible. You will wear the heart rate monitor whilst doing this.

We will also ask you to run 100 m as fast as you can while using your RaceRunner so that we can analyse your running style using a video camera.

Do I have to take part?

No! It is up to you. If you do wish to take part:

- > You will be asked to sign a form giving consent
- > You will be given a copy of the information sheet to keep
- > Your are free to stop taking part at any time during the research without giving a reason

Is there anything to be worried about?

If you are not used to regular exercise, taking part in RaceRunning may result in some muscle soreness during the first few sessions, but this should pass after a while and is a normal response to exercise. The fitness test will require you to give an 'all out' effort so you will feel out of breath. Of course, you can also stop at any time in the test without having to give a reason.

What are the possible benefits of taking part?

People taking part in RaceRunning have reported to enjoy RaceRunning and some feel taking part has improved their ability to transfer, stand or walk. However, this has not been scientifically proven and not everyone may experience the same positive effects. Our ultimate aim is to provide scientific evidence for possible positive and negative effects of RaceRunning on people's fitness, health and everyday mobility.

Who is organising and funding the research?

This research is conducted by researchers from the University of Gloucestershire and Queen Margaret University. The research is funded by Action Medical Research and the Chartered Society for Physiotherapy Charitable Trust.

What happens when the research project stops?

The information from the study will be collected and analysed and will be reported in a research paper. When you agree to take part in a research study, researchers from QMU and UoG will collect the minimum personally-identifiable information needed for the purposes of the research project. Information that you provide will only be used in the ways needed to conduct and analyse the research study. QMU and UoG will act as the data controller for this study. This means that we are responsible for looking after your information and using it properly. Both universities will keep identifiable information about you for 5 years after the study has finished.

Who has reviewed the study?

Every research study is checked by an ethics committee to make sure it is okay to do. This research has been checked and approved by the Queen Margaret University Divisional Research Ethics Committee and an NHS research ethical committee.

Contact details:

If you have any questions, then you can contact one of the research team:

Lizzie Thacker, Postgraduate Researcher,
Tel:
Dr Nicola Theis, Tel:

Thank you for reading this. You are welcome to ask any questions about this research

Appendix 1.3 Parent/Guardian Information Letter







The effect of RaceRunning on fitness and mobility in young people with cerebral palsy

'RaceRunning' is a sport that allows people who usually have problems walking or propelling a wheelchair, to move on their own using a 'running bike' or RaceRunner. We are trying to find out how RaceRunning affects your child's fitness and your everyday movement.

Before you decide whether you would like your child to join the study, it is important you know why this research is being done and what your child's role would be in it. So please read this leaflet carefully. Talk about it with your family, friends, physiotherapist if you want to. You can contact one of us on the email given at the end of this leaflet and ask any questions or concerns you may have.

Why are we doing this research?

People who take part in RaceRunning have told us that RaceRunning makes them feel better and fitter but there is no proper scientific evidence (proof) of this. With this study we want to find out if RaceRunning can improve fitness and mobility (e.g. walking, propelling a wheelchair or transferring in and out of a wheelchair).

Why has my child been asked to take part?

Your child has been asked to take part, because they have cerebral palsy and take part in RaceRunning.

What does the study involve?

If you agree for your child to take part we will ask them to continue taking part in RaceRunning. We will measure a number of things at the start and 6 and 12 weeks later.

What will happen to my child if we take part?

3. Before any assessments take place

We will start by making sure your child is still happy to take part and we will ask you and your child to sign a consent form.

We will ask you and your child some questions about their use of a walking aid or wheelchair, if they take any medication, and if they have had surgery for their legs. We will also ask about their everyday mobility.

4. Assessment sessions (at your child's RaceRunning session) (0, 6 and 12 weeks)

We will ask you and your child to complete some questionnaires, with questions such as how much physical activity they do, how many times they have visited a doctor or a therapist in the past 3 months and quality of life. You can complete these at home.

At each of the three testing sessions, we will start by measuring resting heart rate and blood pressure, which will take around 10 minutes. We will also measure muscle strength of the muscles in your child's legs, using a special machine called a hand-held dynamometer.

After this, your child will be asked to do a RaceRunning specific fitness test on the track. We will ask them to run around the track for 6 minutes and cover as much distance as possible. They will wear the heart rate monitor whilst doing this.

We will also ask your child to run 100 m as fast as they can while they are using the RaceRunner so that we can analyse their running style using a video camera.

Does my child have to take part?

No! It is up to you and your child. If you do wish your child to take part:

- > They will be asked to sign a form giving consent
- > They will be given a copy of the information sheet to keep

> Your child is free to stop taking part at any time during the research without giving a reason

Is there anything to be worried about?

If your child is not used to regular exercise in which they use their legs, taking part in RaceRunning may result in some muscle soreness during the first few sessions, but this should pass after a while and is a normal response to exercise. The fitness test will require your child to give their 'all out' effort so they will feel out of breath. For safety reasons, somebody will walk/run alongside your child throughout the test and will stop the test if necessary. Of course, your child can also stop at any time in the test without having to give a reason.

What are the possible benefits to my child, of taking part?

People taking part in RaceRunning have reported to enjoy RaceRunning and some feel taking part has improved their ability to transfer, stand or walk. However, this has not been scientifically proven and not everyone may experience the same positive effects. Our ultimate aim is to provide scientific evidence for possible positive and negative effects of RaceRunning on people's fitness, health and everyday mobility.

Who is organising and funding the research?

This research is conducted by researchers from the University of Gloucestershire and Queen Margaret University. The research is funded by Action Medical Research and the Chartered Society for Physiotherapy Charitable Trust.

What happens when the research project stops?

The information from the study will be collected and analysed and will be reported in a research paper. When you agree for your child to take part in a research study, researchers from QMU and UoG will collect the minimum personally-identifiable information needed for the purposes of the research project. Information about your child will be used in the ways needed to conduct and analyse the research study. QMU and UoG will act as the data controller for this study. This means that we are responsible for looking after your child's information and using it properly. Both universities will keep identifiable information about your child for 5 years after the study has finished.

Who has reviewed the study?

Every research study is checked by an ethics committee to make sure it is okay to do. This research has been checked and approved by the Queen Margaret University Divisional Research Ethics Committee and an NHS research ethical committee.

Contact details:

If you have any questions, then you can contact one of the research team:

- Lizzie Thacker, Postgraduate Researcher,

Thank you for reading this. You are welcome to ask any questions about this research

Appendix 1.4 Informed Consent Form

Informed consent form

Title of Project:	The effect of RaceRunning on fitness and mobility in young people with cerebral palsy
Principal investigator:	Nicola Theis Senior Lecturer in Sport & Exercise Biomechanics Faculty of Applied Sciences, University of Gloucestershire, Oxstalls Campus Oxstalls Lane, Gloucester, GL2 9HW

I am happy for myself/my child to take part in this study:

Printed Name: _____

Date: _____

Do you understand that we have asked you/your child to participate in a research study?	Yes	No
Have you read and received a copy of the information letter?	Yes	No
Do you understand the benefits and risks involved in you/your child taking part in this research study?	Yes	No
Do you understand that you are free to contact the research team to ask questions and discuss this study?	Yes	No
Do you understand that you are free to refuse your/your child's participation, or to withdraw from the study at any time, without consequence, and that your/your child's information will be withdrawn at your request?	Yes	No
Do you understand that we will keep your/your child's data confidential?	Yes	No
Do you understand who will have access to your/your child's information?	Yes	No

Signature:

For any questions, contact Dr Nicola Theis E: ntheis@glos.ac.uk T: 01242 715288

Appendix 1.5 Raw Data

1.5.1 SPSS Output for Descriptives (Mean and SD)

		ipuves		Std.
			Statistic	Error
RHRPR	Mean		84.33	7.232
E	95% Confidence	Lower	67.66	
	Interval for Mean	Bound		
		Upper	101.01	
		Bound		
	5% Trimmed Mean		83.87	
	Median		80.00	
	Variance		470.750	
	Std. Deviation		21.697	
	Minimum		56	
	Maximum		121	
	Range		65	
	Interquartile Range		33	
	Skewness		.835	.717
	Kurtosis		064	1.400
RHRPO	Mean		74.33	5.022
ST	95% Confidence	Lower	62.75	
	Interval for Mean	Bound		
		Upper	85.91	
		Bound		
	5% Trimmed Mean		73.31	
	Median		74.00	
	Variance		227.000	
	Std. Deviation		15.067	
	Minimum		57	
	Maximum		110	
	Range		53	
	Interquartile Range		13	
	Skewness		1.782	.717
	Kurtosis		4.437	1.400
	Descr	iptives		

Descriptives				
		Std.		
	Statistic	Error		
Mean	137.00	7.146		

SYSPR E	95% Confidence Interval for Mean	Lower Bound	118.63	
		Upper Bound	155.37	
	5% Trimmed Mean	200110	136.28	
	Median		132.50	
	Variance		306.400	
	Std. Deviation		17.504	
	Minimum		118	
	Maximum		169	
	Range		51	
	Interquartile Range		23	
	Skewness		1.405	.845
	Kurtosis		2.600	1.741
SYSPO	Mean		144.17	7.918
ST	95% Confidence	Lower	123.81	
	Interval for Mean	Bound		
		Upper	164.52	
		Bound		
	5% Trimmed Mean		143.85	
	Median		141.00	
	Variance		376.167	
	Std. Deviation		19.395	
	Minimum		122	
	Maximum		172	
	Range		50	
	Interquartile Range		37	
	Skewness		.439	.845
	Kurtosis		-1.330	1.741
DIAPRE	Mean		92.50	3.990
	95% Confidence	Lower	82.24	
	Interval for Mean	Bound		
		Upper Bound	102.76	
	5% Trimmed Mean		92.06	
	Median		90.00	
	Variance		95.500	
	Std. Deviation		9.772	
	Minimum		84	
	Maximum		109	
	Range		25	

	Interquartile Range		17	
	Skewness		1.049	.845
	Kurtosis		.381	1.741
DIAPOS	Mean		95.00	11.413
Т	95% Confidence	Lower	65.66	
	Interval for Mean	Bound		
		Upper	124.34	
		Bound		
	5% Trimmed Mean		95.50	
	Median		89.00	
	Variance		781.600	
	Std. Deviation		27.957	
	Minimum		53	
	Maximum		128	
	Range		75	
	Interquartile Range		48	
	Skewness		170	.845
	Kurtosis		386	1.741

Descriptives				
				Std.
			Statistic	Error
SIXMRTPR E	Mean		802.0000	168.372 60
	95% Confidence Interval for Mean	Lower Bound	369.1844	
		Upper Bound	1234.815 6	
	5% Trimmed Mean		810.2222	
	Median		788.5000	
	Variance		170096.0 00	
	Std. Deviation		412.4269 6	
	Minimum		131.00	
	Maximum		1325.00	
	Range		1194.00	
	Interquartile Range		620.25	
	Skewness		574	.845
	Kurtosis		.677	1.741

SIXMRTP OST	Mean		722.5000	160.263 48
	95% Confidence Interval for Mean	Lower Bound	310.5296	
		Upper Bound	1134.470 4	
	5% Trimmed Mean		727.0000	
	Median		669.0000	
	Variance		154106.3 00	
	Std. Deviation		392.5637 5	
	Minimum		121.00	
	Maximum		1243.00	
	Range		1122.00	
	Interquartile Range		638.25	
	Skewness		215	.845
	Kurtosis		.146	1.741

Descriptives				
				Std.
			Statistic	Error
TCLEFTPRE	Mean		44.8125	3.67974
	95% Confidence	Lower	36.1113	
	Interval for Mean	Bound		
		Upper	53.5137	
		Bound		
	5% Trimmed Mean		44.8917	
	Median		44.2500	
	Variance		108.324	
	Std. Deviation		10.4078	
			9	
	Minimum		29.00	
	Maximum		59.20	
	Range		30.20	
	Interquartile Range		19.00	
	Skewness		025	.752
	Kurtosis		906	1.481
	Mean		44.7000	4.01853

		-		
TCLEFTPOS T	95% Confidence Interval for Mean	Lower Bound	35.1977	
		Upper	54.2023	
		Bound		
	5% Trimmed Mean		44.9444	
	Median		43.1500	
	Variance		129.189	
	Std. Deviation		11.3661	
			2	
	Minimum		26.00	
	Maximum		59.00	
	Range		33.00	
	Interquartile Range		18.67	
	Skewness		237	.752
	Kurtosis		833	1.481
TCRIGHTPR	Mean		45.5250	3.94619
E	95% Confidence	Lower	36.1937	
	Interval for Mean	Bound		
		Upper	54.8563	
		Bound		
	5% Trimmed Mean		45.6278	
	Median		45.4500	
	Variance		124.579	
	Std. Deviation		11.1615	
			1	
	Minimum		28.00	
	Maximum		61.20	
	Range		33.20	
	Interquartile Range		19.17	
	Skewness		143	.752
	Kurtosis		839	1.481
TCRIGHTPO	Mean		44.2500	3.90343
ST	95% Confidence	Lower	35.0198	
	Interval for Mean	Bound		
		Upper	53.4802	
		Bound		
	5% Trimmed Mean		44.4944	
	Median		41.7500	
	Variance		121.894	
	Std. Deviation		11.0405	
			7	

	Minimum		26.00	
	Maximum		58.10	
	Range		32.10	
	Interquartile Range		17.30	
	Skewness		190	.752
	Kurtosis		765	1.481
CCLEFTPRE			32.8500	2.85319
	95% Confidence	Lower	26.1033	2.00010
	Interval for Mean	Bound	20.1000	
		Upper	39.5967	
		Bound		
	5% Trimmed Mean		32.7056	
	Median		30.5500	
	Variance		65.126	
	Std. Deviation		8.07005	
	Minimum		21.80	
	Maximum		46.50	
	Range		24.70	
	Interquartile Range		12.45	
	Skewness		.496	.752
	Kurtosis		457	1.481
CCLEFTPO	Mean		31.6375	2.17830
ST	95% Confidence	Lower	26.4866	
	Interval for Mean	Bound		
		Upper	36.7884	
		Bound		
	5% Trimmed Mean		31.8194	
	Median		31.3500	
	Variance		37.960	
	Std. Deviation		6.16115	
	Minimum		20.50	
	Maximum		39.50	
	Range		19.00	
	Interquartile Range		8.95	
	Skewness		548	.752
	Kurtosis		.119	1.481
CCRIGHTPR	Mean		30.8625	2.25531
E	95% Confidence	Lower	25.5295	
	Interval for Mean	Bound		
		Upper	36.1955	
		Bound		

	5% Trimmed Mean		30.8194	
	Median		30.5500	
	Variance		40.691	
	Std. Deviation		6.37897	
	Minimum		22.50	
	Maximum		40.00	
	Range		17.50	
	Interquartile Range		11.43	
	Skewness		.069	.752
	Kurtosis		-1.602	1.481
CCRIGHTP	Mean		31.7375	2.11508
OST	95% Confidence	Lower	26.7361	
	Interval for Mean	Bound		
		Upper	36.7389	
		Bound		
	5% Trimmed Mean		31.9861	
	Median		31.3000	
	Variance		35.788	
	Std. Deviation		5.98234	
	Minimum		20.50	
	Maximum		38.50	
	Range		18.00	
	Interquartile Range		8.22	
	Skewness		747	.752
	Kurtosis		.424	1.481

				Std.
			Statistic	Error
LEFTKEPRE	Mean		87.8213	17.9103
				2
	95% Confidence	Lower	46.5200	
	Interval for Mean	Bound		
		Upper	129.122	
		Bound	6	
	5% Trimmed Mean		87.7601	
	Median		71.8092	
	Variance		2887.01	
			5	

Std. Deviation 5.3.730 % Minimum 17.66 Maximum 159.09 Range 141.43 Interquartile Range 102.84 Skewness .247 Kurtosis -1.704 LEFTKEPOS Mean 110.780 21.2314 3 2 95% Confidence Lower Interval for Mean Bound Upper 159.740 Bound 1 5% Trimmed Mean 109.736 Median 90.5790 Variance 4056.96 1 5td. Deviation 63.6942 - 7 Minimum Maximum 209.28 Range 178.22 Interquartile Range 113.31 Skewness .713 Maximum 209.28 Range 131.31 Skewness .713 Maximum 209.20 95% Confidence Lower Interval for Mean <th></th> <th>Old Davietien</th> <th></th> <th>50 7000</th> <th></th>		Old Davietien		50 7000	
Minimum 17.66 Maximum 159.09 Range 141.43 Interquartile Range 102.84 Skewness .247 Kurtosis -1.704 1.400 LEFTKEPOS Mean 110.780 21.2314 T 3 2 95% Confidence Lower 61.8206 Interval for Mean Bound 1 5% Trimmed Mean 109.736 8 Median 90.5790 Variance 4056.96 Variance 4056.96 1 Std. Deviation 63.6942 7 Minimum 31.07 1 Maximum 209.28 1 Std. Deviation 63.6942 1 Kurtosis 618 1.400 Skewness .713 .717 Maximum 209.28 1.400 Range 113.31 .717 Kurtosis 618 1.400 0 95% Confidence Lower 49.		Std. Deviation		53.7309 5	
Maximum 159.09 Range 141.43 Interquartile Range 102.84 Skewness .247 .717 Kurtosis -1.704 1.400 LEFTKEPOS Mean 110.780 21.2314 7 3 2 95% Confidence Lower 61.8206 Interval for Mean Bound 1 5% Trimmed Mean 109.736 5% Trimmed Mean 90.5790 Variance 4056.96 1 1 Std. Deviation 63.6942 Range 178.22 Interquartile Range 113.31 Skewness .713 Range 178.22 Interquartile Range 113.31 Skewness .713 Skewness .713 Skewness .713 90.6008 17.7141 0 0 95% Confidence Lower Interval for Mean 89.6259 Median 85.0200 </td <td></td> <td>Minimum</td> <td></td> <td></td> <td></td>		Minimum			
Range 141.43 Interquartile Range 102.84 Skewness .247 .717 Kurtosis -1.704 1.400 LEFTKEPOS Mean 110.780 21.2314 7 3 2 95% Confidence Lower 61.8206 1 Interval for Mean Bound 1 1 5% Trimmed Mean 109.736 1 1 5% Trimmed Mean 90.5790 1 1 Variance 4056.96 1 1 100 7 1 1 1 Std. Deviation 63.6942 1 1 Minimum 310.7 1 1 Maximum 209.28 1 1 Range 178.22 1 1 Interquartile Range 113.31 1 1 Stewness .713 .717 1 0 95% Confidence Lower 49.7520 1 0 95%					
Interquartile Range 102.84 Skewness .247 .717 Kurtosis -1.704 1.400 LEFTKEPOS Mean 110.780 21.2314 T 3 2 95% Confidence Lower 61.8206 Interval for Mean Bound 1 5% Trimmed Mean 109.736 6% Trimmed Mean 90.5790 Variance 4056.942 1 1 Std. Deviation 63.6942 Range 178.22 Interquartile Range 113.31 Skewness .713 .717 Kurtosis -618 1.400 RIGHTKEPR Mean 90.6008 17.7141 0 95% Confidence Lower 49.7520 Interval for Mean Bound 6 0 95% Confidence Lower 49.7520 0 Interval for Mean Bound 6 5 5% Trimmed Mean 89.6259 1 1					
Skewness .247 .7.17 Kurtosis -1.704 1.400 LEFTKEPOS T Mean 110.780 21.2314 3 2 95% Confidence Interval for Mean Lower Bound 61.8206 5% Trimmed Mean 109.736 5% Trimmed Mean 90.5790 Variance 4056.96 1 55 Std. Deviation 63.6942 7 7 Minimum 31.07 Maximum 209.28 Range 178.22 Interquartile Range 113.31 Skewness .713 .717 Kurtosis -618 1.400 0 95% Confidence Interval for Mean Bound 0 95% Confidence Lower 49.7520 0 95% Confidence Bound 0 0 95% Confidence Sourd 0 0 95% Confidence Bound 6 5 95% Confidence Sourd 6 5					
Kurtosis -1.704 1.400 LEFTKEPOS Mean 110.780 21.2314 T 3 2 95% Confidence Interval for Mean Lower Bound 61.8206 2 Wedian Upper 159.740 2 Median 90.5790 Variance 4056.96 Variance 4056.96 1 Std. Deviation 63.6942 7 Minimum 31.07 Maximum 209.28 Range 178.22 113.31 717 Kurtosis 618 1.400 Skewness .713 .717 Kurtosis 618 1.400 Skewness .713 .717 Kurtosis 618 1.400 95% Confidence Interval for Mean Bound 6 95% Confidence Lower 49.7520 2 Std. Deviation 53.1423 3 3 5td. Deviation 53.1423 3 3 5td. Deviation 53.1423					.717
LEFTKEPOS Mean 110.780 21.2314 T 3 2 95% Confidence Interval for Mean Lower Bound 61.8206 Upper 159.740 Bound 1 5% Trimmed Mean 109.736 8 Median 90.5790 Variance 4056.96 Variance 4056.96 1 Std. Deviation 63.6942 7 Minimum 31.07 Maximum 209.28 Range 178.22 1 1 Interquartile Range 113.31 5 717 Kurtosis 618 1.400 0 95% Confidence Interval for Mean Bound 1 0 95% Confidence Interval for Mean Bound 6 1 5% Trimmed Mean 89.6259 1 0 95% Confidence S0.0200 1 1 Upper 131.449 0 0 5% Trimmed Mean 89.6259 1 5 Std. Deviation 53.1423 <td< td=""><td></td><td></td><td></td><td></td><td></td></td<>					
T 3 2 95% Confidence Interval for Mean Lower Bound 61.8206 Upper 159.740 Bound 1 5% Trimmed Mean 109.736 8 8 Median 90.5790 Variance 4056.96 1 5 Std. Deviation 63.6942 7 7 Minimum 31.07 Maximum 209.28 Range 178.22 Interquartile Range 113.31 Skewness .713 .717 Kurtosis -618 1.400 RIGHTKEPR Mean 90.6008 17.7141 0 95% Confidence Lower 49.7520 Interval for Mean Bound 6 5 5% Trimmed Mean 89.6259 1 Median 85.0200 1 2 Variance 2824.10 5 5 5Xtd. Deviation 53.1423 1 1 <t< td=""><td>LEFTKEPOS</td><td>Mean</td><td></td><td></td><td></td></t<>	LEFTKEPOS	Mean			
Interval for Mean Bound Upper 159.740 Bound 1 1 5% Trimmed Mean 109.736 8 Median 90.5790 1 Variance 4056.96 1 Std. Deviation 63.6942 7 Minimum 31.07 1 Maximum 209.28 7 Range 178.22 1 Interquartile Range 113.31 1 Skewness .713 .717 Kurtosis 618 1.400 0 95% Confidence Lower 49.7520 Interval for Mean Bound 6 1 0 95% Confidence Lower 49.7520 Interval for Mean 89.6259 1 1 Wedian 85.0200 1 5 Variance 2824.10 5 5 Std. Deviation 53.1423 1 1 Minimum 10.73 1 1	т				
Upper Bound 159.740 1 5% Trimmed Mean 109.736 8 Median 90.5790 Variance 4056.96 1 Std. Deviation 63.6942 7 Minimum 31.07 Maximum 209.28 Range 178.22 Interquartile Range 113.31 Skewness .713 Kurtosis 618 Skewness .713 Std. Deviation 0 95% Confidence Lower 49.7520 Interval for Mean Bound 6 5% Trimmed Mean 89.6259 1 Median 85.0200 2 Variance 2824.10 5 Std. Deviation 53.1423 1 Minimum 10.73 1		95% Confidence	Lower	61.8206	
Bound 1 5% Trimmed Mean 109.736 Median 90.5790 Variance 4056.96 1 1 Std. Deviation 63.6942 7 7 Minimum 31.07 Maximum 209.28 Range 178.22 Interquartile Range 113.31 Skewness .713 .717 Kurtosis 618 1.400 RiGHTKEPR Mean 90.6008 17.7141 0 95% Confidence Lower 49.7520 0 95% Confidence Lower 49.7520 0 95% Trimmed Mean 89.6259 0 0 95% Trimmed Mean 89.6259 0 0 Variance 2824.10 5 5 5td. Deviation 53.1423 1 1 Minimum 10.73 1 1		Interval for Mean	Bound		
5% Trimmed Mean 109.736 Median 90.5790 Variance 4056.96 1 1 Std. Deviation 63.6942 7 7 Minimum 31.07 Maximum 209.28 Range 178.22 Interquartile Range 113.31 Skewness .713 Kurtosis 618 Skewness .713 Skewness .713 Skewness .713 Skewness .618 1.400 0 95% Confidence Lower 49.7520 Interval for Mean Bound 0 95% Trimmed Mean 89.6259 0 Median 85.0200 2824.10 5 5td. Deviation 53.1423 1 1 1 Minimum 10.73 1			Upper	159.740	
Median 90.5790 Variance 4056.96 1 1 Std. Deviation 63.6942 7 7 Minimum 31.07 Maximum 209.28 Range 178.22 Interquartile Range 113.31 Skewness .713 .717 Kurtosis 618 1.400 P 0 0 95% Confidence Lower 49.7520 Interval for Mean Bound 0 95% Confidence Lower 49.7520 Interval for Mean 89.6259 0 Wedian 85.0200 0 Variance 2824.10 5 Std. Deviation 53.1423 1 Minimum 10.73 1			Bound	1	
Median 90.5790 Variance 4056.96 1 1 Std. Deviation 63.6942 7 7 Minimum 31.07 Maximum 209.28 Range 178.22 Interquartile Range 113.31 Skewness .713 Kurtosis 618 Skewness .713 Kurtosis 618 90.6008 17.7141 0 0 95% Confidence Lower Interval for Mean Bound 0 0 95% Crifidence Lower Upper 131.449 Bound 6 5% Trimmed Mean 89.6259 Median 85.0200 Variance 5 Std. Deviation 53.1423 1 1 Minimum 10.73		5% Trimmed Mean		109.736	
Variance 4056.96 1 Std. Deviation 63.6942 7 Minimum 31.07 Maximum 209.28 Range 178.22 Interquartile Range 113.31 Skewness .713 .717 Kurtosis 618 1.400 RIGHTKEPR Mean 90.6008 17.7141 0 95% Confidence Lower 49.7520 10 95% Confidence Lower 49.7520 0 0 95% Trimmed Mean 89.6259 0 <t< td=""><td></td><td></td><td></td><td>8</td><td></td></t<>				8	
Std. Deviation1Std. Deviation63.6942 7Minimum31.07Maximum209.28Range178.22Interquartile Range113.31Skewness.713.717.717Kurtosis6181.400PS% Confidence Interval for MeanLower Bound95% Confidence Interval for MeanLower Bound95% Confidence Interval for MeanLower Bound95% Confidence Interval for Mean131.449 Bound05% Trimmed Mean89.6259Median85.0200Variance2824.10 55td. Deviation53.1423 110.7310.73		Median		90.5790	
Std. Deviation 63.6942 7 Minimum 31.07 Maximum 209.28 Range 178.22 Interquartile Range 113.31 Skewness .713 Kurtosis 618 RightTKEPR Mean 95% Confidence Lower Interval for Mean 90.6008 95% Confidence Lower 90.6008 17.7141 0 95% Confidence Interval for Mean Bound 0 6 5% Trimmed Mean 89.6259 Median 85.0200 Variance 2824.10 5 53.1423 1 1 Minimum 10.73		Variance		4056.96	
Minimum 31.07 Maximum 209.28 Range 178.22 Interquartile Range 113.31 Skewness .713 .717 Kurtosis 618 1.400 RIGHTKEPR Mean 90.6008 17.7141 0 95% Confidence Lower 49.7520 Interval for Mean Bound 0 95% Trimmed Mean 89.6259 131.449 Median 85.0200 1 Variance 2824.10 5 Std. Deviation 53.1423 1 Minimum 10.73 1				1	
Maximum209.28Range178.22Interquartile Range113.31Skewness.713Kurtosis6181.400RIGHTKEPR EMean95% Confidence Interval for MeanLower Bound95% Confidence Interval for MeanLower Bound95% Confidence Interval for MeanLower Bound95% Confidence Interval for Mean209.2895% Confidence Interval for Mean131.449 Bound05% Trimmed Mean89.6259Median85.0200Variance2824.10 55td. Deviation53.1423 110.7310.73		Std. Deviation			
Range 178.22 Interquartile Range 113.31 Skewness .713 .717 Kurtosis 618 1.400 RIGHTKEPR Mean 90.6008 17.7141 0 95% Confidence Lower 49.7520 Interval for Mean Bound 0 95% Trimmed Mean 89.6259 1 Median 85.0200 1 Variance 2824.10 5 Std. Deviation 53.1423 1 1 10.73 1		Minimum		31.07	
Interquartile Range 113.31 Skewness .713 .717 Kurtosis 618 1.400 RIGHTKEPR Mean 90.6008 17.7141 0 95% Confidence Lower 49.7520 17 95% Confidence Lower 49.7520 10 10 95% Confidence Lower 49.7520 10 10 95% Confidence Lower 49.7520 10 10.73 Median 89.6259 10 10.73 10.73		Maximum		209.28	
Skewness .713 .717 Kurtosis 618 1.400 RIGHTKEPR Mean 90.6008 17.7141 0 95% Confidence Lower 49.7520 Interval for Mean Bound 0 95% Trimmed Mean 89.6259 0 Median 85.0200 0 Variance 2824.10 5 Std. Deviation 53.1423 1 1 10.73 1		Range		178.22	
Kurtosis 618 1.400 RIGHTKEPR Mean 90.6008 17.7141 0 95% Confidence Lower 49.7520 Interval for Mean Bound 0 0 0 0 5% Trimmed Mean 89.6259 Median 85.0200 Variance 2824.10 5 53.1423 1 1 Minimum 10.73		Interquartile Range		113.31	
RIGHTKEPR Mean 90.6008 17.7141 95% Confidence Lower 49.7520 0 95% Confidence Bound 0 0 Upper 131.449 0 0 5% Trimmed Mean 89.6259 0 0 Median 85.0200 0 0 Variance 2824.10 5 5 Std. Deviation 53.1423 1 1 Minimum 10.73 1 1		Skewness		.713	.717
E 0 95% Confidence Interval for Mean Lower 49.7520 Upper 131.449 Bound 6 5% Trimmed Mean 89.6259 Median 85.0200 Variance 2824.10 5 53.1423 1 1		Kurtosis		618	1.400
95% Confidence Interval for Mean Lower Bound 49.7520 Upper 131.449 Bound 6 5% Trimmed Mean 89.6259 Median 85.0200 Variance 2824.10 5 53.1423 1 1 Minimum 10.73		Mean		90.6008	
Interval for Mean Bound Upper 131.449 Bound 6 5% Trimmed Mean 89.6259 Median 85.0200 Variance 2824.10 5 53.1423 1 1		95% Confidence	Lower	49.7520	3
Bound 6 5% Trimmed Mean 89.6259 Median 85.0200 Variance 2824.10 5 5 Std. Deviation 53.1423 1 1					
Bound 6 5% Trimmed Mean 89.6259 Median 85.0200 Variance 2824.10 5 5 Std. Deviation 53.1423 1 1			Upper	131.449	
Median 85.0200 Variance 2824.10 5 5 Std. Deviation 53.1423 1 1				6	
Variance 2824.10 5 5 Std. Deviation 53.1423 1 1 Minimum 10.73		5% Trimmed Mean		89.6259	
Std. Deviation 53.1423 1 1 Minimum 10.73		Median		85.0200	
Std. Deviation 53.1423 1 1 Minimum 10.73		Variance		2824.10	
1 Minimum 10.73				5	
Minimum 10.73		Std. Deviation		53.1423	
				1	
Maximum 188.03		Minimum		10.73	
		Maximum		188.03	

	Range		177.30	
	Interquartile Range		71.91	
	Skewness		.411	.717
	Kurtosis		.089	1.400
RIGHTKEPO	Mean		106.166	17.6064
ST	Moun		0	5
	95% Confidence	Lower	65.5654	-
	Interval for Mean	Bound		
		Upper	146.766	
		Bound	6	
	5% Trimmed Mean		106.281	
			1	
	Median		117.066	
			0	
	Variance		2789.88	
			5	
	Std. Deviation		52.8193	
			6	
	Minimum		28.12	
	Maximum		182.14	
	Range		154.02	
	Interquartile Range		93.85	
	Skewness		075	.717
	Kurtosis		-1.417	1.400
LEFTKFPRE	Mean		45.1878	14.6792
	050/ 0	1	44.0074	2
	95% Confidence Interval for Mean	Lower Bound	11.3374	
			79.0381	
		Upper Bound	79.0301	
	5% Trimmed Mean		44.2318	
	Median		30.0840	
	Variance		1939.31	
			6	
	Std. Deviation		44.0376	
			6	
	Minimum		.00	
	Maximum		107.58	
	Range		107.58	
	Interquartile Range		88.86	

			-1.689	1.400
LEFTKFPOS T	Mean		64.4917	16.2666 5
	95% Confidence Interval for Mean	Lower Bound	26.9807	
		Upper Bound	102.002 6	
	5% Trimmed Mean		61.3751	
	Median		44.7990	
	Variance		2381.43 7	
	Std. Deviation		48.7999 6	
	Minimum		18.64	
	Maximum		166.44	
	Range		147.80	
	Interquartile Range		69.16	
	Skewness		1.350	.717
	Kurtosis		1.208	1.400
RIGHTKFPR	Mean		40.9767	9.94040
E	95% Confidence	Lower	18.0541	
	Interval for Mean	Bound		
		Upper Bound	63.8993	
	5% Trimmed Mean		40.8245	
	Median		35.6430	
	Variance		889.304	
	Std. Deviation		29.8212 0	
	Minimum		.00	
	Maximum		84.69	
	Range		84.69	
	Interquartile Range		53.10	
	Skewness		.442	.717
	Kurtosis		-1.007	1.400
RIGHTKFPO ST	Mean		71.0680	17.0426 5
	95% Confidence Interval for Mean	Lower Bound	31.7676	
		Upper Bound	110.368 4	

	E0/ Tringrad Magn		CO 0440	
	5% Trimmed Mean		69.8448	
	Median		47.4150	
	Variance		2614.06	
			7	
	Std. Deviation		51.1279	
			4	
	Minimum		5.89	
	Maximum		158.27	
	Range		152.38	
	Interquartile Range		86.98	
	Skewness		.577	.717
	Kurtosis		883	1.400
LEFTPLFPR E	Mean		56.2767	14.0906 6
	95% Confidence	Lower	23.7836	
	Interval for Mean	Bound		
		Upper	88.7698	
		Bound		
	5% Trimmed Mean		53.6298	
	Median		37.9320	
	Variance		1786.92 2	
	Std. Deviation		42.2719	
			42.2719	
	Minimum		14.72	
	Maximum		145.48	
	Range		130.77	
	Interquartile Range		56.24	
	Skewness		1.319	.717
	Kurtosis		1.486	1.400
LEFTPLFPO ST	Mean		74.1563	13.3138 2
	95% Confidence	Lower	43.4546	
	Interval for Mean	Bound		
		Upper	104.858	
		Bound	1	
	5% Trimmed Mean		73.8394	
	Median		58.2060	
	Variance		1595.32	
			1000.02	

Minimum 15.04 Maximum 138.98 Range 123.93 Interquartile Range 61.64 Skewness .244 Skewness .244 Kurtosis 878 RIGHTPLFP Mean 95% Confidence Lower Interval for Mean 42.0050 Median 41.2020 Variance 1059.08 Std. Deviation 32.5435 Std. Deviation 32.5435 Minimum 13.34 Maximum 125.24 Range 111.90 Interquartile Range 20.70 Skewness 2.176 Std. Deviation 5.850 Stewness 2.176		Std. Deviation		39.9414	
Minimum 15.04 Maximum 138.98 Range 123.93 Interquartile Range 61.64 Skewness .244 .717 Kurtosis 878 1.400 RIGHTPLFP Mean 44.7336 10.8478 RE 95% Confidence Interval for Mean Lower 19.7184 4 95% Confidence Interval for Mean Lower 19.7184 4 5% Trimmed Mean 42.0050 4 4 5% Trimmed Mean 42.0050 1 4 Median 41.2020 1 1 1 Variance 1059.08 1		Std. Deviation			
Maximum 138.98 Range 123.93 Interquartile Range 61.64 Skewness .244 .717 Kurtosis 878 1.400 RIGHTPLFP Mean 44.7336 10.8478 P5% Confidence Lower 19.7184 4 95% Confidence Lower 19.7184 4 Sternal for Mean Bound 10 4 5% Trimmed Mean 42.0050 4 4 Variance 1059.08 1 1 Kurtosis 32.5435 3 1 Maximum 125.24 1 1 Maximum 125.24 1 1 Maximum 125.24 717 1 Maximum 125.24 717 1 Range 111.90 1 1 1 Interquartile Range 20.70 5 5 1.400 Std. Deviation 5.850 1.400 6 6 95%		Minimum			
Range 123.93 Interquartile Range 61.64 Skewness .244 .717 Kurtosis 878 1.400 RIGHTPLFP Mean 44.7336 10.8478 P5% Confidence Lower 19.7184 4 95% Confidence Lower 19.7184 4 Stormed Mean 42.0050 4 4 5% Trimmed Mean 42.0050 4 4 Variance 1059.08 1 1 Std. Deviation 32.5435 3 1 Std. Deviation 32.5435 3 1 Maximum 125.24 1 1 Range 11.90 1 1 Interquartile Range 20.70 1 1 Skewness 2.176 .717 1 1 GOT 5.850 1.400 1 6 Skewness 2.176 .717 1 6 OST 95% Confidence Lower <td< td=""><td></td><td></td><td></td><td></td><td></td></td<>					
Interquartile Range 61.64 Skewness .244 .717 Kurtosis 878 1.400 RIGHTPLFP Mean 44.7336 10.8478 RE 95% Confidence Interval for Mean Lower 19.7184 4 95% Confidence Interval for Mean Lower 19.7184 4 5% Trimmed Mean 42.0050 4 Variance 1059.08 1 Std. Deviation 32.5435 1 Std. Deviation 32.5435 3 Minimum 13.34 111.90 Interquartile Range 111.90 11 Interquartile Range 20.70 3 Skewness 2.176 .717 Kurtosis 5.850 1.400 RIGHTPLFP Mean 62.1300 11.0142 0ST 95% Confidence Interval for Mean Bound 67.5289 Bound 01.91.82 5 5 Std. Deviation 56.3310 1091.82 Variance 091.82					
Skewness.244.717Kurtosis8781.400RIGHTPLFP REMean44.733610.847895% Confidence Interval for MeanLower Bound19.71845% Trimmed Mean42.0050Median41.2020Variance1Std. Deviation32.543533Minimum13.34Maximum125.24Range111.90Interquartile Range20.70Skewness2.1762.1765.850Std. Deviation5.8501.101426Skewness2.176Skewness5.8501.40011.014265.850Std. Deviation11.014265.850Std. Deviation5.8501.40011.0142Skewness5.8501.40011.014265.850Std. Deviation33.04275555551091.825555510Minimum17.33Maximum114.78					
Kurtosis8781.400RIGHTPLFP REMean44.733610.847895% Confidence Interval for MeanLower Bound19.718495% Confidence Interval for MeanLower Bound19.71845% Trimmed Mean42.0050Median41.2020Variance1059.081Std. Deviation32.5435Std. Deviation32.543533Minimum13.34Maximum125.24Range111.90Interquartile Range20.70Skewness2.1762.1767.177Kurtosis5.850Std. Deviation5.850Skewness2.17695% Confidence Interval for MeanLower 					747
RIGHTPLFP RE Mean 44.7336 10.8478 95% Confidence Interval for Mean Lower Bound 19.7184 5% Trimmed Mean 42.0050 Median 41.2020 Variance 1059.08 1 1059.08 5% Confidence 1059.08 69.7488 1 5% Trimmed Mean 42.0050 Median 41.2020 Variance 1059.08 1 1 Std. Deviation 32.5435 3 3 Minimum 13.34 Maximum 125.24 Range 111.90 Interquartile Range 20.70 Skewness 2.176 7.17 5.850 Kurtosis 5.850 1.400 11.0142 69 69.5% Confidence Interval for Mean Bound 05% Confidence Lower 100142 5 55% Trimmed Mean 61.6940 Median 66.3810 Variance 1091.82 5 5 5td. Deviation 33.0427 8 1 Minimum 17.33 Maximum 114.78					
RE 95% Confidence Interval for Mean Lower Bound 19.7184 0 Upper Bound 69.7488 Bound 1 5% Trimmed Mean 42.0050 Median 41.2020 Variance 1059.08 1 1 Std. Deviation 32.5435 3 3 Minimum 13.34 Maximum 125.24 Range 111.90 Interquartile Range 20.70 Skewness 2.176 Std. Deviation 5.850 1.400 11.0142 62.1300 11.0142 63 62.1300 Std. Deviation 36.7311 65% Confidence Interval for Mean Lower Bound 5% Confidence Lower Bound 5% Trimmed Mean 61.6940 Median 66.3810 Variance 1091.82 5 5 Std. Deviation 33.0427 8 1091.82 5 5 Std. Deviation 33.0427 8 114.78					
Interval for Mean Bound Upper Bound 69.7488 5% Trimmed Mean 42.0050 Median 41.2020 Variance 1059.08 1 1 Std. Deviation 32.5435 3 3 Minimum 13.34 Maximum 125.24 Range 111.90 Interquartile Range 20.70 Skewness 2.176 Std. Deviation 5.850 1.400 1.400 Range 111.90 Interquartile Range 20.70 Skewness 2.176 Solution 5.850 Solution 5.850 Interval for Mean 62.1300 Polyper 87.5289 Bound 11.0142 S% Trimmed Mean 66.3810 Variance 1091.82 S% Trimmed Mean 66.3810 Variance 5 Std. Deviation 33.0427 8 114.78		wean		44.7330	
Upper Bound 69.7488 5% Trimmed Mean 42.0050 Median 41.2020 Variance 1059.08 1 1 Std. Deviation 32.5435 3 3 Minimum 13.34 Maximum 125.24 Range 111.90 Interquartile Range 20.70 Skewness 2.176 2.176 .717 Kurtosis 5.850 1.400 11.0142 6 95% Confidence Interval for Mean 61.6940 Median 66.3810 Upper 87.5289 Bound 1091.82 5% Trimmed Mean 61.6940 Median 66.3810 Variance 1091.82 5 5 Std. Deviation 33.0427 8 1 Minimum 17.33 Maximum 114.78		95% Confidence	Lower	19.7184	
Bound 42.0050 Median 41.2020 Variance 1059.08 1 1 Std. Deviation 32.5435 3 3 Minimum 13.34 Maximum 125.24 Range 111.90 Interquartile Range 20.70 Skewness 2.176 Std. Deviation 5.850 Skewness 2.176 Kurtosis 5.850 95% Confidence Lower 95% Confidence Lower 10treval for Mean 66.3810 Upper 87.5289 Bound 5 5% Trimmed Mean 61.6940 Median 66.3810 Variance 1091.82 5 5 Std. Deviation 33.0427 8 114.78		Interval for Mean	Bound		
5% Trimmed Mean 42.0050 Median 41.2020 Variance 1059.08 1 1 Std. Deviation 32.5435 3 3 Minimum 13.34 Maximum 125.24 Range 111.90 Interquartile Range 20.70 Skewness 2.176 Skewness 2.176 Std. Deviation 5.850 Skewness 5.850 11.0142 6 95% Confidence Lower 36.7311 Interval for Mean Bound 6 95% Confidence Lower 36.7311 Upper 87.5289 6 5% Trimmed Mean 61.6940 Median 66.3810 0 Variance 1091.82 5 5td. Deviation 33.0427 8 Minimum 17.33 8 Maximum 114.78 114.78			Upper	69.7488	
Median 41.2020 Variance 1059.08 1 1 Std. Deviation 32.5435 3 3 Minimum 13.34 Maximum 125.24 Range 1111.90 Interquartile Range 20.70 Skewness 2.176 .717 Kurtosis 5.850 1.400 RIGHTPLFP Mean 62.1300 11.0142 OST 95% Confidence Lower 36.7311 Interval for Mean Bound 6 6 95% Trimmed Mean 61.6940 Median 66.3810 Variance 1091.82 5 5 Std. Deviation 33.0427 8 8 Minimum 17.33 8 114.78			Bound		
Variance 1059.08 Std. Deviation 32.5435 3 3 Minimum 13.34 Maximum 125.24 Range 111.90 Interquartile Range 20.70 Skewness 2.176 Skewness 2.176 Skewness 2.176 Std. Deviation 62.1300 Skewness 5.850 Std. Deviation 62.1300 Std. Deviation 36.7311 OST 95% Confidence Lower 36.7311 Interval for Mean Bound Upper 87.5289 Bound 0 5% Trimmed Mean 61.6940 Median 66.3810 Variance 1091.82 5 5 Std. Deviation 33.0427 8 10 Minimum 17.33 Maximum 114.78		5% Trimmed Mean		42.0050	
Image: Std. Deviation 32.5435 Minimum 13.34 Maximum 125.24 Range 111.90 Interquartile Range 20.70 Skewness 2.176 .717 Kurtosis 5.850 1.400 RIGHTPLFP Mean 62.1300 11.0142 0ST 95% Confidence Lower 36.7311 6 Variance 1091.82 5 5 Std. Deviation 33.0427 5 5 Std. Deviation 17.33 8 6		Median		41.2020	
Std. Deviation 32.5435 Minimum 13.34 Maximum 125.24 Range 111.90 Interquartile Range 20.70 Skewness 2.176 .717 Kurtosis 5.850 1.400 RIGHTPLFP Mean 62.1300 11.0142 0ST 95% Confidence Lower 36.7311 6 Variance 1091.82 5 5 Std. Deviation 33.0427 5 5 Std. Deviation 17.33 8 6		Variance			
Maximum125.24Range111.90Interquartile Range20.70Skewness2.176Skewness2.176Kurtosis5.8501.400RIGHTPLFP OSTMeanMean62.130095% Confidence Interval for MeanLower Bound95% Confidence Interval for MeanS7.5289 Bound5% Trimmed Mean61.6940Variance1091.82 55% Ct. Deviation33.0427 8Std. Deviation33.0427 8Minimum17.33 114.78		Std. Deviation		32.5435	
Range 111.90 Interquartile Range 20.70 Skewness 2.176 Kurtosis 5.850 RIGHTPLFP OST Mean 95% Confidence Lower Interval for Mean 36.7311 Upper 87.5289 Bound 5% Trimmed Mean 5% Trimmed Mean 61.6940 Median 66.3810 Variance 1091.82 5 5 Std. Deviation 33.0427 8 1114.78		Minimum		13.34	
Interquartile Range 20.70 Skewness 2.176 .717 Kurtosis 5.850 1.400 RIGHTPLFP OST Mean 62.1300 11.0142 95% Confidence Lower 36.7311 6 95% Confidence Lower 36.7311 6 95% Confidence Bound 0 6 95% Confidence Lower 36.7311 6 95% Confidence Lower 36.7311 6 Variance 1091.82 6 6 Std. Deviation 33.0427 8 6 Minimum 17.33 114.78 6		Maximum		125.24	
Interquartile Range 20.70 Skewness 2.176 .717 Kurtosis 5.850 1.400 RIGHTPLFP OST Mean 62.1300 11.0142 95% Confidence Lower 36.7311 6 95% Confidence Lower 36.7311 6 95% Confidence Bound Upper 87.5289 6 5% Trimmed Mean 66.3810 6 6 6 Variance 1091.82 5 5 5 Std. Deviation 33.0427 8 6 6 Minimum 17.33 114.78 114.78 6		Range		111.90	
Skewness 2.176 .717 Kurtosis 5.850 1.400 RIGHTPLFP OST Mean 62.1300 11.0142 95% Confidence Lower 36.7311 6 95% Confidence Lower 36.7311 6 95% Confidence Lower 87.5289 6 95% Trimmed Mean 61.6940 6 6 Median 66.3810 1091.82 5 Std. Deviation 33.0427 8 6 Minimum 17.33 114.78 6				20.70	
RIGHTPLFP OSTMean62.130011.0142 695% Confidence Interval for MeanLower Bound36.7311695% Crimmed MeanBound005% Trimmed Mean61.694000Median66.381000Variance1091.82 555Std. Deviation33.0427 880Minimum17.33114.780				2.176	.717
OST 6 95% Confidence Interval for Mean Lower 36.7311 Bound Upper 87.5289 5% Trimmed Mean 61.6940 Median 66.3810 Variance 1091.82 5 5 Std. Deviation 33.0427 8 17.33 Maximum 114.78		Kurtosis		5.850	1.400
95% Confidence Interval for Mean Lower Bound 36.7311 Upper Bound 87.5289 5% Trimmed Mean 61.6940 Median 66.3810 Variance 1091.82 5 5 Std. Deviation 33.0427 8 114.78		Mean		62.1300	-
Interval for MeanBoundUpper Bound87.5289 Bound5% Trimmed Mean61.6940Median66.3810Variance1091.82 5Std. Deviation33.0427 8Minimum17.33 114.78	001	95% Confidence	Lower	36 7311	0
Upper Bound 87.5289 5% Trimmed Mean 61.6940 Median 66.3810 Variance 1091.82 5 5 Std. Deviation 33.0427 8 114.78				00.7011	
Bound Bound 5% Trimmed Mean 61.6940 Median 66.3810 Variance 1091.82 5 5 Std. Deviation 33.0427 8 114.78				87 5289	
5% Trimmed Mean 61.6940 Median 66.3810 Variance 1091.82 5 5 Std. Deviation 33.0427 8 8 Minimum 17.33 Maximum 114.78				07.0200	
Median 66.3810 Variance 1091.82 5 5 Std. Deviation 33.0427 8 8 Minimum 17.33 Maximum 114.78		5% Trimmed Mean	Dodina	61,6940	
Variance 1091.82 5 5 Std. Deviation 33.0427 8 8 Minimum 17.33 Maximum 114.78					
5 Std. Deviation 33.0427 8 Minimum 17.33 Maximum 114.78					
Minimum 17.33 Maximum 114.78					
Minimum 17.33 Maximum 114.78		Std. Deviation		33.0427	
Maximum 114.78					
		Minimum		17.33	
		Maximum		114.78	
		Range		97.45	

Interquartile Range	58.21	
Skewness	011	.717
Kurtosis	929	1.400

	Descrip	tives		
				Std.
			Statistic	Error
ICANKLEPR E	Mean		102.496 0	6.91932
	95% Confidence Interval for Mean	Lower Bound	83.2849	
		Upper Bound	121.707 1	
	5% Trimmed Mean		102.686 1	
	Median		105.640 0	
	Variance		239.385	
	Std. Deviation		15.4720 7	
	Minimum		81.87	
	Maximum		119.70	
	Range		37.83	
	Interquartile Range		29.55	
	Skewness		400	.913
	Kurtosis		-1.580	2.000
ICANKLEP OST	Mean		100.160 0	4.83845
	95% Confidence Interval for Mean	Lower Bound	86.7263	
		Upper Bound	113.593 7	
	5% Trimmed Mean		99.9333	
	Median		100.200 0	
	Variance		117.053	
	Std. Deviation		10.8191	
			0	
	Minimum		87.50	
	Maximum		116.90	

	Range		29.40	
	Interquartile Range		17.80	
	Skewness		.831	.913
	Kurtosis		1.573	2.000
ICKNEEPR E	Mean		155.942 0	3.66118
	95% Confidence	Lower	145.776	
	Interval for Mean	Bound	9	
		Upper	166.107	
		Bound	1	
	5% Trimmed Mean		155.756 1	
	Median		153.060 0	
	Variance		67.021	
	Std. Deviation		8.18664	
	Minimum		148.40	
	Maximum		166.83	
	Range		18.43	
	Interquartile Range		15.70	
	Skewness		.592	.913
	Kurtosis		-2.174	2.000
ICKNEEPO ST	Mean		150.260 0	4.69080
	95% Confidence	Lower	137.236	
	Interval for Mean	Bound	3	
		Upper	163.283	
		Bound	7	
	5% Trimmed Mean		150.138 9	
	Median		145.400 0	
	Variance		110.018	
	Std. Deviation		10.4889	
	Std. Deviation		5	
	Minimum		140.90	
	Maximum		161.80	
	Range		20.90	
	Interquartile Range		20.25	
	Skewness		.498	.913
	Kurtosis		-3.199	2.000

ICHIPPRE	Mean		110.822 0	6.43089
	95% Confidence	Lower	92.9670	
	Interval for Mean	Bound	92.9070	
	Interval for mean	Upper	128.677	
		Bound	0	
	5% Trimmed Mean	Dound	111.197	
			8	
	Median		109.040	
			0	
	Variance		206.782	
	Std. Deviation		14.3799	
			1	
	Minimum		90.08	
	Maximum		124.80	
	Range		34.72	
	Interquartile Range		26.35	
	Skewness		556	.913
	Kurtosis		552	2.000
ICHIPPOST	Mean		113.900 0	6.44787
	95% Confidence	Lower	95.9978	
	Interval for Mean	Bound		
		Upper	131.802	
		Bound	2	
	5% Trimmed Mean		114.594 4	
	Median		118.300 0	
	Variance		207.875	
	Std. Deviation		14.4178	
			7	
	Minimum		89.10	
	Maximum		126.20	
	Range		37.10	
	Interquartile Range		21.10	
	Skewness		-1.810	.913
	Kurtosis		3.670	2.000

•	Std.
Statistic	Error

MSTANKLEP	Mean		92.6400	6.30801
RE	95% Confidence	Lower	75.1261	
	Interval for Mean	Bound		
		Upper	110.153	
		Bound	9	
	5% Trimmed Mean		91.8889	
	Median		86.7000	
	Variance		198.955	
	Std. Deviation		14.1051	
			5	
	Minimum		81.70	
	Maximum		117.10	
	Range		35.40	
	Interquartile Range		20.33	
	Skewness		1.908	.913
	Kurtosis		3.849	2.000
MSTANKLEP	Mean		93.4000	5.47932
OST	95% Confidence	Lower	78.1870	
	Interval for Mean	Bound		
		Upper	108.613	
		Bound	0	
	5% Trimmed Mean		93.1500	
	Median		90.7000	
	Variance		150.115	
	Std. Deviation		12.2521	
			4	
	Minimum		79.10	
	Maximum		112.20	
	Range		33.10	
	Interquartile Range		20.65	
	Skewness		.817	.913
	Kurtosis		1.292	2.000
MSTKNEEPR	Mean		150.776	7.71895
E			0	
	95% Confidence	Lower	129.344	
	Interval for Mean	Bound	8	
		Upper	172.207	
		Bound	2	
	5% Trimmed Mean		150.146	
			7	

	Median		144.280	
	Variance		0	
	Variance Std. Deviation		297.911	
	Std. Deviation		17.2601 0	
	Minimum		136.18	
	Maximum		176.70	
	Range		40.52	
	Interquartile Range		31.50	
	Skewness		.987	.913
	Kurtosis		399	2.000
MSTKNEEPO				9.87811
ST			0	
	95% Confidence	Lower	122.474	
	Interval for Mean	Bound	0	
		Upper	177.326	
		Bound	0	
	5% Trimmed Mean		149.700	
			0	
	Median		145.600 0	
	Variance		487.885	
	Std. Deviation		22.0881	
			2	
	Minimum		124.90	
	Maximum		178.50	
	Range		53.60	
	Interquartile Range		42.45	
	Skewness		.317	.913
	Kurtosis		-1.801	2.000
MSTHIPPRE	Mean		125.196	8.86788
			0	
	95% Confidence	Lower	100.574	
	Interval for Mean	Bound	8	
		Upper	149.817	
	50/ Tria 114	Bound	2	
	5% Trimmed Mean		124.815	
	Madian		6	
	Median		124.810	
	Varianco		0 202 106	
	Variance		393.196	

Std. Deviation	19.8291	
	7	
Minimum	102.14	
Maximum	155.10	
Range	52.96	
Interquartile Range	34.41	
Skewness	.705	.913
Kurtosis	.880	2.000

Descriptives					
				Std.	
			Statistic	Error	
TOANKLEP	Mean		109.772	5.45039	
RE			0		
	95% Confidence	Lower	94.6393		
	Interval for Mean	Bound	_		
		Upper	124.904		
		Bound	7		
	5% Trimmed Mean		109.613		
			3		
	Median		108.720		
			0		
	Variance		148.534		
	Std. Deviation		12.1874		
			3		
	Minimum		94.80		
	Maximum		127.60		
	Range		32.80		
	Interquartile Range		21.37		
	Skewness		.500	.913	
	Kurtosis		.654	2.000	
TOANKLEP	Mean		115.620	4.32879	
OST			0		
	95% Confidence	Lower	103.601		
	Interval for Mean	Bound	4		
		Upper	127.638		
		Bound	6		
	5% Trimmed Mean		115.855		
			6		
	Median		118.900		
			0		
	Variance		93.692		

Std. Deviation 9.67946 Minimum 102.30 Maximum 124.70	
Range 22.40	
Interquartile Range 18.40	
Skewness657	.913
	2.000
TOKNEEPR Mean 132.308 2.3	
E 0	
95% Confidence Lower 125.871	
Interval for Mean Bound 0	
Upper 138.745	
Bound 0	
5% Trimmed Mean 132.012	
2	
Median 130.300	
0	
Variance 26.875	
Std. Deviation 5.18414	
Minimum 128.60	
Maximum 141.34	
Range 12.74	
Interquartile Range 7.52	
Skewness 1.960	.913
Kurtosis 3.980	2.000
TOKNEEPO Mean 135.340 7.5	52633
ST 0	
95% Confidence Lower 114.443	
Interval for Mean Bound 6	
Upper 156.236	
Bound 4	
5% Trimmed Mean 135.855	
6	
Median 143.900 0	
Variance 283.228	
Std. Deviation 16.8293	
8	
Minimum 110.70	
Maximum 150.70	
Range 40.00	

	Interquartile Range		30.40	
	Skewness		916	.913
	Kurtosis		938	2.000
TOHIPPRE	Mean		138.622	7.17959
			0	
	95% Confidence	Lower	118.688	
	Interval for Mean	Bound	3	
		Upper	158.555	
		Bound	7	
	5% Trimmed Mean		138.947 2	
	Median		141.720 0	
	Variance		257.733	
	Std. Deviation		16.0540	
			5	
	Minimum		115.69	
	Maximum		155.70	
	Range		40.01	
	Interquartile Range		30.00	
	Skewness		626	.913
	Kurtosis		774	2.000
TOHIPPOST	Mean		132.120 0	8.66443
	95% Confidence	Lower	108.063	
	Interval for Mean	Bound	7	
		Upper	156.176	
		Bound	3	
	5% Trimmed Mean		133.138 9	
	Median		136.500	
	Variance		275.262	
	Variance Std. Deviation		375.362	
	Std. Deviation		19.3742 6	
	Minimum		99.30	
	Maximum		146.60	
	Range		47.30	
	Interquartile Range		30.65	
	Skewness		-1.690	.913
	Kurtosis		3.026	2.000

				Std.
			Statistic	Error
DBANKLEP RE	Mean		121.316 0	4.01909
	95% Confidence	Lower	110.157	
	Interval for Mean	Bound	2	
		Upper	132.474	
		Bound	8	
	5% Trimmed Mean		121.078 9	
	Median		119.500 0	
	Variance		80.765	
	Std. Deviation		8.98696	
	Minimum		113.00	
	Maximum		133.90	
	Range		20.90	
	Interquartile Range		17.13	
	Skewness		.620	.913
	Kurtosis		-1.358	2.000
DBANKLEP OST	Mean		118.460 0	6.53105
	95% Confidence	Lower	100.326	
	Interval for Mean	Bound	9	
		Upper	136.593	
		Bound	1	
	5% Trimmed Mean		117.827 8	
	Median		111.300 0	
	Variance		213.273	
	Std. Deviation		14.6038 7	
	Minimum		106.50	
	Maximum		141.80	
	Range		35.30	
	Interquartile Range		24.90	
	Skewness		1.331	.913
	Kurtosis		1.020	2.000

DBKNEEPR E	Mean		104.478 0	9.65161
	95% Confidence	Lower	77.6808	
	Interval for Mean	Bound		
		Upper	131.275	
		Bound	2	
	5% Trimmed Mean		105.618 9	
	Median		111.970	
	Variance		0 465.768	
			21.5816	
	Std. Deviation		21.0816	
	Minimum		66.82	
	Maximum		121.60	
	Range		54.78	
	Interquartile Range		29.69	
	Skewness		-1.957	.913
	Kurtosis		4.138	2.000
DBKNEEPO	Mean		123.040	5.11083
ST	MEall		123.040	5.11005
01	95% Confidence	Lower	108.850	
	Interval for Mean	Bound	1	
		Upper	137.229	
		Bound	9	
	5% Trimmed Mean		123.461	
			1	
	Median		124.700	
			0	
	Variance		130.603	
	Std. Deviation		11.4281	
			7	
	Minimum		104.70	
	Maximum		133.80	
	Range		29.10	
	Interquartile Range		19.55	
	Skewness		-1.235	.913
	Kurtosis		1.569	2.000
DBHIPPRE	Mean		123.644	6.50184
			0	

	95% Confidence	Lower	105.592	
	Interval for Mean	Bound	0	
		Upper	141.696	
		Bound	0	
	5% Trimmed Mean		124.001	
			1	
	Median		127.160	
			0	
	Variance		211.370	
	Std. Deviation		14.5385	
			7	
	Minimum		102.26	
	Maximum		138.60	
	Range		36.34	
	Interquartile Range		26.77	
	Skewness		778	.913
	Kurtosis		387	2.000
DBHIPPOST	Mean		131.180	6.07918
			0	
	95% Confidence	Lower	114.301	
	Interval for Mean	Bound	5	
		Upper	148.058	
		Bound	5	
	5% Trimmed Mean		131.677	
			8	
	Median		133.200	
			0	
	Variance		184.782	
	Std. Deviation		13.5934	
			5	
	Minimum		110.40	
	Maximum		143.00	
	Range		32.60	
	Interquartile Range		24.65	
	Skewness		958	.913
	Kurtosis		.277	2.000

Descriptives		
		Std.
	Statistic	Error
Mean	87.1760	6.88638

MSWANKLEP RE 95% Confidence Interval for Mean Lower Bound 68.0564 Bound Upper Bound 106.295 Bound 107.968 Bound 107.96
Bound 6 5% Trimmed Mean 87.1844 Median 82.3900 Variance 237.111 Std. Deviation 15.3984 0 0 Minimum 69.80 Maximum 104.40 Range 34.60 Interquartile Range 29.85 Skewness .241 Kurtosis -2.646 Stores .241 Mean -2.646 Stores .241 Mean .2000 Mean .2000 Stores .2000 Upper 87.4468 Bound
5% Trimmed Mean87.1844Median82.3900Variance237.111Std. Deviation15.3984Std. Deviation0Minimum69.80Maximum104.40Range34.60Interquartile Range29.85Skewness.241Skewness.241Skewness.241Kurtosis-2.646ScontidenceLower95% ConfidenceLowerInterval for MeanBoundUpper87.4468Bound0
Median 82.3900 Variance 237.111 Std. Deviation 15.3984 0 0 Minimum 69.80 Maximum 104.40 Range 34.60 Interquartile Range 29.85 Skewness .241 .913 Kurtosis -2.646 2.000 MSWANKLEP Mean 82.7000 1.70968 OST 95% Confidence Lower 77.9532 Interval for Mean Bound Upper 87.4468 Bound Upper 87.4468
Variance237.111Std. Deviation15.398400Minimum69.80Maximum104.40Range34.60Interquartile Range29.85Skewness.241Skewness.241Kurtosis-2.646Kurtosis-2.646Strong95% ConfidenceInterval for MeanBoundUpper87.4468Bound0
Std. Deviation15.3984 0Minimum69.80Maximum104.40Range34.60Interquartile Range29.85Skewness.241Skewness.241Kurtosis-2.646Kurtosis-2.646Stroppen82.7000MSWANKLEP OST95% Confidence Interval for MeanLower BoundUpper Bound87.4468 Bound
Minimum69.80Maximum104.40Range34.60Interquartile Range29.85Skewness.241Skewness.241Kurtosis-2.646Kurtosis-2.646SST95% Confidence Interval for MeanBoundUpper BoundVpper Bound87.4468 Bound
Minimum 69.80 Maximum 104.40 Range 34.60 Interquartile Range 29.85 Skewness .241 .913 Kurtosis -2.646 2.000 MSWANKLEP Mean 82.7000 1.70968 OST 95% Confidence Lower 77.9532 Interval for Mean Bound Upper 87.4468 Bound Upper 87.4468 0.000
Maximum104.40Range34.60Interquartile Range29.85Skewness.241Skewness.241Kurtosis-2.646Kurtosis-2.646SSKewnese82.7000MSWANKLEPMeanSSK ConfidenceLowerInterval for MeanBoundUpper87.4468Bound0
Range34.60Interquartile Range29.85Skewness.241Skewness.241Kurtosis-2.646Kurtosis2000MSWANKLEP OSTMean95% Confidence Interval for MeanLower Bound77.9532Upper Bound87.4468 Bound
Interquartile Range29.85Skewness.241Skewness.241Kurtosis-2.646Kurtosis-2.646MSWANKLEPMean95% ConfidenceLowerInterval for MeanBoundUpper87.4468BoundBound
Skewness .241 .913 Kurtosis -2.646 2.000 MSWANKLEP OST Mean 82.7000 1.70968 95% Confidence Interval for Mean Lower Bound 77.9532 1.70968 Upper Bound 87.4468 1.70968 1.70968
Kurtosis-2.6462.000MSWANKLEP OSTMean82.70001.7096895% Confidence Interval for MeanLower Bound77.9532Upper Bound87.44680
MSWANKLEP Mean 82.7000 1.70968 OST 95% Confidence Lower 77.9532 Interval for Mean Bound Upper 87.4468 Bound
OST 95% Confidence Lower 77.9532 Interval for Mean Upper 87.4468 Bound
Interval for Mean Bound Upper 87.4468 Bound
Upper 87.4468 Bound
Bound
Bound
5% Trimmed Mean 82 4332
Median 80.8000
Variance 14.615
Std. Deviation 3.82296
Minimum 80.70
Maximum 89.50
Range 8.80
Interquartile Range 4.85
Skewness 2.175 .913
Kurtosis 4.765 2.000
MSWKNEEPR Mean 100.348 11.1755
E 0 8
95% Confidence Lower 69.3196
Interval for Mean Bound
Upper 131.376
Bound 4
5% Trimmed Mean 100.547
070 minined wear
8
8

	Otal Davieties		04.0000	
	Std. Deviation		24.9893 6	
	Minimum		66.50	
	Maximum		130.60	
	Range		64.10	
	Interquartile Range		46.29	
	Skewness		322	.913
	Kurtosis		835	
MSWKNEEPO			116.920	
ST			0	
	95% Confidence	Lower	108.312	
	Interval for Mean	Bound	4	
		Upper	125.527	
		Bound	6	
	5% Trimmed Mean		116.805	
			6	
	Median		116.100	
			0	
	Variance		48.057	
	Std. Deviation		6.93232	
	Minimum		108.30	
	Maximum		127.60	
	Range		19.30	
	Interquartile Range		10.75	
	Skewness		.716	.913
	Kurtosis		2.035	2.000
MSWHIPPRE	Mean		91.4560	8.27555
	95% Confidence	Lower	68.4794	
	Interval for Mean	Bound		
		Upper	114.432	
		Bound	6	
	5% Trimmed Mean		91.4789	
	Median		95.8400	
	Variance		342.424	
	Std. Deviation		18.5047	
	Minimalum		0	
	Minimum		66.40	
	Maximum		116.10	
	Range		49.70	
	Interquartile Range		32.18	
	Skewness		088	.913

	Kurtosis		.227	2.000
MSWHIPPOS	Mean		101.880	8.21440
Т			0	
	95% Confidence	Lower	79.0732	
	Interval for Mean	Bound		
		Upper	124.686	
		Bound	8	
	5% Trimmed Mean		101.255	
			6	
	Median		90.6000	
	Variance		337.382	
	Std. Deviation		18.3679	
			6	
	Minimum		87.50	
	Maximum		127.50	
	Range		40.00	
	Interquartile Range		33.40	
	Skewness		.836	.913
	Kurtosis		-1.913	2.000

	Descrip	Juves		
				Std.
			Statistic	Error
HPANKLEP	Mean		101.530	4.19596
RE			0	
	95% Confidence	Lower	89.8802	
	Interval for Mean	Bound		
		Upper	113.179	
		Bound	8	
	5% Trimmed Mean		101.194	
			4	
	Median		101.940	
			0	
	Variance		88.030	
	Std. Deviation		9.38245	
	Minimum		92.60	
	Maximum		116.50	
	Range		23.90	
	Interquartile Range		15.65	
	Skewness		1.166	.913
	Kurtosis		1.497	2.000
	Mean		96.3800	5.44329

HPANKLEP OST	95% Confidence Interval for Mean	Lower Bound	81.2670	
		Upper	111.493	
		Bound	0	
	5% Trimmed Mean		96.8500	
	Median		100.900	
			0	
	Variance		148.147	
	Std. Deviation		12.1715	
			7	
	Minimum		77.70	
	Maximum		106.60	
	Range		28.90	
	Interquartile Range		21.90	
	Skewness		-1.083	.913
	Kurtosis		.080	2.000
HPKNEEPR	Mean		138.510	8.80911
E			0	
	95% Confidence	Lower	114.052	
	Interval for Mean	Bound	0	
		Upper	162.968	
		Bound	0	
	5% Trimmed Mean		139.229	
			4	
	Median		145.000	
			0	
	Variance		388.002	
	Std. Deviation		19.6977	
			6	
	Minimum		105.87	
	Maximum		158.20	
	Range		52.33	
	Interquartile Range		30.40	
	Skewness		-1.442	.913
	Kurtosis		2.713	2.000
HPKNEEPO	Mean		150.080	5.36017
ST			0	
	95% Confidence	Lower	135.197	
	Interval for Mean	Bound	8	
		Upper	164.962	
		Bound	2	

	5% Trimmed Mean		150.338	
			9	
	Median		152.000 0	
	Variance		-	
	Variance		143.657	
	Std. Deviation		11.9857 0	
	Minimum		131.30	
	Maximum		164.20	
	Range		32.90	
	Interquartile Range		19.20	
	Skewness		904	.913
	Kurtosis		1.960	2.000
HPHIPPRE	Mean		91.4980	7.78628
	95% Confidence	Lower	69.8798	
	Interval for Mean	Bound		
		Upper	113.116	
		Bound	2	
	5% Trimmed Mean		91.5183	
	Median		98.8600	
	Variance		303.131	
	Std. Deviation		17.4106	
			6	
	Minimum		72.43	
	Maximum		110.20	
	Range		37.77	
	Interquartile Range		33.38	
	Skewness		355	.913
	Kurtosis		-2.871	2.000
HPHIPPOST	Mean		104.260	6.16479
			0	
	95% Confidence	Lower	87.1438	
	Interval for Mean	Bound	_	
		Upper	121.376	
		Bound	2	
	5% Trimmed Mean		103.627	
			8	
	Median		98.3000	
	Variance		190.023	
	Std. Deviation		13.7848	
			8	

Minimum	92.50	
Maximum	127.40	
Range	34.90	
Interquartile Range	21.70	
Skewness	1.625	.913
Kurtosis	2.713	2.000

IC2MSTANKLEPMeanStatisticErrRE95% ConfidenceLower80.1439Interval for MeanBoundUpper117.332	
RE 95% Confidence Lower 80.1439 Interval for Mean Bound	708
Interval for Mean Bound	
Upper 117 332	
Opper 117.002	
Bound 1	
5% Trimmed Mean 98.4544	
Median 98.1800	
Variance 224.255	
Std. Deviation 14.9751	
3	
Minimum 81.66	
Maximum 120.92	
Range 39.26	
Interquartile Range 26.80	
Skewness .646 .	913
Kurtosis .343 2.	000
IC2MSTANKLEP Mean 99.8660 4.37	463
OST 95% Confidence Lower 87.7201	
Interval for Mean Bound	
Upper 112.011	
Bound 9	
5% Trimmed Mean 100.020	
6	
Median 103.730	
0	
Variance 95.687	
Std. Deviation 9.78197	
Minimum 87.50	
Maximum 109.45	
Range 21.95	

	Interquartile Range		18.80	
	Skewness		513	.913
	Kurtosis		-2.572	2.000
IC2MSTKNEEP	Mean		155.644	
RE	Mean		0	4.00000
	95% Confidence	Lower	141.817	
	Interval for Mean	Bound	1	
		Upper	169.470	
		Bound	9	
	5% Trimmed Mean		155.517	
			8	
	Median		152.150	
			0	
	Variance		124.006	
	Std. Deviation		11.1358	
			2	
	Minimum		141.89	
	Maximum		171.67	
	Range		29.78	
	Interquartile Range		19.20	
	Skewness		.465	.913
	Kurtosis		.346	2.000
IC2MSTKNEEP	Mean		149.500	5.15053
OST	050/ 0 51		0	
	95% Confidence	Lower	135.199	
	Interval for Mean	Bound	8	
		Upper	163.800	
	5% Trimmed Mean	Bound	2	
			149.013 9	
	Median		148.450	
	Median		0	
	Variance		132.640	
	Std. Deviation		11.5169	
			4	
	Minimum		139.18	
	Maximum		168.57	
	Range		29.39	
	Interquartile Range		18.54	
	Skewness		1.467	.913
	Kurtosis		2.452	2.000

95% Confidence Interval for Mean Lower Bound 96.0082 Upper Bound 137.367 Bound 137.367 Bound 137.367 Bound 5% Trimmed Mean 116.397 2 Median 114.750 0 Variance 277.385 5 Std. Deviation 16.648 8 Minimum 96.45 8 Maximum 142.16 8 Range 45.71 1 Interquartile Range 27.43 5 Skewness .723 .913 Kurtosis 1.590 2.000 T 0 0 0 95% Confidence Interval for Mean Lower .94.6697 Interval for Mean 112.06 6.28010 T 0 0 0 95% Confidence Interval for Mean Bound 3 5% Trimmed Mean .0 0 0 Variance 197.198 .0 .0 Variance .0 .0 .0 Variance <th>IC2MSTHIPPRE</th> <th>Mean</th> <th></th> <th>116.688 0</th> <th>7.44829</th>	IC2MSTHIPPRE	Mean		116.688 0	7.44829
Interval for Mean Bound Upper 137.367 Second <		95% Confidence	Lower		
Upper Bound 137.367 8 5% Trimmed Mean 116.397 2 Median 114.750 0 Variance 277.385 Std. Deviation 16.6548 8 Minimum 96.45 Maximum 142.16 Range 45.71 Interquartile Range 27.43 Skewness .723 .913 Kurtosis 1.590 2.000 IC2MSTHIPPOS T Mean 112.106 6.28010 95% Confidence Interval for Mean Lower 94.6697				00.0002	
Bound 8 5% Trimmed Mean 116.397 2 2 Median 114.750 0 0 Variance 277.385 Std. Deviation 16.6548 Maximum 16.6548 Maximum 96.45 Maximum 142.16 Range 45.71 Interquartile Range 27.43 Skewness .723 .913 Kurtosis 1.590 2.000 IC2MSTHIPPOS Mean 112.106 6.28010 95% Confidence Lower 94.6697 112.106 Interval for Mean Bound 112.645 6 Median 112.645 6 112.645 6 Median 115.500 0 10 112.645 111 Std. Deviation 14.0427 3 1111 111 <td></td> <td></td> <td></td> <td>137,367</td> <td></td>				137,367	
5% Trimmed Mean 116.397 Median 114.750 0 0 Variance 277.385 Std. Deviation 16.6548 8 8 Minimum 96.45 Maximum 142.16 Range 45.71 Interquartile Range 27.43 Skewness .723 .913 Kurtosis 1.590 2.000 IC2MSTHIPPOS Mean 112.106 6.28010 7 0 95% Confidence Lower 94.6697 Interval for Mean Bound 112.645 6 Median 112.645 6 6 Median 112.645 6 6 Variance 197.198 3 3 5% Trimmed Mean 112.645 6 6 Variance 197.198 3 3 5K1. Deviation 14.0427 3 3 Minimum 89.10 89.10 3 3					
Median114.750Variance277.385Std. Deviation16.6548Minimum96.45Maximum142.16Range45.71Interquartile Range27.43Skewness.723Nurtosis1.590IC2MSTHIPPOSMeanMean112.10695% ConfidenceLower94.6697095% ConfidenceLower95% ConfidenceBoundUpper129.542Bound35% Trimmed Mean112.64560Variance197.198Std. Deviation14.042733Minimum89.10Maximum125.40Range36.30Interquartile Range36.30Interquartile Range36.30Interquartile Range36.30Interquartile Range36.30Skewness-1.390.913.913		5% Trimmed Mean		116.397	
Variance 277.385 Std. Deviation 16.6548 8 8 Minimum 96.45 Maximum 142.16 Range 45.71 Interquartile Range 27.43 Skewness .723 .913 Kurtosis 1.590 2.000 IC2MSTHIPPOS Mean 112.106 6.28010 7 0 95% Confidence Lower 94.6697 Interval for Mean Bound 112.064 6.28010 95% Confidence Lower 94.6697 112.064 Wedian 112.645 6 112.00 5% Trimmed Mean 112.645 6 112.00 Variance 197.198 112.645 6 Median 115.500 0 112.00 Variance 197.198 3 112.00 Std. Deviation 14.0427 3 3 Minimum 89.10 3 1 Maximum 125.40 3					
Variance 277.385 Std. Deviation 16.6548 Minimum 96.45 Maximum 142.16 Range 45.71 Interquartile Range 27.43 Skewness .723 .913 Kurtosis 1.590 2.000 IC2MSTHIPPOS Mean 112.106 6.28010 T 0 95% Confidence Lower 94.6697 Interval for Mean Bound 0 112.106 5% Trimmed Mean 112.645 6 Median 115.500 0 Variance 197.198 112.645 Std. Deviation 14.0427 3 Median 115.500 0 Variance 197.198 112.645 Std. Deviation 14.0427 3 Minimum 89.10 3 Maximum 125.40 3 Maximum 125.40 3 Maximum 125.40 3 Maximum 125.40		Median		114.750	
Std. Deviation 16.6548 Minimum 96.45 Maximum 142.16 Range 45.71 Interquartile Range 27.43 Skewness .723 .913 Kurtosis 1.590 2.000 IC2MSTHIPPOS Mean 112.106 6.28010 T 0 95% Confidence Lower 94.6697 Interval for Mean Bound 0 112.106 6.28010 0 95% Confidence Lower 94.6697 112.006 6.28010 0 95% Confidence Bound 0 112.645 6 Median 112.645 6 6 6 Variance 197.198 5 5 15.500 0 1 Variance 197.198 3 1 1 1 1 1 Minimum 89.10 1 3 1 1 1 1 1 1 1 1 1 1 1 <td></td> <td></td> <td></td> <td>0</td> <td></td>				0	
Minimum96.45Maximum142.16Range45.71Interquartile Range27.43Skewness.723.913KurtosisKurtosis1.5902.000112.1066.28010095% Confidence Interval for MeanLower Bound95% Crifidence Interval for Mean112.645 65% Trimmed Mean112.645 65% Trimmed Mean112.645 65% Trimmed Mean115.500 0Variance197.198Std. Deviation14.0427 3Minimum89.10Maximum125.40Range36.30Interquartile Range Skewness36.30Interquartile Range23.22Skewness-1.390.913		Variance		277.385	
Minimum96.45Maximum142.16Range45.71Interquartile Range27.43Skewness.723Kurtosis1.590IC2MSTHIPPOSMeanMean112.1066.280100095% ConfidenceLower94.669794.6697Interval for MeanBoundUpper129.542Bound35% Trimmed Mean112.64566Median115.50000Variance197.198Std. Deviation14.042733Minimum89.10Maximum125.40Range36.30Interquartile Range23.22Skewness-1.390.913		Std. Deviation		16.6548	
Maximum 142.16 Range 45.71 Interquartile Range 27.43 Skewness .723 .913 Kurtosis 1.590 2.000 IC2MSTHIPPOS Mean 112.106 6.28010 T 0 0 0 95% Confidence Lower 94.6697 0 Interval for Mean Bound 0 0 95% Trimmed Mean 112.645 6 0 5% Trimmed Mean 115.500 0 0 Variance 197.198 5 5 14.0427 3 3 3 3 3 Maximum 125.40 3 3 Minimum 89.10 3 3 Maximum 125.40 3 3 Maximum 125.40 3 3 Maximum 125.40 3 3 Skewness -1.390 .913 .913				8	
Range 45.71 Interquartile Range 27.43 Skewness .723 .913 Kurtosis 1.590 2.000 IC2MSTHIPPOS Mean 112.106 6.28010 T 0 0 0 95% Confidence Lower 94.6697 0 Interval for Mean Bound 0 0 95% Confidence Lower 94.6697 0 Upper 129.542 Bound 3 5% Trimmed Mean 112.645 6 Median 115.500 0 0 Variance 197.198 5 5 Std. Deviation 14.0427 3 3 Minimum 89.10 3 3 Maximum 125.40 1 3 Range 36.30 1 3 Interquartile Range 36.30 3 3		Minimum		96.45	
Interquartile Range 27.43 Skewness .723 .913 Kurtosis 1.590 2.000 IC2MSTHIPPOS Mean 112.106 6.28010 T 95% Confidence Lower 94.6697 Interval for Mean Bound 112.542 112.542 Bound 3 112.645 6 Median 115.500 0 112.645 6 Variance 197.198 114.0427 3 Minimum 89.10 3 1125.40 3 Maximum 125.40 3 3 1125.40 Range 36.30 1112.645 3 3 3		Maximum		142.16	
Skewness .723 .913 Kurtosis 1.590 2.000 IC2MSTHIPPOS Mean 112.106 6.28010 T 0 0 0 95% Confidence Lower 94.6697 0 Interval for Mean Bound 0 0 5% Trimmed Mean 112.645 6 Median 115.500 0 Variance 197.198 0 Std. Deviation 14.0427 3 Minimum 89.10 3 Maximum 125.40 8 Range 36.30 1 Interquartile Range 23.22 Skewness -1.390 .913		Range		45.71	
Kurtosis 1.590 2.000 IC2MSTHIPPOS T Mean 112.106 6.28010 95% Confidence Interval for Mean Lower 94.6697 94.6697 95% Confidence Interval for Mean Bound 129.542 96 5% Trimmed Mean 112.645 6 6 Median 115.500 0 Variance 197.198 5 5td. Deviation 14.0427 3 Minimum 89.10 3 3 Maximum 125.40 3 3 Range 36.30 1 3 Interquartile Range 23.22 5 5 Skewness -1.390 .913 .913		Interquartile Range		27.43	
IC2MSTHIPPOS Mean 112.106 6.28010 T 0 0 0 0 95% Confidence Lower 94.6697 0 Interval for Mean Bound 0 0 Upper 129.542 0 0 5% Trimmed Mean 112.645 6 0 Median 115.500 0 0 Variance 197.198 0 0 Std. Deviation 14.0427 3 0 Minimum 89.10 3 0 0 Maximum 125.40 125.40 0 0 0 Skewness -1.390 .913 .913 .913		Skewness		.723	.913
T 0 95% Confidence Interval for Mean Lower Bound 94.6697 Upper 129.542 Bound 3 5% Trimmed Mean 112.645 6 6 Median 115.500 0 0 Variance 197.198 Std. Deviation 14.0427 3 3 Minimum 89.10 Maximum 125.40 Range 36.30 Interquartile Range 23.22 Skewness -1.390 .913		Kurtosis		1.590	2.000
Interval for MeanBoundUpper129.542Bound35% Trimmed Mean112.64566Median115.50000Variance197.198Std. Deviation14.042733Minimum89.10Maximum125.40Range36.30Interquartile Range23.22Skewness-1.390.913		Mean			6.28010
Upper Bound 129.542 3 5% Trimmed Mean 112.645 6 6 Median 115.500 0 0 Variance 197.198 Std. Deviation 14.0427 3 3 Minimum 89.10 Maximum 125.40 Range 36.30 Interquartile Range 23.22 Skewness -1.390 .913		95% Confidence	Lower	94.6697	
Bound 3 5% Trimmed Mean 112.645 6 6 Median 115.500 0 0 Variance 197.198 Std. Deviation 14.0427 3 3 Minimum 89.10 Maximum 125.40 Range 36.30 Interquartile Range 23.22 Skewness -1.390 .913		Interval for Mean	Bound		
5% Trimmed Mean 112.645 6 Median 115.500 0 0 Variance 197.198 Std. Deviation 14.0427 3 3 Minimum 89.10 Maximum 125.40 Range 36.30 Interquartile Range 23.22 Skewness -1.390 .913			Upper	129.542	
Median 115.500 Variance 197.198 Std. Deviation 14.0427 3 3 Minimum 89.10 Maximum 125.40 Range 36.30 Interquartile Range 23.22 Skewness -1.390 .913			Bound	3	
Median115.500 0Variance197.198Std. Deviation14.0427 3Minimum89.10Maximum125.40Range36.30Interquartile Range23.22Skewness-1.390.913		5% Trimmed Mean		112.645	
Variance197.198Std. Deviation14.042733Minimum89.10Maximum125.40Range36.30Interquartile Range23.22Skewness-1.390.913				6	
Variance 197.198 Std. Deviation 14.0427 3 3 Minimum 89.10 Maximum 125.40 Range 36.30 Interquartile Range 23.22 Skewness -1.390 .913		Median		115.500	
Std. Deviation14.0427 3Minimum89.10Maximum125.40Range36.30Interquartile Range23.22Skewness-1.390.913				0	
Minimum89.10Maximum125.40Range36.30Interquartile Range23.22Skewness-1.390		Variance		197.198	
Minimum89.10Maximum125.40Range36.30Interquartile Range23.22Skewness-1.390.913		Std. Deviation		14.0427	
Maximum125.40Range36.30Interquartile Range23.22Skewness-1.390.913				3	
Range36.30Interquartile Range23.22Skewness-1.390.913		Minimum		89.10	
Interquartile Range23.22Skewness-1.390.913		Maximum		125.40	
Skewness -1.390 .913		Range		36.30	
		Interquartile Range		23.22	
Kurtosis 2.160 2.000		Skewness		-1.390	.913

				Std.
			Statistic	Error
MST2TOANKLE	Mean		96.5980	5.42781
PRE	95% Confidence	Lower	81.5280	
	Interval for Mean	Bound		
		Upper	111.668	
		Bound	0	
	5% Trimmed Mean		95.8572	
	Median		91.5400	
	Variance		147.306	
	Std. Deviation		12.1369	
			6	
	Minimum		88.54	
	Maximum		117.99	
	Range		29.45	
	Interquartile Range		16.58	
	Skewness		2.077	.913
	Kurtosis		4.420	2.000
MST2TOANKLE	Mean		98.4520	3.23086
POST	95% Confidence	Lower	89.4817	
	Interval for Mean	Bound		
		Upper	107.422	
		Bound	3	
	5% Trimmed Mean		98.2717	
	Median		97.8200	
	Variance		52.192	
	Std. Deviation		7.22443	
	Minimum		90.28	
	Maximum		109.87	
	Range		19.59	
	Interquartile Range		11.77	
	Skewness		1.003	.913
	Kurtosis		1.899	2.000
MST2TOKNEEP	Mean		149.290	6.30449
RE			0	
	95% Confidence	Lower	131.785	
	Interval for Mean	Bound	9	
		Upper	166.794	
		Bound	1	
	5% Trimmed Mean		149.210	
			6	

	Median		145.470 0	
	Variance		198.733	
	Std. Deviation		14.0972	
	Std. Deviation		14.0372	
	Minimum		134.77	
	Maximum		165.24	
	Range		30.47	
	Interquartile Range		27.73	
	Skewness		.307	.913
	Kurtosis		-2.910	2.000
MST2TOKNEEP	Mean		146.754	8.32458
OST			0	
	95% Confidence	Lower	123.641	
	Interval for Mean	Bound	2	
		Upper	169.866	
		Bound	8	
	5% Trimmed Mean		147.325	
			0	
	Median		151.440 0	
	Variance		346.494	
	Std. Deviation		18.6143	
			4	
	Minimum		118.93	
	Maximum		164.30	
	Range		45.37	
	Interquartile Range		34.22	
	Skewness		889	.913
	Kurtosis		267	2.000
MST2HIPPRE	Mean		134.282	8.53183
			0	
	95% Confidence	Lower	110.593	
	Interval for Mean	Bound	8	
		Upper	157.970	
		Bound	2	
	5% Trimmed Mean		134.373	
	N.A IV		3	
	Median		137.340	
	Verience		0	
	Variance		363.960	

	Std. Deviation		19.0777	
			5	
	Minimum		107.25	
	Maximum		159.67	
	Range		52.42	
	Interquartile Range		32.13	
	Skewness		211	.913
	Kurtosis		.985	2.000
MST2TOHIPPOS	Mean		126.282	9.42014
Т			0	
	95% Confidence	Lower	100.127	
	Interval for Mean	Bound	5	
		Upper	152.436	
		Bound	5	
	5% Trimmed Mean		127.432	
			2	
	Median		132.900	
			0	
	Variance		443.695	
	Std. Deviation		21.0640	
			7	
	Minimum		90.23	
	Maximum		141.63	
	Range		51.40	
	Interquartile Range		32.64	
	Skewness		-1.793	.913
	Kurtosis		3.334	2.000

Descriptives				
				Std.
			Statistic	Error
TO2DBANKLEP	Mean		128.064	6.17090
RE			0	
	95% Confidence	Lower	110.930	
	Interval for Mean	Bound	8	
		Upper	145.197	
		Bound	2	
	5% Trimmed Mean		128.117	
			8	
	Median		132.110	
			0	
	Variance		190.400	

	Std. Deviation		13.7985 4	
	Minimum		112.77	
	Maximum		142.39	
	Range		29.62	
	Interquartile Range		27.09	
	Skewness		312	.913
	Kurtosis		-2.938	
TO2BDANKLEP	Mean		122.518	
OST			0	
	95% Confidence	Lower	109.844	
	Interval for Mean	Bound	6	
		Upper	135.191	
		Bound	4	
	5% Trimmed Mean		122.397	
			2	
	Median		121.650	
			0	
	Variance		104.179	
	Std. Deviation		10.2068 1	
	Minimum		110.55	
	Maximum		136.66	
	Range		26.11	
	Interquartile Range		19.05	
	Skewness		.381	.913
	Kurtosis		712	2.000
TO2DBKNEEPR	Mean		125.446	3.65168
E			0	
	95% Confidence	Lower	115.307	
	Interval for Mean	Bound	3	
		Upper	135.584	
		Bound	7	
	5% Trimmed Mean		125.527	
			8	
	Median		129.810	
			0	
	Variance		66.674	
	Std. Deviation		8.16541	
	Minimum		115.48	
	Maximum		133.94	

	Range		18.46	
	Interquartile Range		15.23	
	Skewness		469	.913
	Kurtosis		-2.675	2.000
TO2DBKNEEPO			134.430	
ST	Wear		0	4.40020
	95% Confidence	Lower	121.938	
	Interval for Mean	Bound	0	
		Upper	146.922	
		Bound	0	
	5% Trimmed Mean		134.966 7	
	Median		138.750 0	
	Variance		101.218	
	Std. Deviation		10.0607	
	Minimum		117.30	
	Maximum		141.90	
	Range		24.60	
	Interquartile Range		15.67	
	Skewness		-1.763	.913
	Kurtosis		3.090	2.000
TO2DBHIPPRE	Mean		137.488	
	in our		0	1.00010
	95% Confidence	Lower	125.281	
	Interval for Mean	Bound	5	
		Upper	149.694	
		Bound	5	
	5% Trimmed Mean		137.621 7	
	Median		137.570 0	
	Variance		96.644	
	Std. Deviation		9.83075	
	Minimum		123.88	
	Maximum		148.69	
	Range		24.81	
	Interquartile Range		18.45	
	Skewness		375	.913
	Kurtosis		865	2.000
				2.000

TO2DBHIPPOS T	Mean		128.952 0	9.28234
	95% Confidence	Lower	103.180	
	Interval for Mean	Bound	1	
		Upper	154.723	
		Bound	9	
	5% Trimmed Mean		130.340	
			0	
	Median		138.490	
			0	
	Variance		430.809	
	Std. Deviation		20.7559	
			5	
	Minimum		92.04	
	Maximum		140.88	
	Range		48.84	
	Interquartile Range		26.44	
	Skewness		-2.172	.913
	Kurtosis		4.763	2.000

	Descriptiv	ves		
	-			Std.
			Statistic	Error
DB2MSWANKLE PRE	Mean		106.278 0	3.97691
	95% Confidence Interval for Mean	Lower Bound	95.2363	
		Upper Bound	117.319 7	
	5% Trimmed Mean		106.429 4	
	Median		105.240 0	
	Variance		79.079	
	Std. Deviation		8.89264	
	Minimum		93.75	
	Maximum		116.08	
	Range		22.33	
	Interquartile Range		16.42	
	Skewness		415	.913
	Kurtosis		688	2.000

DB2MSWANKLE POST	Mean		107.556 0	3.13720
	95% Confidence	Lower	98.8457	
	Interval for Mean	Bound		
		Upper	116.266	
		Bound	3	
	5% Trimmed Mean		107.353 9	
	Median		106.230	
			0	
	Variance		49.210	
	Std. Deviation		7.01499	
	Minimum		99.77	
	Maximum		118.98	
	Range		19.21	
	Interquartile Range		10.41	
	Skewness		1.218	.913
	Kurtosis		2.698	2.000
DB2MSWKNEEP	Mean		96.4840	7.99300
RE	95% Confidence	Lower	74.2919	
	Interval for Mean	Bound		
		Upper	118.676	
		Bound	1	
	5% Trimmed Mean		97.2483	
	Median		98.7400	
	Variance		319.440	
	Std. Deviation		17.8728	
			8	
	Minimum		66.82	
	Maximum		112.39	
	Range		45.57	
	Interquartile Range		28.85	
	Skewness		-1.490	.913
	Kurtosis		2.508	2.000
DB2MSWKNEEP	Mean		122.726	4.94810
OST			0	
	95% Confidence	Lower	108.987	
	Interval for Mean	Bound	9	
		Upper	136.464	
		Bound	1	

	5% Trimmed Mean		123.242	
	Median		126.340	
			0	
	Variance		122.419	
	Std. Deviation		11.0643	
			0	
	Minimum		103.93	
	Maximum		132.23	
	Range		28.30	
	Interquartile Range		17.05	
	Skewness		-1.706	.913
	Kurtosis		3.196	2.000
DB2MSWHIPPRE	Mean		112.002	3.55872
			0	
	95% Confidence	Lower	102.121	
	Interval for Mean	Bound	4	
		Upper	121.882	
		Bound	6	
	5% Trimmed Mean		112.100 6	
	Median		112.600	
			0	
	Variance		63.322	
	Std. Deviation		7.95754	
	Minimum		102.26	
	Maximum		119.97	
	Range		17.71	
	Interquartile Range		15.70	
	Skewness		209	.913
	Kurtosis		-2.502	2.000
DB2MSWHIPPOS T	Mean		123.348	7.31940
	95% Confidence	Lower	103.026	
	Interval for Mean	Bound	103.020	
	intorvarior mour	Upper	143.669	
		Bound	9	
	5% Trimmed Mean		123.433	
			3	
	Median		121.400	
			0	

Variance	267.868	
Std. Deviation	16.3666	
	7	
Minimum	100.23	
Maximum	144.93	
Range	44.70	
Interquartile Range	27.89	
Skewness	188	.913
Kurtosis	.808	2.000
	Std. Deviation Minimum Maximum Range Interquartile Range Skewness	Std. Deviation16.3666 7Minimum100.23Maximum144.93Range44.70Interquartile Range27.89Skewness188

	-			Std.
			Statistic	Error
MSW2HPANKLE	Mean		94.3600	6.75918
PRE	95% Confidence	Lower	75.5935	
	Interval for Mean	Bound		
		Upper	113.126	
		Bound	5	
	5% Trimmed Mean		93.9056	
	Median		87.2000	
	Variance		228.433	
	Std. Deviation		15.1139	
			8	
	Minimum		81.63	
	Maximum		115.27	
	Range		33.64	
	Interquartile Range		28.28	
	Skewness		.762	.913
	Kurtosis		-1.892	2.000
MSW2HPANKLE	Mean		93.3680	3.63361
POST	95% Confidence	Lower	83.2795	
	Interval for Mean	Bound		
		Upper	103.456	
		Bound	5	
	5% Trimmed Mean		93.5850	
	Median		96.9100	
	Variance		66.015	
	Std. Deviation		8.12499	
	Minimum		81.03	
	Maximum		101.80	
	Range		20.77	

	Interquartile Range		14.14	
	Skewness		947	.913
	Kurtosis		.257	2.000
MSW2HPKNEEP	Mean		116.180	10.5716
RE	Mean		0	10.3710
	95% Confidence	Lower	86.8283	
	Interval for Mean	Bound	00.0200	
		Upper	145.531	
		Bound	7	
	5% Trimmed Mean		116.480	
			6	
	Median		123.130	
			0	
	Variance		558.801	
	Std. Deviation		23.6389	
			8	
	Minimum		85.18	
	Maximum		141.77	
	Range		56.59	
	Interquartile Range		45.18	
	Skewness		442	.913
	Kurtosis		-1.919	2.000
MSW2HPKNEEP OST	Mean		131.716 0	5.73362
	95% Confidence	Lower	115.796	
	Interval for Mean	Bound	9	
		Upper	147.635	
		Bound	1	
	5% Trimmed Mean		131.958	
			3	
	Median		132.880 0	
	Variance		164.372	
	Std. Deviation		12.8207	
	Minima		7	
	Minimum		112.47	
	Maximum		146.60	
	Range		34.13	
	Interquartile Range		22.50	0.10
	Skewness		700	.913
	Kurtosis		.742	2.000

MSW2HPHIPPRE	Mean		91.0260	6.93467
	95% Confidence	Lower	71.7723	
	Interval for Mean	Bound		
		Upper	110.279	
		Bound	7	
	5% Trimmed Mean		91.1911	
	Median		95.6700	
	Variance		240.448	
	Std. Deviation		15.5063	
			9	
	Minimum		69.48	
	Maximum		109.60	
	Range		40.12	
	Interquartile Range		28.11	
	Skewness		427	.913
	Kurtosis		564	2.000
MSW2HPHIPPOS T	Mean		100.510 0	10.9112 3
	95% Confidence	Lower	70.2156	
	Interval for Mean	Bound		
		Upper	130.804	
		Bound	4	
	5% Trimmed Mean		100.605	
			6	
	Median		91.6000	
	Variance		595.274	
	Std. Deviation		24.3982	
			4	
	Minimum		69.35	
	Maximum		129.95	
	Range		60.60	
	Interquartile Range		44.58	
	Skewness		.039	.913
	Kurtosis		-1.460	2.000

Descript	1463	
		Std.
	Statistic	Error
HPANKLEP Mean	107.492	4.43897
RE	0	

	95% Confidence Interval for Mean	Lower Bound	95.1674	
		Upper	119.816	
		Bound	6	
	5% Trimmed Mean		107.471 1	
	Median		109.800 0	
	Variance		98.522	
	Std. Deviation		9.92584	
	Minimum		96.83	
	Maximum		118.53	
	Range		21.70	
	Interquartile Range		19.50	
	Skewness		197	.913
	Kurtosis	-2.770	2.000	
HPANKLEP	Mean		98.9920	5.91945
OST	95% Confidence	Lower	82.5570	0.01010
	Interval for Mean	Bound	02.0010	
		Upper	115.427	
		Bound	0	
	5% Trimmed Mean	99.5894		
	Median		106.600	
			0	
	Variance		175.199	
	Std. Deviation		13.2362	
			9	
	Minimum		77.70	
	Maximum		109.53	
	Range		31.83	
	Interquartile Range		21.98	
	Skewness		-1.381	.913
	Kurtosis		1.164	2.000
HPKNEEPR	Mean		146.112	5.36630
E			0	
	95% Confidence	Lower	131.212	
	Interval for Mean	Bound	8	
		Upper	161.011	
		Bound	2	
	5% Trimmed Mean		146.899	
			4	

	Median	151.940		
		0		
	Variance		143.986	
	Std. Deviation		11.9994	
			1	
	Minimum		125.02	
	Maximum		153.03	
	Range		28.01	
	Interquartile Range		16.69	0.40
	Skewness		-2.057	.913
	Kurtosis		4.274	2.000
HPKNEEPO	Mean			5.60066
ST			0	
	95% Confidence	Lower	135.676	
	Interval for Mean	Bound	1	
		Upper	166.775	
		Bound	9	
	5% Trimmed Mean		151.634	
	N de aliene		4	
	Median	154.200 0		
	Variance	156.837		
	Std. Deviation	12.5234		
			5	
	Minimum	131.30		
	Maximum	163.80		
	Range		32.50	
	Interquartile Range		21.44	
	Skewness		-1.172	.913
	Kurtosis		1.440	2.000
HPHIPPRE	Mean		94.5580	6.33857
	95% Confidence	Lower	76.9593	
	Interval for Mean	Bound		
		Upper	112.156	
		Bound	7	
	5% Trimmed Mean		94.2139	
	Median	92.2300		
	Variance		200.887	
	Std. Deviation		14.1734	
			7	
	Minimum		81.01	

	Maximum		114.30	
	Range		33.29	
	Interquartile Range	27.07		
	Skewness		.574	.913
	Kurtosis		-1.367	2.000
HPHIPPOST	Mean		104.698	6.05392
			0	
	95% Confidence	Lower	87.8896	
	Interval for Mean	Bound		
		Upper	121.506	
		Bound	4	
	5% Trimmed Mean	104.039		
			4	
	Median		98.2700	
	Variance		183.250	
	Std. Deviation	13.5369		
			7	
	Minimum		93.85	
	Maximum	127.40		
	Range	33.55		
	Interquartile Range		21.46	
	Skewness		1.639	.913
	Kurtosis		2.578	2.000

		-		Std.
			Statistic	Error
SpeedPr	Mean		3.2160	.93650
е	95% Confidence	Lower	.6159	
	Interval for Mean	Bound		
		Upper	5.8161	
		Bound		
	5% Trimmed Mean		3.2261	
	Median		3.2900	
	Variance		4.385	
	Std. Deviation		2.09408	
	Minimum		.37	
	Maximum		5.88	
	Range		5.51	
	Interquartile Range		3.84	
	Skewness		171	.913

	Kurtosis		282	2.000
SpeedPo	Mean		2.2560	.57885
st	95% Confidence	Lower	.6489	
	Interval for Mean	Bound		
		Upper	3.8631	
		Bound		
	5% Trimmed Mean		2.2828	
	Median		2.4500	
	Variance		1.675	
	Std. Deviation		1.29435	
	Minimum		.24	
	Maximum	Maximum		
	Range	3.55		
	Interquartile Range		2.09	
	Skewness	861	.913	
	Kurtosis		1.844	2.000

				Std.
			Statistic	Error
SPSIXMRTP	Mean		2.2278	.46770
RE	95% Confidence	Lower	1.0255	
	Interval for Mean	Bound		
		Upper	3.4300	
		Bound		
	5% Trimmed Mean		2.2506	
	Median		2.1903	
	Variance		1.312	
	Std. Deviation		1.14563	
	Minimum		.36	
	Maximum		3.68	
	Range		3.32	
	Interquartile Range		1.72	
	Skewness		574	.845
	Kurtosis		.677	1.741
SPSIXMRTP	Mean		2.0068	.44528
OST	95% Confidence	Lower	.8622	
	Interval for Mean	Bound		
		Upper	3.1514	
		Bound		
	5% Trimmed Mean		2.0193	

Median	1.8583	
Variance	1.190	
Std. Deviation	1.09071	
Minimum	.34	
Maximum	3.45	
Range	3.12	
Interquartile Range	1.77	
Skewness	216	.845
Kurtosis	.147	1.741

1.5.2 SPSS Output for Normality Test

Tests of Normality						
	Kolmo	gorov-Sm	irnov ^a	Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
RHRPR E	.247	9	.120	.895	9	.224
RHRPO ST	.293	9	.025	.821	9	.036

a. Lilliefors Significance Correction

Tests of Normality						
Kolmogorov-Smirnov ^a Shapiro-Wilk					lk	
	Statistic	df	Sig.	Statistic	df	Sig.
SYSPR	.257	6	.200*	.884	6	.290
E						

SYSPO ST	.163	6	.200*	.951	6	.749
DIAPRE	.213	6	.200*	.883	6	.283
DIAPOS	.238	6	.200*	.901	6	.381
Т						

a. Lilliefors Significance Correction

Tests of Normality

	Kolmogorov-Smirnov ^a				Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.	
SIXMRTPR E	.212	6	.200*	.964	6	.848	
SIXMRTP OST	.203	6	.200*	.956	6	.792	

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Tests of Normality

	Kolmogorov-Smirnov ^a				Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.	
TCLEFTPRE	.125	8	.200*	.975	8	.932	
TCLEFTPOS T	.193	8	.200*	.943	8	.640	
TCRIGHTPR E	.123	8	.200*	.982	8	.970	
TCRIGHTPO ST	.205	8	.200*	.917	8	.403	
CCLEFTPRE	.235	8	.200*	.955	8	.766	
CCLEFTPO ST	.169	8	.200*	.947	8	.676	
CCRIGHTPR E	.174	8	.200*	.937	8	.584	
CCRIGHTP OST	.199	8	.200*	.909	8	.344	

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
LEFTKEPRE	.182	9	.200*	.906	9	.288
LEFTKEPOS T	.185	9	.200*	.898	9	.243
RIGHTKEPR E	.169	9	.200*	.960	9	.797
RIGHTKEPO ST	.161	9	.200*	.951	9	.702
LEFTKFPRE	.235	9	.164	.815	9	.030
LEFTKFPOS T	.321	9	.008	.836	9	.052
RIGHTKFPR E	.169	9	.200*	.924	9	.429
RIGHTKFPO ST	.234	9	.169	.925	9	.433
LEFTPLFPR E	.223	9	.200*	.872	9	.130
LEFTPLFPO ST	.211	9	.200*	.959	9	.792
RIGHTPLFP RE	.328	9	.006	.730	9	.003
RIGHTPLFP OST	.123	9	.200*	.959	9	.784

a. Lilliefors Significance Correction

				,		
	Kolmo	gorov-Sm	irnov ^a	Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
ICANKLEPR E	.181	5	.200*	.957	5	.789
ICANKLEP OST	.262	5	.200*	.945	5	.703
ICKNEEPR E	.238	5	.200*	.883	5	.321
ICKNEEPO ST	.278	5	.200*	.788	5	.064
ICHIPPRE	.222	5	.200*	.909	5	.461

ICHIPPOST	.341	5	.057	.806	5	.091
-----------	------	---	------	------	---	------

a. Lilliefors Significance Correction

	Tests of Normality							
	Kolmo	gorov-Sm	irnov ^a	S	hapiro-Wi	lk		
	Statistic	df	Sig.	Statistic	df	Sig.		
MSTANKLEP RE	.333	5	.073	.773	5	.048		
MSTANKLEP OST	.197	5	.200*	.958	5	.791		
MSTKNEEPR E	.247	5	.200*	.879	5	.303		
MSTKNEEPO ST	.177	5	.200*	.955	5	.775		
MSTHIPPRE	.206	5	.200*	.969	5	.866		
MSTELBOPO ST	.255	5	.200*	.871	5	.271		

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Tests of Normality

	Kolmo	aorov Sm	irpova	Shanira Wilk			
	KUIIIU	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.	
TOANKLEP RE	.169	5	.200*	.986	5	.962	
TOANKLEP OST	.233	5	.200*	.900	5	.409	
TOKNEEPR E	.339	5	.062	.757	5	.035	
TOKNEEPO ST	.294	5	.180	.882	5	.317	
TOHIPPRE	.177	5	.200*	.958	5	.791	
TOHIPPOST	.300	5	.162	.807	5	.093	

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
DBANKLEP RE	.210	5	.200*	.907	5	.448

DBANKLEP OST	.288	5	.200*	.852	5	.201
DBKNEEPR E	.378	5	.019	.756	5	.033
DBKNEEPO ST	.229	5	.200*	.906	5	.443
DBHIPPRE	.196	5	.200*	.948	5	.720
DBHIPPOST	.208	5	.200*	.893	5	.375

a. Lilliefors Significance Correction

Tests of Normality

	Kolmo	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.	
MSWANKLEP RE	.235	5	.200*	.890	5	.357	
MSWANKLEP OST	.403	5	.008	.629	5	.002	
MSWKNEEPR E	.186	5	.200*	.980	5	.935	
MSWKNEEPO ST	.272	5	.200*	.928	5	.585	
MSWHIPPRE	.194	5	.200*	.976	5	.915	
MSWHIPPOS T	.330	5	.078	.810	5	.097	

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Tests of Normality

	Kolmo	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.	
HPANKLEP RE	.280	5	.200*	.887	5	.340	
HPANKLEP OST	.245	5	.200*	.878	5	.298	
HPKNEEPR E	.280	5	.200*	.874	5	.282	
HPKNEEPO ST	.254	5	.200*	.936	5	.639	
HPHIPPRE	.264	5	.200*	.850	5	.194	
HPHIPPOST	.267	5	.200*	.839	5	.161	

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

	rests of Normanty								
	Kolmo	gorov-Sm	irnov ^a	Shapiro-Wilk					
	Statistic	df	Sig.	Statistic	df	Sig.			
IC2MSTANKLEP RE	.172	5	.200*	.974	5	.898			
IC2MSTANKLEP OST	.254	5	.200*	.881	5	.315			
IC2MSTKNEEP RE	.223	5	.200*	.964	5	.838			
IC2MSTKNEEP OST	.300	5	.161	.863	5	.237			
IC2MSTHIPPRE	.230	5	.200*	.957	5	.789			
IC2MSTHIPPOS T	.246	5	.200*	.895	5	.383			

Tests of Normality

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
MST2TOANKLE PRE	.375	5	.021	.711	5	.012
MST2TOANKLE POST	.263	5	.200*	.935	5	.633
MST2TOKNEEP RE	.234	5	.200*	.869	5	.262
MST2TOKNEEP OST	.199	5	.200*	.921	5	.536
MST2HIPPRE	.192	5	.200*	.976	5	.914
MST2TOHIPPOS T	.302	5	.154	.793	5	.071

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
TO2DBANKLEP RE	.242	2 5 .200*		.861	5	.233

TO2BDANKLEP OST	.143	5	.200*	.984	5	.954
TO2DBKNEEPR E	.303	5	.149	.862	5	.237
TO2DBKNEEPO ST	.272	5	.200*	.798	5	.078
TO2DBHIPPRE	.168	5	.200*	.975	5	.904
TO2DBHIPPOS T	.408	5	.007	.649	5	.003

a. Lilliefors Significance Correction

	Т	ests of I	Normalit	y		
	Kolmo	gorov-Sm	irnov ^a	S	hapiro-Wi	lk
	Statistic	df	Sig.	Statistic	df	Sig.
DB2MSWANKLE PRE	.189	5	.200*	.954	5	.769
DB2MSWANKLE POST	.320	5	.103	.879	5	.305
DB2MSWKNEEP RE	.293	5	.186	.863	5	.241
DB2MSWKNEEP OST	.298	5	.169	.834	5	.150
DB2MSWHIPPRE	.225	5	.200*	.898	5	.396
DB2MSWHIPPOS T	.208	5	.200*	.979	5	.928

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

	Kolmo	gorov-Sm	irnov ^a	Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
MSW2HPANKLE PRE	.282	5	.200*	.851	5	.199
MSW2HPANKLE POST	.269	5	.200*	.923	5	.552
MSW2HPKNEEP RE	.216	5	.200*	.937	5	.644
MSW2HPKNEEP OST	.182	5	.200*	.974	5	.901
MSW2HPHIPPRE	.218	5	.200*	.970	5	.878

MSW2HPHIPPOS	.243	5	.200*	.934	5	.626
Т						

a. Lilliefors Significance Correction

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
HPANKLEP RE	.243	5	.200*	.878	5	.299
HPANKLEP OST	.317	5	.111	.828	5	.134
HPKNEEPR E	.349	5	.046	.688	5	.007
HPKNEEPO ST	.205	5	.200*	.926	5	.570
HPHIPPRE	.208	5	.200*	.918	5	.516
HPHIPPOST	.283	5	.200*	.823	5	.123

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
SpeedPr e	.114	5	.200*	.998	5	.999
SpeedPo st	.246	5	.200*	.943	5	.688

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
SPSIXMRTP RE	.212	6	.200*	.964	6	.848
SPSIXMRTP OST	.203	6	.200*	.956	6	.792

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

1.5.3 SPSS Output Differences Tests

Test Statistics ^a					
RHRPOST -					
	RHRPRE				
Z	-2.079 ^b				
Asymp. Sig. (2-	.038				
tailed)					

a. Wilcoxon Signed Ranks Test

b. Based on positive ranks.

			Paired S	Samples	Test				
		Pa	ired Differ	rences				Signifi	cance
				95% Co	nfidence				
		Std.	Std.	Interva	l of the			One-	Two-
Μ	ea	Deviati	Error	Differ	ence			Sided	Sided
	n	on	Mean	Lower	Upper	t	df	р	р
Pai SYSPRE -	-	13.243	5.406	-21.064	6.731	-	5	.121	.242
r 1 SYSPOST 7	.16					1.32			
	7					6			
Pai DIAPRE -	-	30.032	12.260	-34.016	29.016	204	5	.423	.846
r 2 DIAPOST 2	.50								
	0								

Paired	Samples	Test

	Paired Differences								cance
	Mean	Std. Deviation	Std. Error Mean	Interva	onfidence al of the rence Upper	t	df	One- Sided p	Two- Sided p
Pair SIXMRTPRE - 7 1 SIXMRTPOST	79.500	116.543	47.579	-42.805	201.805	1.671	5	.078	.156

Paired Samples Test

	Paired Samples Test												
								Signif	ficanc				
		Paire	d Differe	nces				e	e				
				95	%								
			Confidence					One	Two				
		Std.	Std.	Interva	l of the			-	-				
		Deviatio	Error	Difference			d	Side	Side				
	Mean	n	Mean	Lower Upper		t	f	d p	dp				
Pai TCLEFTPRE	-	3.64650	1.2155	-	2.6807	-	8	.461	.922				
r1 -	.12222		0	2.9251	2	.101							
TCLEFTPOS				7									
Т													
Pai TCRIGHTPR	1.0222	3.47699	1.1590	-	3.6948	.882	8	.202	.404				
r2 E-	2		0	1.6504	7								
TCRIGHTPO				3									
ST													
Pai CCLEFTPRE	1.2125	3.63610	1.2855	-	4.2523	.943	7	.188	.377				
r3 -	0		6	1.8273	6								
CCLEFTPOS				6									
Т													
Pai CCRIGHTPR	-	2.26258	.79994	-	1.0165	-	7	.155	.310				
r4 E-	.87500			2.7665	7	1.09							
CCRIGHTPO				7		4							
ST													

-	Paired D	ifference	s					Signifi	cance
		95% Confidence							
		Std.	Std.	Interval o			One-	Two-	
		Deviatio	Error	Difference	е		d	Sided	Sided
	Mean	n	Mean	Lower	Upper	t	f	р	р
Pai LEFTKEPRE -	-	23.2155	7.7385	-	-	-	8	.009	.018
r 1 LEFTKEPOST	22.9590	1	0	40.80405	5.11402	2.96			
	3					7			

Pai RIGHTKEPRE -	-	22.4626	7.4875	-	1.70109-	8	.036	.071
r 2 RIGHTKEPOST	15.5652	2	4	32.83149	2.	07		
	0				9			

	LEFTKFPO
	ST -
	LEFTKFPR
	E
Z	-2.310 ^b
Asymp. Sig. (2-	.021
tailed)	

a. Wilcoxon Signed Ranks Test

b. Based on negative ranks.

	Paired Samples Test													
									fican					
	Paired Differences								е					
				95% Co	nfidence			One	Two					
		Std.	Std.	Interva	l of the			-	-					
	Deviati Error Difference						d	Side	Side					
	Mean	on	Mean	Lower	Upper	t	f	dp	dp					
Pai RIGHTKFPR	-	24.119	8.039	-	-	-	8	.003	.006					
r1 E-	30.091	56	85	48.631	11.551	3.74								
RIGHTKFPO	27			20	33	3								
ST														

Paired Samples Test Significan Paired Differences се 95% Confidence One Two Std. Std. Interval of the _ d Side Side Deviati Error Difference Lower Upper Mean f on Mean t dp dp

Pai LEFTPLFPR	-	35.324	11.774	-	9.273	-	8	.084	.167
r1 E-	17.879	91	97	45.032	49	1.51			
LEFTPLFPO	63			76		8			
ST									

	RIGHTPLFP
	OST -
	RIGHTPLFP
	RE
Z	-1.779 ^b
Asymp. Sig. (2-	.075
tailed)	

a. Wilcoxon Signed Ranks Test

b. Based on negative ranks.

			Signit	ficanc				
	Pair	ed Differ	ences				6	e
			95% Co	nfidence			One	Two
	Std. Std. Interval of th							-
	Deviatio	Error	Diffe	rence		d	Side	Side
Mea	n n	Mean	Lower	Upper	t	f	dp	dp
Pai ANKICPRE 2.33	60 22.6437	10.126	-	30.4519	.231	4	.414	.829
r1 -		6	25.7799					
ANKICPOS								
Т								
Pai ANKTOPR	- 16.1109	7.2050	-	14.1563	-	4	.231	.463
r 2 E - 5.84	30 0	1	25.8523	3	.812			
ANKTOPO	0		3					
ST								
Pai ANKDBPR 2.85	60 20.2303	9.0472	-	27.9752	.316	4	.384	.768
r3 E-	0 4	9	22.2632	9				
ANKDBPO			9					
ST								
Pai ANKHPPR 5.15	00 7.36025	3.2916	-	14.2889	1.56	4	.096	.193
r4 E-	0	0	3.98896	6	5			
ANKHPPO								
ST								

	ANKMSTPO	ANKMSWP
	ST -	OST -
	ANKMSTPR	ANKMSWP
	E	RE
Z	135 ^b	674 ^b
Asymp. Sig. (2-	.893	.500
tailed)		

a. Wilcoxon Signed Ranks Test

b. Based on positive ranks.

										ifican
			Paire	d Differ	ences				С	е
					95	%				
					Confid	dence			One	Two
			Std.	Std.	Interva	l of the			-	-
			Deviati	Error	Differ	ence		d	Side	Side
		Mean	on	Mean	Lower	Upper	t	f	dp	dp
Ра	ANKIC2MSTPR	-	14.948	6.685	-	17.433	-	4	.437	.874
ir	E -	1.128	67	25	19.689	23	.169			
1	ANKIC2MSTPO	00			23					
_	ST									
	ANKTO2DBPRE		12.890	5.765	-		.962	4	.195	.391
ir	-	00	95	01	10.460	23				
2	ANKTO2DBPO ST				23					
Ра	ANKTO2MSWP	-	4.6422	2.076	_	4.4860	-	4	.286	.571
ir	RE -	1.278	0	05	7.0420	5	.616			
3	ANKTO2MSWP	00			5					
	OST									
Pa	ANKMSW2HPP	.9920	12.813	5.730	-	16.902	.173	4	.435	.871
ir	RE -	0	82	52	14.918	46				
4	ANKMSW2HPP OST				46					

Pa	ANKHPPLUSPR	8.500	11.282	5.045	-	22.508	1.68	4	.084	.167
ir	E -	00	29	59	5.5088	81	5			
5	ANKHPPLUSP				1					
	OST									

	ANKMST2T
	OPOST -
	ANKMST2T
	OPRE
Z	674 ^b
Asymp. Sig. (2-	.500
tailed)	

a. Wilcoxon Signed Ranks Test

b. Based on negative ranks.


r anea Gampies rest										
									Significan	
Paired Differences									ce	
	95%									
					Confid	dence			One	Two
			Std.	Std.	Interva	l of the			-	-
			Deviati	Error	Differ	ence		d	Side	Side
		Mean	on	Mean	Lower	Upper	t	f	dp	dp
Ра	KNICPRE -	5.6820	12.379	5.5363	-	21.053	1.02	4	.181	.363
ir	KNICPOST		6		9.6892	2	6			
1										
Pa	KNMSTPRE -	.87600	6.6034	2.9531	-	9.0753	.297	4	.391	.782
ir	KNMSTPOST		9	7	7.3233	2				
2					2					
Ра	KNMSWPRE -	-	30.197	13.504	-	20.923	-	4	.144	.287
ir	KNMSWPOST	16.572	46	71	54.067	10	1.22			
3		00			10		7			
Ра	KNHPPRE -	-	24.406	10.914	-	18.734	-	4	.174	.349
ir	KNHPPOST	11.570	10	74	41.874	18	1.06			
4		00			18		0			

ir	KNIC2MSTPR E - KNIC2MSTPO ST	6.1440 0	7.0682 5	- 2.6323 9		1.94 4	4	.062	.124
ir	KNMST2TOPR E - KNMST2TOP OST	2.5360 0	8.0443 5	- 7.4523 8		.705	4	.260	.520
ir	KNTO2DBPRE - KNTO2DBPOS T	8.9840	6.7740 5	- 17.395 09	- .57291		4	.021	.041
Pa ir 8	KNTO2MSWP RE - KNTO2MSWP OST	26.242		- 35.831 78	- 16.652 22			<.00 1	.002
Pa ir 9	KNMSW2HPP RE - KNMSW2HPP OST	15.536	28.957 62	- 51.491 63		- 1.20 0	4	.148	.296

			KNHPPLUS
			POST -
	KNTOPOST	KNDBPOST	KNHPPLUS
	- KNTOPRE	- KNDBPRE	PRE
Z	405 ^b	-2.023 ^b	405 ^b
Asymp. Sig. (2-	.686	.043	.686
tailed)			

a. Wilcoxon Signed Ranks Test

b. Based on negative ranks.



					Lower	Upper				
Pa	HIPICPRE -	-	9.0357	4.040	-	8.1413	-	4	.244	.489
ir	HIPICPOST	3.0780		9	14.297		.762			
1					3					
Ра	HIPMSTPRE -	6.9560	11.902	5.322	-	21.734	1.30	4	.131	.261
ir	HIPMSTPOST	0	32	88	7.8226	68	7			
2					8					
Ра	HIPTOPRE -	6.5020	10.736	4.801	-	19.832	1.35	4	.124	.247
	HIPTOPOST	0	00	28	6.8285	50	4			
3					0					
	HIPDBPRE -		12.257					4	.121	.241
	HIPDBPOST		07	53	22.755	6				
4		0			16		5			
	HIPMSWPRE -		13.018					4	.074	.148
	HIPMSWPOST		57	80	26.588	9				
5		00	44.004	5 0 5 0	69	0.4404	0	_		070
	HIPHPPRE -	-			-			4	.038	.076
	HIPHPPOST	12.762	84	78	27.643	4				
6		00	40 740	4 700	14	47.000	1	4	407	202
	HIPIC2MSTPR E -	4.5820 0	10.719 56		- 8.7281		.956	4	.197	.393
	L - HIPIC2MSTPO	U	00	94	0.7201	10				
1	ST				U					
Pa	HIPMST2TOPR	8 0000	13 294	5 945		24 506	1.34	4	125	250
	E -	0			8.5067			Ľ.	.120	.200
	- HIPMST2TOP	· ·			0		Ū			
	OST									
Pa	HIPTO2MSWP	-	9.8994	4.427	-	.94575	-	4	.031	.062
ir	RE -	11.346	2	16	23.637		2.56			
9	HIPTO2MSWP	00			75		3			
	OST									
Ра	HIPMSW2HPP	-	11.698	5.231	-	5.0410	-	4	.072	.144
ir	RE -	9.4840	08	54	24.009	9	1.81			
10	HIPMSW2HPP	0			09		3			
	OST									
	HIPHPPLUSPR				-			4	.032	.065
	E -	10.140	5	72	21.283	7	2.52			
11	HIPHPPLUSPO	00			87		6			
	ST									

HIPDB2MS WPOST -HIPDB2MS WPRE Z -1.753^b Asymp. Sig. (2tailed)

a. Wilcoxon Signed Ranks Test

b. Based on negative ranks.

Paired Samples Test										
	Signi			icanc						
	Paired	Differe	nces				e	e		
		95%								
			Confi							
	Std.	Std.	Interval of the				One-	Two-		
	Deviatio	Error	Difference			d	Side	Side		
Mea	n n	Mean	Lower	Upper	t	f	dp	dp		
Pai AVSPEEDPRE .220	9.32363	.1321	-	.5606	1.67	5	.078	.155		
r 1 -	7	2	.1186	0	2					
AVSPEEDPOS			6							
Т										

Paired Samples Test Significanc **Paired Differences** е 95% Confidence Interval of the One- Two-Std. Std. Deviatio Error Difference d Side Side Mean Lower Upper Mean t f dp dp n

Pai SIXM	RTSPPR	.8047	1.15233	.4704	-	2.0140	1.71	5	.074	.148
r1 E-		7		4	.4045	6	1			
SIXM	RTSPPO				3					
ST										